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Abstract 
 
The melanocortin receptor (MCR) family consists of five G-protein coupled receptors 
(MC1R-MC5R) involved in a wide range of physiological and disease processes. 
MC2R is a critical component of the hypothalamic-pituitary-adrenal axis whilst MC3R 
and MC4R have an essential role in energy homeostasis. Mutations in MC4R are the 
most common cause of monogenic obesity. Investigating the way these receptors signal 
and traffic to the surface is vital in understanding disease processes related to MCR 
dysfunction.  
 
The identification of MRAP in 2005 as the first and only MC2R accessory protein 
provided insight into the regulation of the MCR system. Studies showed that MRAP 
was responsible for adrenal MC2R trafficking and function. Mutations in MRAP cause 
familial glucocorticoid deficiency, an autosomal recessive disorder resulting in isolated 
cortisol deficiency.  
 
MRAP2 is a novel conserved homologue of MRAP. In this study the role of MRAP2 as 
an accessory protein to one or more MCR was analysed. MRAP2 mRNA is expressed in 
the brain and adrenal gland. In heterologous cells, MRAP2 is a glycosylated protein 
localised to the cell membrane and ER. On co-immunoprecipitation, MRAP2 can 
homodimerise and heterodimerise with MRAP. Western blotting of tissues using an 
MRAP2 antibody reveals an immunoreactive band of high molecular weight (~47.5 
kDa) consistent with an MRAP2 dimer resistant to SDS and heat, a phenomenon similar 
to endogenous MRAP. MRAP2 can interact with all five MCRs. This interaction results 
in MC2R surface expression and signalling. In contrast, MRAP2 can reduce MC1R, 
 i
MC3R, MC4R and MC5R responsiveness to NDP-MSH in the presence or absence of 
MRAP. Furthermore, MRAP2 mRNA localisation in the hypothalamus and 
paraventricular nucleus points to a potential accessory role in the central regulation of 
MC4R and/or MC3R. In summary, this is the first report to identify MRAP2 as a unique 
bidirectional regulator of the melanocortin receptor family.  
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Introduction                    
1.1 Melanocortin system 
The melanocortin system regulates a large number of physiological functions 
including skin and hair pigmentation, inflammation, adrenal steroidogenesis, energy 
homeostasis, feeding behaviour and exocrine function. The system consists of the 
melanocortin peptides (α-, β-, γ-MSH and ACTH) derived from the 
proopiomelanocortin (POMC) preprohormone precursor, the five G protein-coupled 
melanocortin receptors (MCRs), endogenous melanocortin inverse agonists/antagonists 
(Gantz and Fong, 2003) and the more recently described MC2R accessory protein 
(Metherell et al., 2005). Each part of the melanocortin system plays an essential role and 
disruption of each component has been associated with a variety of disease states 
described later in this chapter.  
1.1.1 Melanocortin peptides (α-, β-, γ-MSH and ACTH) derivatives of 
POMC 
The POMC gene is expressed primarily in the brain, where expression localises 
to the hypothalamus, arcuate nucleus, pituitary and nucleus of the solitary tract in the 
brain stem. POMC is also expressed in cutaneous melanocytes and keratinocytes. 
Furthermore, POMC mRNA and immunoreactivity have been reported in a number of 
other peripheral tissues, including adrenal, spleen, lung, thyroid, immune system, 
genitourinary tract and gastrointestinal tract (Wikberg, 1999). In the central nervous 
system, POMC biosynthesis is regulated by a complex network of factors, including 
corticotropin-releasing hormone (CRH), vasopressin, dopamine, neuropeptide Y, 
GABA, thyrotropin-releasing hormone (TRH), sauvagine, oxytocin, acetylcholine, 
serotonin, steroid hormones, catecholamines, somatostatin and opiates (Eberle, 2000). 
POMC gene regulation differs in different cell-types and tissues. Homozygous and 
 2
Introduction                    
compound heterozygous loss-of-function mutations in POMC result in adrenal 
insufficiency, severe early onset obesity and red hair in children (Krude et al., 1998). 
Furthermore, parents of index patients who are heterozygous for POMC mutations are 
at increased risk of obesity (Krude et al., 2003; Farooqi et al., 2006). A similar 
phenotype is observed in POMC knockout (KO) mice (Yaswen et al., 1999; Smart and 
Low, 2003; Coll et al., 2004).  
The melanocortin peptides, α-, β-, γ-MSH and ACTH are endogenous agonists 
for the melanocortin receptors (MCRs). These peptides are derived from the cleavage of 
the precursor proopiomelanocortin (POMC) protein, a 231 amino-acid protein, 
produced and secreted in the pituitary (Fig. 1.1). POMC also undergoes post-
translational modifications including glycosylation, phosphorylation and sulphation. 
These modifications do not affect biosynthesis and processing of the prohormone but 
rather heterogeneity of peptides in the circulation (Eberle, 2000).  
The cleavage products in each tissue are dependent upon the prohormone 
convertase (PC) enzymes present and result in tissue specific patterns of expression of 
the POMC derivatives. These enzymes are subtilisin/kexin type serine proteinases. 
Seven mammalian precursor proteases have been identified: PC1 (also known as PC3), 
PC2, furin (also known as PACE), PACE4, PC4, PC5 (also known as PC6) and PC7 
(also called SPC7, LPC or PC8). They act by cleaving single and/or pairs of basic 
residues (Seidah et al., 1999b). PC1/3 and PC2 are the primary enzymes responsible for 
the cleavage of POMC, but are known to act on other prohormones such as proinsulin, 
proglucagon and prorenin in other tissues (Smeekens et al., 1992).  
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Fig. 1.1: Processing of POMC. ACTH and the various melanocyte stimulating hormones (αβγ) are 
all derived from the precursor protein, POMC. POMC undergoes cleavage and post translational 
modification in the pituitary, hypothalamus and skin, by action of PC1/3 and PC2. 
Carboxypeptidases and aminopeptidases subsequently remove dibasic residues. Enzymes PAM and 
N-AT perform COOH terminal amidation and N-α-acetylation respectively. Further modification 
is necessary for potency of biologically active peptides.  
 
Abbreviations: POMC: proopiomelanocortin precursor protein; LPH: lipotrophin; MSH: melanococyte 
stimulating hormone; CLIP: corticotrophinlike intermediate peptide; JP:  joining peptide; endo: 
endorphin; CPE: carboxypeptidase; PAM: α-amidating monooxygenase; N-AT: N-acetyltransferase 
 
The differential expression of PC1/3 and PC2 determines which of the 
biologically active peptides are produced from the cleavage of POMC. In the anterior 
pituitary, PC1/3 cleavage sites are used to produce N-terminal proopiocortin, joining 
peptide, ACTH and β-lipotropin. In the absence of PC2, in pituitary corticotroph cells, 
these peptides are not cleaved further. The presence of PC2, in addition to PC1/3, in the 
hypothalamus, skin and the intermediate lobe of the pituitary gland (rodents and human 
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fetus), enables further cleavage at additional sites resulting in more extensive peptide 
products such as β-MSH, γ-MSH, corticotrophin-like intermediate lobe peptide (CLIP), 
γ-lipotrophin and β-endorphin (Wakamatsu et al., 1997; Pritchard et al., 2002; Pritchard 
and White, 2007). The absence of the intermediate pituitary in humans after the fetal 
stage means that ACTH is not processed to α-MSH and is not secreted or measurable in 
blood at high quantities (Lu et al., 2000).  
Fully biologically active α-MSH requires further processing using additional 
enzymes including carboxypeptidase E, α-amidating monooxygenase (COOH-terminal 
amidation) and N-acetyltransferase (N-α-acetylation) (Pritchard and White, 2007). 
These modifications prevent exopeptidase action on the α-MSH molecule and increase 
peptide potency (Eberle, 2000).  
Although PC1/3 and PC2 are accepted as the POMC processing enzymes, other 
enzymes of the same family are also capable of processing POMC in vitro such as 
PACE4 and furin convertase (Seidah et al., 1999a). The in vivo role, if any, in the 
processing of POMC has yet to be established, although it has been suggested that such 
enzymes may act to compensate the lack of PC1 activity in patients with PC1 mutations 
(Jackson et al., 1997). This processing pathway is complex and tightly regulated. PC1/3 
is inhibited by proSAAS, a neuroendocrine-specific inhibitor (Fricker et al., 2000) and 
PC2 is regulated by secretory protein 7B2 (secretogranin V) (Lindberg et al., 1995; Lee 
and Lindberg, 2008).  
ACTH secreted from pituitary corticotrophs binds to the MC2R in the adrenal 
gland to regulate steroidogenesis. In the hypothalamus, α-MSH and β-MSH bind the 
MC3R and MC4R to control appetite and energy homeostasis. In skin, α-MSH acts on 
the MC1R and MC5R to determine pigmentation and exocrine function (Cone, 2006). 
These melanocortin peptide derivatives of POMC all contain amino acid sequence His-
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Phe-Arg-Trp (HFRW) which is essential for biological activity. The HFRW core 
peptide binds all members of the MCR family with little specificity (Schioth et al., 
1997).  
In addition, α-MSH has a potent anti-inflammatory and immunomodulatory role, 
by acting on MC1R (Maaser et al., 2006). The antipyretic effect of α-MSH in 
experimentally induced fever and brain inflammation is thought to be mediated through 
MC3R and MC4R in the hypothalamus and brain stem (Tatro, 2000). MCR independent 
actions have also been described (Mugridge et al., 1991; Poole et al., 1992; Ichiyama et 
al., 1999; Getting et al., 2003; Cooper et al., 2005). In vitro and in vivo evidence 
demonstrate that α-MSH reduces binding of IL-1β hence reducing its hyperalgesic 
effect of IL-1β in rats (Mugridge et al., 1991; Poole et al., 1992). 
 Other POMC derived peptides may have additional roles that are yet to be 
confirmed. For example, the N-terminal peptide from POMC, N-POC[1-28] has been 
implicated in stimulation of adrenal growth (Estivariz et al., 1982; Estivariz et al., 
1988). Melanocortin peptide involvement in adrenal gland growth and development 
may explain how hypophysectomy leads to adrenal atrophy (Robinson et al., 1983). 
ACTH may have a role in adrenal growth and ZF differentiation, although ACTH 
replacement does not restore adrenal size in hypophysectomised rats (Payet and Lehoux, 
1980; Arola et al., 1993; Heikkila et al., 1995). Work on POMC KO mice provide 
further support for a role of POMC derived peptides in adrenal growth and 
development. However, the adrenal morphology described in each study varied from 
absent adrenal glands to small atrophied glands with disrupted architechture (Yaswen et 
al., 1999; Smart and Low, 2003; Coll et al., 2004). Furthermore, in contrast to studies 
on hypophysectomised rats, administration of ACTH but not N-POC[1-28] restored 
adrenal weight, cortical morphology, and plasma corticosterone concentrations in 
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POMC KO mice (Coll et al., 2004; Coll et al., 2006). β-endorphin, not a melanocortin 
peptide, is an endogenous opioid neurotransmitter found in the neurons of the 
hypothalamus and pituitary and is important in analgesia (Guillemin et al., 1977; Nicoll 
et al., 1977).  
1.1.2 Melanocortin receptors  
The melanocortin receptor family consists of five seven-transmembrane G 
protein-coupled receptors (GPCRs), MC1R to MC5R (Fig. 1.2). These receptors are 
involved in a diverse range of physiological and disease processes. Ligand specificity of 
each receptor varies, as shown in Table 1.1. MC1R controls skin pigmentation, MC2R 
plays a critical role in the hypothalamic-pituitary-adrenal axis, whilst MC3R and MC4R 
have essential roles in energy homeostasis and MC5R is believed to be involved in 
exocrine function (Cone, 2006). The receptor nomenclature is based on the order of 
cloning i.e. MC1R was the first receptor to be cloned, followed by MC2R (Mountjoy et 
al., 1992), MC3R (Roselli-Rehfuss et al., 1993) , MC4R (Gantz et al., 1993b) and 
finally MC5R (Gantz et al., 1994a; Griffon et al., 1994). All five MCRs act via the 
stimulatory G protein (Gs), which in turn activates adenylate cyclase, ultimately 
resulting in cAMP generation. However, other secondary signalling pathways have been 
implicated involving inositol triphosphate (Konda et al., 1994), influx of extracellular 
calcium (Kojima et al., 1985; Elliott et al., 2004), MAP kinase (Englaro et al., 1995), 
janus kinase (Buggy, 1998) and protein kinase C (Buffey et al., 1992; Kapas et al., 
1995). The MCRs do not appear closely related to other GPCRs, although some distant 
relationship is noted with the cannabinoid receptors (Mountjoy et al., 1992). Supporting 
evidence for a possible evolutionary relationship between the two receptor families 
came from the description of a chimeric cannabinoid/melanocortin receptor in the leech 
central nervous system (CNS) (Elphick, 1998).  
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Fig. 1.2: Protein alignment of human melanocortin receptors. 
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Table 1.1: The members of the melanocortin receptor family, their ligand specificities, action and phenotype of individuals with mutations.  
Receptor Ligand specificity 
Known 
antagonists/ 
inverse agonists 
Main site of 
expression Physiological functions Phenotype of mutations OMIM 
MC1R α-MSH=β-MSH =ACTH>γ-MSH Agouti Melanocytes Pigmentation, Inflammation 
Increased risk of skin 
cancers 155555 
MC2R ACTH - Adrenal cortex Adrenal steroidogenesis FGD 202200 
MC3R γ-MSH=ACTH= α-MSH=β-MSH AgRP 
CNS, GI tract, 
Kidney Energy homeostasis Obesity 155540 
MC4R α-MSH=β-MSH =ACTH >γ-MSH AgRP, Agouti CNS 
Energy homeostasis, Appetite 
regulation, Erectile function Obesity 155541 
MC5R α-MSH>β-MSH =ACTH>γ-MSH - Exocrine cells
Exocrine function, Regulation of 
sebaceous glands 
Decreased production of 
sebaceous lipids in mice 600042 
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1.1.2.1 MC1R 
MC1R plays a key role in determining skin and hair pigmentation. The human 
MC1R gene maps to 16q24.3 and encodes a 317 amino acid GPCR (Chhajlani and 
Wikberg, 1992; Mountjoy et al., 1992). Melanin polymers synthesised by the follicular 
melanocytes (neural crest-derived cells) are divided into yellow-red pheomelanins, and 
the brown-black eumelanins. α-MSH acts on the MC1R which results in activation of 
the relevant heterotrimeric Gαs protein, which in turn activates adenylyl cyclase 
resulting in an increase in intracellular cAMP in the melanocyte (Mountjoy et al., 1992; 
Chhajlani and Wikberg, 1992). cAMP promotes tyrosinase transcription by permitting 
binding of the microphalmia protein to the promoter region of the tyrosinase gene 
(Bertolotto et al., 1996). α-MSH also increases tyrosinase posttranslational events 
resulting in increased tyrosinase protein and tyrosinase related protein expression which 
ultimately promotes eumelanin synthesis (brown or black pigment) (Aroca et al., 1993; 
Hunt et al., 1994). Melanin is secreted via melanosomes which are specialised ER-
derived vesicles. Absorption of melanin by surrounding keratinocytes or by the growing 
hair shaft results in hair and skin pigmentation (Lu et al., 2000). Loss-of-function 
mutations in the MC1R gene result in the synthesis of pheomelanins rather than 
eumelanins. In mice, such mutations result in a yellow coat and in humans they result in 
red hair (shades of auburn to strawberry blonde) and pale skin (Robbins et al., 1993; 
Valverde et al., 1995). MC1R gene variations are associated with an increased risk of 
melanoma formation and other skin cancers (Bastiaens et al., 2001; Sturm, 2002).  
Both the human and mouse MC1R are known to be constitutively active. In 
heterologous cell-lines, such as HEK293 cells, ligand independent signalling was 200-
400 times higher than in vector only transfected control cells (Sanchez-Mas et al., 2004; 
Garcia-Borron et al., 2005; Jackson et al., 2007). In addition to expression in the 
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melanocytes, the receptor is also expressed in leucocytes and antigen presenting cells 
and has a role in inflammation and immunomodulation (Luger et al., 1999). Expression 
in other tissues including testes, ovary, pituitary, placenta and endothelial cells have 
also been described (Schioth et al., 1995; Xia et al., 1995; Chhajlani, 1996; Thornwall et 
al., 1997; Schiller et al., 2004). The physiological relevance of this is unclear. ACTH 
and α-MSH are equipotent on human MC1R, but α-MSH is five times more potent in 
the activation of mouse MC1R than ACTH (Lu et al., 2000). In humans, equipotency of 
ACTH and α-MSH may explain why hyperpigmentation results from high ACTH 
levels.  
 
1.1.2.2 MC2R 
The MC2R is the smallest member of the GPCR family. The human MC2R gene 
maps to 18p11.2, and contains two exons, the second of which is the coding exon. 
MC2R encodes a receptor 297 amino acids in length. MC2R, also known as the ACTH 
receptor since ACTH is its sole ligand, is expressed in the adrenal cortex and is 
responsible for ACTH mediated steroidogenesis. The adrenal cortex is divided into 
three distinct zones, the outer zona glomerulosa (ZG), the middle zona fasciculata (ZF) 
and the inner zona reticularis (ZR). These three zones secrete steroids in the form of the 
mineralocorticoid aldosterone (ZG), glucocorticoid (cortisol in humans and primates 
and corticosterone in rodents) (ZF) and adrenal androgens (ZR) in humans and 
primates. The production of aldosterone by the ZG is controlled by Angiotensin II 
acting on the angiotensin receptor through the phospholipase C pathway (Bernstein and 
Alexander, 1992). There is evidence that ACTH, acting through the MC2R, may play a 
role in aldosterone production (Lin et al., 2007; Chida et al., 2007; Chan et al., 2009b), 
although the physiological significance of this is unclear. This is discussed in more 
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detail in section 1.2. The principal role of the MC2R is in the generation of cortisol 
from the ZF, a hormone which is essential for life. In the ZR the MC2R determines the 
secretion of adrenal androgens, which normally occurs in childhood and is termed 
adrenarche (Weber et al., 1997). MC2R polymorphisms have been associated with early 
adrenarche in childhood (Lappalainen et al., 2008).  
Besides the adrenal gland, MC2R is also expressed in rodent adipose tissue 
(Wikberg, 1999). ACTH has an effect on adipocyte lipolysis and has been shown to 
cause insulin induced glucose uptake in white adipose tissue (Iwen et al., 2008). MC2R 
expression in a number of other tissues and cell-types is shown in Table 1.2.  
MC2R expression appears to be regulated by its own ligand. In vitro, exposing 
NCI-H295 human adrenocortical carcinoma cells to ACTH or forskolin for 24 hr 
resulted in a 2 to 4 fold increase in MC2R expression (Mountjoy et al., 1994a). In 
primary cell-lines a 21 fold increase in gene expression with a 4 fold increase in 
receptor number was demonstrated (Lebrethon et al., 1994). Interestingly, angiotensin II 
had similar effects (Lebrethon et al., 1994).  
 
1.1.2.3 MC3R 
Human MC3R maps to 20q13.2 and encodes a protein which is 360 amino acids 
in length. MC3R is expressed in over 35 nuclei in the CNS, primarily in the areas of the 
brain that receive direct innervation from POMC immunoreactive neurons (Jacobowitz 
and O'Donohue, 1978; Roselli-Rehfuss et al., 1993; Chhajlani, 1996). The ventromedial 
nucleus (VMN) of the hypothalamus appears to contain the highest density of receptors 
followed by the medial preoptic area (Table 1.3) (Lindblom et al., 1998). Moderate 
expression in the arcuate nucleus also points to a role in neuromodulation (Roselli-
Rehfuss et al., 1993). MC3R is also expressed in several peripheral tissues including 
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those in the gastrointestinal (GI) tract, placenta, heart and pancreas (Gantz et al., 1993a; 
Chhajlani, 1996). Gantz et al. did not find expression in the adrenal gland or 
melanocytes (Table 1.2) (Gantz et al., 1993a).  
MC3R is thought to play an important role in energy homeostasis. Association 
studies demonstrate linkage of a 20q locus, encompassing MC3R, to obesity and non-
insulin-dependent diabetes mellitus (NIDDM) (Lembertas et al., 1997; Zouali et al., 
1997; Ji et al., 1997; Bowden et al., 1997; Ghosh et al., 1999). MC3R 
mutations/polymorphisms have been identified in severely obese patients (Li et al., 
2000; Wong et al., 2002; Feng et al., 2005; Lee et al., 2007; Mencarelli et al., 2008). In 
vitro analysis of one of these mutations, I183N, demonstrated that mutant MC3R binds 
ligand but fails to signal and generate cAMP (Tao and Segaloff, 2004), hence 
supporting the theory that MC3R mutations can cause obesity. It was, however, pointed 
out that some members of the same family without the mutation were also obese (Lee et 
al., 2002). Other studies have failed to detect MC3R mutations in obese cohorts  (Calton 
et al., 2009; Hani et al., 2001). MC3R single nucleotide polymorphisms were shown to 
affect substrate oxidation and first-phase insulin secretion in children of NIDDM 
parents (Rutanen et al., 2007).  
Overall, there is still controversy regarding the contribution of MC3R 
mutations/polymorphisms to human obesity and diabetes (Hani et al., 2001; Calton et 
al., 2009). Animal data, however, are more convincing, and MC3R homozygous 
knockout (KO) mice exhibit exacerbated diet-induced obesity and develop mild 
metabolic abnormalities later on in life due to failure to regulate fatty acid and 
carbohydrate metabolism, despite normal food intake and energy expenditure (Chen et 
al., 2000; Butler et al., 2000; Sutton et al., 2006; Ellacott et al., 2007). These KO mice 
exhibit abnormal daily patterns of feeding, suggesting that MC3R is important for 
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entrainment of feeding time (Sutton et al., 2008). In contrast, MC4R appears to 
primarily regulate food intake (Huszar et al., 1997). Double KO mice lacking both 
MC3R and MC4R have enhanced obesity compared to single KO animals, suggesting 
that they regulate different aspects of energy homeostasis (Chen et al., 2000).   
 
1.1.2.4 MC4R 
The human MC4R gene is located on 18q22 and encodes a 332 amino acid 
protein. MC4R is expressed predominantly in the CNS in more than 100 nuclei (Gantz 
et al., 1993b; Mountjoy et al., 1994b). In the hypothalamus, expression is predominantly 
in the para-ventricular nucleus (PVN), as well as the POMC positive arcuate nucleus, 
lateral hypothalamic area and dorsomedial nucleus. These areas are involved in the 
regulation of feeding behaviour and metabolism (Mountjoy et al., 1994b). Faint 
expression in the pituitary gland has been described (Chhajlani, 1996). In comparison to 
the widespread brain MC4R expression, with mRNA expression in virtually every area 
including cortex, thalamus, hypothalamus, and brain stem (Mountjoy et al., 1994b), 
brain MC3R distribution is more limited, being seen only in the hypothalamus, thalamus 
and brainstem (Roselli-Rehfuss et al., 1993). The distribution of MC3R and MC4R in 
the developing rat brain was studied using in situ hybridisation (Mountjoy and Wild, 
1998; Kistler-Heer et al., 1998). These studies showed that MC4R expression was 
detected from E14 onwards throughout development, whereas MC3R mRNA expression 
was only detectable in the postnatal period. Other sites of expression include the 
sympathetic nervous system and spinal cord with clinical implications in pain sensation 
and sexual function (Van der et al., 1999; Van der Ploeg et al., 2002; Beltramo et al., 
2003). mRNA was also seen in some highly innervated tissues including the adrenal 
gland (Dhillo et al., 2003). Hypothalamic MC4R expression is summarised in Table 1.3.  
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Both MC4R KO mice and humans with MC4R mutations display severe early 
onset obesity associated with hyperphagia, hyperinsulinaemia and increased somatic 
growth (Huszar et al., 1997; Farooqi et al., 2003). MC4R-/+ heterozygous mice have 
body weights intermediate between wild-type and MC4R-/- litter mates (Huszar et al., 
1997), consistent with findings in humans (Farooqi et al., 2003; Lubrano-Berthelier et 
al., 2004). In comparison, MC3R KO mice develop a milder phenotype with later onset 
obesity (Chen et al., 2000; Butler et al., 2000).  
MC4R negatively regulates appetite and food intake in response to agonist, 
thought to be α-MSH, and conversely its inverse agonist/antagonist AgRP provides an 
orexigenic signal (Lu et al., 1994; Huszar et al., 1997; Breit et al., 2006). However, β-
MSH action on the MC4R may also have an important role in human energy regulation. 
This was highlighted by the description of a rare POMC variant, resulting in Y221G 
change of the β-MSH protein, causing early onset obesity in childhood (Lee et al., 
2006). Binding of this variant protein to the MC4R was impaired compared to wild-type 
β-MSH.  
Mutations in MC4R were first reported in 1998 as the cause of dominantly 
inherited obesity (Yeo et al., 1998; Vaisse et al., 1998). Further heterozygous and 
homozygous mutations have since been described (Hinney et al., 1999; Farooqi et al., 
2000; Vaisse et al., 2000; Lubrano-Berthelier et al., 2004). MC4R mutations are now the 
most common cause of monogenic obesity in humans present in 0.5% - 6% of obese 
adults and severely obese children respectively (Farooqi et al., 2003; Larsen et al., 2005; 
Alharbi et al., 2007). Larsen et al. reports a prevalence of MC4R mutations in 2.5% of 
Scandinavian men with a BMI > 30 kg/m2 (Larsen et al., 2005). Similar prevalence was 
shown in a French cohort of severely obese adults (Lubrano-Berthelier et al., 2006). 
Homozygotes were more severely affected than heterozygotes, although there are some 
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reports of non-obese obligate heterozygote carriers (Vaisse et al., 2000; Farooqi et al., 
2003). This suggested the presence of additional modulators that contribute to a variable 
phenotype (Farooqi and O'Rahilly, 2006). More recently, fat mass, weight, risk of 
obesity and insulin resistance were associated with common variants near the MC4R 
locus at a population level (Loos et al., 2008; Chambers et al., 2008). This has now been 
replicated in a number of other population groups (Calton et al., 2009; Renstrom et al., 
2009).  
In vitro analysis of MC4R mutations has shown that the majority (70%) result in 
intracellular retention of mutant receptor proteins (Lubrano-Berthelier et al., 2003; Yeo 
et al., 2003). The majority of mutants showed no evidence of dominant negative  
activity, suggesting that haploinsufficiency was a more likely explanation for the 
phenotype (Yeo et al., 2003), although the study did report dominant negative activity 
with the D90N mutation (Biebermann et al., 2003). Other functional defects include 
inability to bind ligand (Yeo et al., 2003). In the same study, the I316S mutation had 
reduced binding affinity to NDP-MSH whilst binding to antagonist/inverse agonist 
AgRP was retained, suggesting that this mutation ultimately affected the selectively of 
the receptor to agonist verses antagonist (Yeo et al., 2003). Certain mutations have also 
been shown to affect constitutive activity of the MC4R (Kim et al., 2008).  
 
1.1.2.5 MC5R 
 Located on chromosome 18p11.2 the MC5R encodes a protein which is 325 
amino acids in length. MC5R is expressed widely in tissues such as the adrenal gland, 
adipose tissue, muscle, kidney, spleen, lung, brain, stomach, skin, exocrine tissues 
(harderian, lacrimal and preputial glands), prostate, pancreas, thyroid, tongue, thymus, 
spleen, bone marrow and testis (Desarnaud et al., 1994; Gantz et al., 1994a; Griffon et 
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al., 1994; Labbe et al., 1994; Fathi et al., 1995; Boston and Cone, 1996). In skin 
expression was found in the sebaceous glands (Chen et al., 1997; Van der et al., 1998).  
In situ hybridisation studies revealed that MC5R was expressed in both the ZG 
and ZF in the neonatal rat (Griffon et al., 1994). Brain expression was also shown and 
was fairly diffuse with expression in the hypothalamus, cerebral cortex, pons, medulla, 
cerebellum, hippocampus, midbrain, striatum and pituitary (Griffon et al., 1994). Due to 
the widespread expression of this receptor, a variety of speculative roles were originally 
suggested including  neuroregenerative and anti-inflammatory effects and stimulation of 
aldosterone production (Gantz et al., 1994b; Griffon et al., 1994; Labbe et al., 1994; 
Fathi et al., 1995). The generation of the MC5R KO mice indicated that null mice were 
able to survive into adulthood and were able to reproduce (Chen et al., 1997). MC5R-/- 
mice were noted to get ‘wetter and colder’ when submerged in water, suggestive of 
defective water repulsion and thermoregulation (Chen et al., 1997). This correlated with 
a long established observation that α-MSH could stimulate sebum production (Thody 
and Shuster, 1973). α-MSH was therefore thought to act through the MC5R in sebaceous 
glands. At present, exocrine function, especially sebaceous gland secretion (Chen et al., 
1997; Zhang et al., 2006), is the only established role of MC5R, although a possible  role 
in pheromone synthesis and/or release has been described (Morgan et al., 2004; Morgan 
and Cone, 2006).  
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Table 1.2: MCR expression in additional tissues and cells types. Data summarised from the following references: (Clarke and Bost, 1989; Gantz et al., 1993a; Schioth 
et al., 1995; Xia et al., 1995; Slominski et al., 1996; Chhajlani, 1996; Thornwall et al., 1997; Zhong et al., 2005).  
Receptor Main site of expression Additional sites of tissue expression Identified cell-type 
MC1R Melanocytes 
Skin, brain, immune system, gut, testis, ovary, 
placenta, lung, liver, adrenal gland, skeletal 
muscle, pituitary, uterus, spleen, lymph node, 
bone  
Melanocytes, keratinocytes, fibroblastic cells, endothelial 
cells, secretory epithelia, microglia, astrocytes, 
monocytes/macrophages, lymphocytes, neutrophils, 
mast cells, intestinal epithelia, Leydig cells, lutein cells, 
trophoblastic cells, skeletal muscle cells 
MC2R Adrenal cortex Testis, skin, adipose tissue, pancreas, pituitary, peripheral blood monocytes, skin, bone  
Cells of the zona fasciculata and glomerulosa, 
adipocytes, keratinocytes, lymphocytes, pancreatic cells 
MC3R CNS, GI tract, kidney Heart, immune system, skeletal muscle, placenta, bone  Macrophages, intestinal epithelial cells, lymphocytes 
MC4R CNS Brain, skin, skeletal muscle, adipose tissue, bone Dermal papilla cells, skeletal muscle cells, lymphocytes 
MC5R Exocrine cells 
Skeletal muscle, brain, skin, exocrine glands, 
lung, heart, spleen, immune system, kidney, 
adipose tissue, adrenal gland, uterus, ovary, 
placenta, bone 
Adipocytes, mast cells, secretory epithelia, 
macrophages, skeletal muscle cells, intestinal epithelial 
cells, lymphocytes 
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Table 1.3: Distribution of MC3R and MC4R mRNA in rat brain hypothalamus detected by in situ 
hybridisation (adapted from (Roselli-Rehfuss et al., 1993; Mountjoy et al., 1994b)).  
Hypothalamic 
region Labelled Nuclei MC3R MC4R 
Periventricular zone  Suprachiasmatic preoptic nucleus - +++ 
 Median preoptic nucleus  +(+) ++/++++ 
 Anteroventral periventricular 
nucleus 
+ ++++ 
 Preoptic periventricular nucleus + +(+) 
 Supraoptic nucleus - +++/+++(+) 
 Paraventricular nucleus  - +/+++ 
 Arcuate nucleus ++ + 
 Posterior periventricular nucleus + ++ 
    
Medial zone Medial preoptic area  - ++/++++ 
 Anterodorsal preoptic nucleus - + 
 Anteroventral preoptic nucleus ++ +++(+) 
 Anterior hypothalamic nucleus +(+) ++(+) 
 Ventromedial nucleus 
        Dorsomedial part 
        Ventrolateral part 
 
+++ 
- 
 
+ 
+++ 
 Dorsomedial nucleus  
        Anterior part 
        Posterior part 
        Ventral part 
 
- 
- 
- 
 
+++ 
+ 
+ 
 Premammillary nucleus +(+) ++ 
 Mammillary body  + ++/+++ 
 Posterior hypothalamic area ++ ++(+) 
    
Lateral zone Lateral preoptic nucleus +(+) ++(+) 
 Lateral hypothalamic area  +(+) +++ 
    
Signal intensities represented by: + (weak), ++ (moderate), +++ (strong), ++++ (very strong), 
parentheses represent intermediate levels, / indicates that the denoted region is further 
subdivided with variable expression in each subdivision.  
 
1.2 Familial Glucocorticoid Deficiency (FGD) 
Familial Glucocorticoid Deficiency (FGD; OMIM 202200), otherwise known as 
hereditary unresponsiveness to ACTH, is a rare autosomal recessive disease first 
described by Shepard et al. in 1959 (Shepard et al., 1959). FGD is characterised by 
glucocorticoid deficiency in the presence of normal plasma renin and aldosterone levels. 
Typically ACTH levels at presentation are extremely high, above 1000 pg/ml (normal 
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range <80 pg/ml by RIA; <50 pg/ml by IRMA) (Clark and Weber, 1998; Brook et al., 
2005). Nevertheless, mild derangements of the renin-angiotensin-aldosterone system at 
the time of diagnosis are sometimes seen with this condition (Davidai et al., 1984; Clark 
and Weber, 1998), and it has been suggested that a partial mineralocorticoid deficient 
state exists in those patients with “severe genotypes” (Lin et al., 2007). The 
physiological explanation of this observation is unclear but two factors may play a part. 
Firstly, there is evidence that ACTH directly activates the production of aldosterone in 
the ZG. It has been found that MC2R mRNA localises to the ZG and administration of 
synthetic ACTH to normal human subjects results in a rise in plasma aldosterone levels 
(Spark and Etzkorn, 1977; Davidai et al., 1984; Xia and Wikberg, 1996; Reincke et al., 
1998; Arvat et al., 2000). Secondly, during periods of illness and acute stress, changes 
in the renin-angiotensin-aldosterone axis are seen (Weise and Zaritsky, 1987; Clark and 
Weber, 1998). Recently published data on the MC2R KO mouse revealed that these 
mice have low serum aldosterone levels leading to hyperkalaemia in females. 
Furthermore, the renin-angiotensin-aldosterone system appears to attempt to 
compensate in the complete absence of MC2R, increasing AT1bR (angiotensin type 1b 
receptor) expression in the ZG, whilst CYP11B2 (aldosterone synthase) expression 
remains low. Renin levels or activity were not measured (Chida et al., 2007). The 
MC2R KO mouse phenotype appears to contrast with the ‘human equivalent’ where 
variations in mineralocorticoid status do not equate to the need for long-term 
fludrocortisone replacement (Chan et al., 2009b).  
 Patients with FGD are usually diagnosed during the neonatal period or by early 
childhood. They may present with hypoglycaemic seizures, transient hepatitis, 
hyperpigmentation, recurrent infections, failure to thrive, collapse, and coma (Lacy et 
al., 1993; Chan et al., 2007). The long-term neurological consequence of FGD can vary 
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from learning difficulties to spastic quadriplegia, which may reflect the severity and 
number of hypoglycaemic episodes during childhood (Modan-Moses et al., 2006). In 
FGD the adrenal glands are usually small in size (Clark and Weber, 1998). Post mortem 
adrenal histology from affected individuals reveals the absence of fasciculata or 
reticularis cells together with disorganisation of glomerulosa cells (Shepard et al., 1959; 
Migeon et al., 1968; Kelch et al., 1972; Clark and Weber, 1998).  
 Several features appear specific to FGD. Tall stature is seen in some patients 
(refer to section 1.2.1). Absent adrenarche (presenting as delayed or absent pubic hair) 
is another feature and represents ACTH dependent production of adrenal androgens by 
the ZR during adrenarche in normal childhood (Weber et al., 1997). The highly elevated 
plasma ACTH seen in most patients and can be difficult to suppress despite treatment 
with high doses of hydrocortisone. The reason for this apparent lack of suppression is 
unclear. There is some suggestion of the existence of a short ACTH negative feedback 
loop at the level of the pituitary/hypothalamus. Hence, patients with mutations which 
render the MC2R inactive would lack negative inhibition of ACTH release at this level 
(Suda et al., 1986; Suda et al., 1987; Boscaro et al., 1988; Morris et al., 2003). 
Hyperpigmentation is almost always observed in FGD and is due to high ACTH levels 
which act on the MC1R in melanocytes.  
 
1.2.1 Mutations in MC2R 
The cloning of the MC2R (1.1.2.2) by Mountjoy et al. in 1992 enabled 
researchers to identify point mutations in the ACTH receptor in patients with FGD 
(Mountjoy et al., 1992; Clark et al., 1993; Tsigos et al., 1993; Tsigos et al., 1995; Weber 
et al., 1995; Naville et al., 1996; Wu et al., 1998; Slavotinek et al., 1998).  More than 30 
mutations have been described in the MC2R (Chan et al., 2007) (Fig. 1.3), the majority 
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of which are homozygous missense or compound heterozygous mutations. The 
functional consequence of various MC2R mutations have been demonstrated by a 
number of groups (Weber et al., 1995; Naville et al., 1996; Naville et al., 1997; Naville 
et al., 1999; Elias et al., 1999; Fluck et al., 2002). The majority of MC2R mutations 
described in FGD result in defective trafficking to the cell surface (Chung et al., 2008). 
To date there is no strong evidence to suggest that heterozygous carriers, i.e. parents or 
siblings of FGD patients, have abnormal cortisol secretion or response. However, there 
is a case report of a FGD patient with a frameshift mutation (G217fs) on one allele and 
a T to C substitution in the -2 position of the MC2R promoter (Tsiotra et al., 2006). 
Functional analysis of the promoter variant resulted in a reduction of MC2R function by 
15% and the combination with a nonsense mutation is thought to lead to FGD (Tsiotra 
et al., 2006). This promoter variant is found in 10% of the population and has been 
proposed to influence pituitary–adrenal axis activity in normal adults and children 
(Lappalainen et al., 2008; Slawik et al., 2004; Reisch et al., 2005).  
As well as the tall stature observed in some FGD patients with MC2R mutations 
(Elias et al., 2000; Imamine et al., 2005), a proportion of these patients have also been 
shown to have advanced or dissociated bone age, i.e. advanced bone maturation in the 
radius and phalanges with delay seen in the carpal bones. This excessive growth is more 
noticeable prior to the initiation of treatment and although hydrocortisone replacement 
appears to bring the height back towards the mid-parental target, children remain tall as 
adults (Clark and Weber, 1998). The rather limited data available suggests that the 
Insulin-like growth factor I-Growth Hormone axis is normal in these patients (Elias et 
al., 2000). It has been proposed that the excessive growth is due to high plasma ACTH 
levels (Imamine et al., 2005). The presence of all five melanocortin receptors in bone 
and the ability of ACTH to stimulate cAMP production and gene expression in bone 
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cells provide a plausible mechanism (Elias et al., 2000; Mountjoy et al., 2003; Zhong et 
al., 2005). However, not all FGD patients with inactivating mutations of the MC2R are 
tall, short stature has also been described (Selva et al., 2004). Around 25% of FGD 
patients have mutations in the MC2R implying that other genetic causes can lead to the 
same clinical phenotype (Chan et al., 2007).  
The search for additional causative genes linked FGD to a locus on 8q (Genin et 
al., 2002) in some patients. This locus was reanalysed by Metherell et al. revealing a 
larger region of homozygosity than previously described, now encompassing the locus 
for the steroidogenic acute regulatory gene (STAR). Mutational analysis of FGD patients 
revealed homozygous STAR mutations. Although mutations in STAR cause lipoid 
congenital adrenal hyperplasia, characterised by adrenal insufficiency together with 
gonadal deficiency, patients described by Metherell et al. habouring STAR mutations 
R192C and R188C were clinically indistinguishable from FGD patients (Metherell et 
al., 2009).  
However, many patients did not show linkage to locus 8q or have a mutation in 
the ACTH receptor, suggesting involvement of other genes. In keeping with this notion, 
distinct phenotypic variation has been described in a subset of FGD patients, such as the 
Irish travellers (O'Riordan et al., 2008).  
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Fig. 1.3: Schematic diagram of the human MC2R showing the locations of known polymorphisms and mutations. Each circle represents an amino acid 
residue. The *F278C mutation is the only known activating MC2R mutation. 
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1.3 MRAP 
1.3.1 Discovery of MRAP as the cause of FGD type 2 
In 2005, Metherell et al. performed a whole genome scan using single 
nucleotide polymorphism (SNP) array genotyping in one highly consanginueous FGD 
family, with three affected individuals all with normal MC2R. A new FGD locus was 
mapped to chromosome 21q22.1 (Metherell et al., 2005). Examination of the tissue 
distribution of the genes expressed within the critical interval revealed a single 
candidate gene C21orf61 (subsequently renamed MRAP) that was highly expressed in 
the adrenal gland. mRNA expression was also detected in other tissues including testis, 
breast, thyroid, lymph node, ovary and in fat (Metherell et al., 2005). The human MRAP 
gene consists of six exons. Exons 5 and 6 are alternatively spliced resulting in two 
transcripts termed MRAPα (exons1-5) and MRAPβ (exons 1-4 & 6) (Fig. 1.4). DNA 
sequencing of MRAP in this and other FGD families led to the identification of a 
number of nonsense and splice site mutations (Fig. 1.5). 
When MRAP was discovered as the second genetic cause of FGD (FGD type 2), 
little was known about the MRAP protein. An earlier study described it as a small 
protein upregulated in a differentiating mouse adiposite derived cell-line (3T3-L1). Xu 
et al. had called this protein of uncertain function FALP (Fat tissue-specific low 
molecular weight protein) (Xu et al., 2002).  However, on the description of MRAP 
mutations in FGD patients, functional analysis as described in section 1.3.2 revealed 
that MRAP was an essential MC2R accessory protein. This led to the protein and gene 
being renamed MRAP for Melancortin-2-receptor accessory protein. MRAP is highly 
conserved between species in the N-terminus and transmembrane domain. It is now 
established that two translated MRAP isoforms are derived from alternative splicing of 
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the gene. The two isoforms MRAPα and MRAPβ differ only in the C-terminus and in 
humans are 19 kDa and 11.5 kDa in size respectively.  
The majority of MRAP mutations described to date are homozygous mutations 
(nonsense and splice-site mutations) that would result in the complete absence or severe 
truncation of the protein. In contrast, the majority of MC2R mutations are missense 
mutations (Modan-Moses et al., 2006; Chan et al., 2007; Chan et al., 2009a). FGD 
patients with MRAP mutations generally present very early in life relative to those with 
MC2R mutations (Chung et al., 2009). This reflects the nature of the mutations, i.e. the 
complete abolition of the MRAP protein compared to some residual function of the 
MC2R protein. To date, only two full length missense MRAP mutations have been 
identified: V26A and Y59D. Functional analysis demonstrates impaired, rather than 
absent, MC2R function with later age of onset of FGD type 2 (Hughes et al., 2009).  
 
 26
Introduction                    
Fig. 1.4: Diagram illustrating the transcription and translation of MRAP. Alternative splicing leads 
to the inclusion of exons 5 and 6 to generate the MRAPα and MRAPβ isoforms respectively. Protein 
prediction programmes suggest that the N-terminus of these proteins lie on the intracellular 
cytoplasmic surface of the membrane, however more recent data suggests a dual topology 
conformation (Sebag and Hinkle, 2007).  
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Fig. 1.5: Schematic representation of the human MRAPα protein showing the locations of 
mutations identified so far. The majority of the mutations result in complete absence or severe 
truncation of MRAP. Two missense mutations (Y59D and V26A) are exceptions and are associated 
with late onset FGD.  
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1.3.2 Structure and function of MRAP  
In the past, studies using the MC2R were hindered by the inability to express the 
receptor at the cell surface and consequently the failure to generate a downstream 
cAMP response to ACTH. Functional expression of MC2R in the absence of other 
melanocortin receptors was only possible in a limited number of cell-types, such as the 
Y6 and OS3 cell-lines that were derived from mouse adrenocortical tumours. In most 
cell-lines, transiently transfected MC2R is retained in the ER (Noon et al., 2002; 
Rached et al., 2005), whereas in Y6 or OS3 cells MC2R localises to the cell surface 
where it forms a functional ACTH responsive receptor (Elias et al., 1999). The inability 
 28
Introduction                    
of MC2R to reach the cell surface in non-adrenal cell-types led to the belief that an 
adrenal-specific accessory factor was required to facilitate MC2R trafficking (Noon et 
al., 2002). Therefore, the identification of MRAP as one of the genes underlying FGD, 
led to the hypothesis that MRAP was an MC2R trafficking factor (Metherell et al., 
2005).  
MRAP is a small transmembrane protein, as demonstrated by 
immun
othesis that MRAP was an MC2R accessory protein, reciprocal 
co-imm
s that 
endoge
etherell et al., Roy et al. suggested that 
althoug
ocytochemistry (Metherell et al., 2005). MRAP cell surface localisation is 
independent of the presence of MC2R (Metherell et al., 2005; Sebag and Hinkle, 2007; 
Cooray et al., 2008).  
To test the hyp
unoprecipitation was undertaken which demonstrated that MRAP and MC2R 
were able to form a complex. Furthermore, co-expression of MRAP and MC2R in non-
adrenal cells enabled the MC2R to localise to the cell surface. MRAP and MC2R not 
only co-localised at the cell surface of heterologous cells, but the presence of MRAP 
enabled MC2R to generate cAMP in response to ACTH (Metherell et al., 2005).  
Further studies were undertaken using mouse Y1 adrenocortical cell
nously express both MC2R and MRAP and show a cAMP response to ACTH 
stimulation. siRNA knockdown of endogenous mouse MRAP in Y1 cells resulted in a 
loss of responsiveness to ACTH. MC2R function was rescued with transient expression 
of human MRAP, which is resistant to silencing by mouse siRNA (Cooray et al., 2008). 
Taken together, these results indicate that MRAP was an essential factor for MC2R 
trafficking and subsequent function (Fig. 1.6).  
However, contrary to the findings of M
h MRAP enhanced MC2R cell surface expression in  HEK293/FRT cells, the 
detection by indirect immunofluorescence of a proportion of MC2R at the cell surface 
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in the absence of MRAP demonstrated that it was not absolutely essential (Roy et al., 
2007). In addition MRAP isoforms were localised near the plasma membrane but did 
not appear to co-localise with Myc tagged MC2R (Roy et al., 2007). There was, 
however, agreement that MRAP was essential for MC2R functioning as assessed by 
ACTH-induced cAMP production (Roy et al., 2007) and both human and mouse 
MRAPα can restore ACTH responsiveness in MC2R transfected HEK293 and SK-N-
SH (neuroblastoma derived) cells (Metherell et al., 2005; Chung et al., 2008; Webb et 
al., 2009).  
Both MRAPα and MRAPβ have been shown to increase MC2R cell surface 
expression and produce an ACTH responsive MC2R. Interestingly, MRAPβ was 
proposed to result in higher MC2R cell surface expression than MRAPα in both 
transiently transfected and stable cell-lines. This observation was reflected in greater 
cAMP production following ACTH stimulation in cells co-transfected with MC2R and 
MRAPβ, however, MRAPα transfected cells were more sensitive to low ACTH 
concentrations (Roy et al., 2007). The in vivo relevance of these observations is 
currently unclear. MRAPα and MRAPβ are expressed in the human adrenal gland at 
similar levels (Metherell et al., 2005), although it is not known whether expression 
changes with age or upon certain stresses or signals. 
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Fig. 1.6: MRAP is required for the functional expression of the MC2R. (A) Confocal microscopy 
demonstrating co-localisation of MRAP-FLAG and MC2R at the plasma membrane co-expressing 
CHO cells (indicated by arrows). ER retention of MC2R-GFP is seen in a cell not expressing 
MRAP. (B) Cell surface expression of MC2R-GFP is seen in cells co-expressing mMRAP and 
mMC2R cAMP generation in response to ACTH 10-6 M stimulation was seen in cells expressing 
both MC2R and MRAP but not in cells expressing, MC2R or MRAP alone or in mock transfected 
cells (Metherell et al., 2005; Cooray et al., 2008).  
 
                        
 
 
1.3.3 MRAP dual topology and secondary modifications  
Recent work suggests that MRAP exists as a unique dual topology homodimer 
(Sebag and Hinkle, 2007; Cooray et al., 2008). The mouse MRAPα protein has a 
predicted molecular weight of 14.1 kDa. However, by Western blot analysis against 
transiently transfected epitope tagged MRAP and using an MRAP antibody to detect 
endogenous protein, a band of over 30 kDa has been reported (Cooray et al., 2008). It 
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was suggested that this species represent an SDS resistant homodimer. Furthermore, 
differentially tagged MRAP proteins were able to interact and co-immunoprecipitate, 
demonstrating the ability to form homodimers (Cooray et al., 2008; Sebag and Hinkle, 
2007). Sebag and Hinkle were able to show that MRAP dimerisation adopted a dual 
antiparallel conformation. They showed that both N- and C-terminal epitope tagged 
MRAP was detected at the cell surface in non-permeabilised transfected cells in equal 
concentrations, indicating that both C- and N- terminal ends were extracellular. Using 
two different MRAP antibodies targetted at the C- and N-terminus, dual orientation of 
endogenous MRAP was shown in mouse adrenocortical Y1 cells. MRAP glycosylation 
studies provided further support. Glycosylation takes place in the lumen of the ER and 
since wild-type MRAP undergoes N-linked glycosylation at asparagine amino acid 
position 3, this would suggest an Nout orientiation. The engineered introduction of a 
glycosylation site in the C-terminus enabled demonstration of wild-type N-terminal 
glycosylation and C-terminal glycosylation together, hence supporting a Nout and Cout 
orientation of  the MRAP protein (Sebag and Hinkle, 2007). It also appears that this 
dual topology homodimer is in a stable complex with MC2R, as suggested by co-
immunoprecipitation studies. However, it is not yet known how MRAP forms this 
structure or its requirement in MC2R functional expression. Using a technique that 
involved co-transfection of N-terminal (yellow fluorescent protein) YFP1-MRAP and 
C-terminal tagged MRAP-YFP2, Sebag and Hinkle were able to demonstrate that these 
dual antiparallel orientation dimers were formed in the ER (Sebag and Hinkle, 2009b).  
Human MRAP with a triple FLAG epitope (MRAP-FLAG) has a predicted 
molecular weight of ~ 24 kDa, and the major band may correspond to an unmodified 
MRAP. MRAP-FLAG resolved as several bands between 16 kDa and 32 kDa on SDS-
PAGE (Webb et al., 2009). Like mouse MRAP, human MRAP contains a predicted N-
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glycosylation site at position Asn3, and glycosylated MRAP corresponds to the slowest 
migrating band detected. The other bands may correspond to post-translational 
modifications or, as some of the bands are smaller than the predicted molecular weight, 
cleavage products (Webb et al., 2009). However, specific immunoreactive species 
migrating at ~50 kDa were also detected, suggesting the presence of SDS resistant 
homodimers, consistent with previous studies (Cooray et al., 2008; Sebag and Hinkle, 
2007). 
 
1.3.4 MRAP functional domains   
MRAP has been shown to directly interact with MC2R and is required for 
trafficking of the receptor to the cell surface (Metherell et al., 2005; Sebag and Hinkle, 
2007). MRAP and MC2R are believed to form a heterodimer in the ER and at the cell 
surface, where they remain in a stable complex. To define MRAP functional domains 
responsible for interaction and functional expression of MC2R, Webb et al. created a 
series of human MRAP truncation constructs FLAG tagged at their C-terminus (Webb 
et al., 2009).  Each of the MRAP truncation constructs could be detected at the cell 
surface by immunofluorescence using the FLAG antibody on permeabilised cells. Co-
immunoprecipitation studies using these FLAG tagged MRAP truncation proteins and 
HA-MC2R mapped the MRAP/MC2R interaction domain to a 27 amino acid region 
between residues 36 and 62 of MRAP that consists almost entirely of the 
transmembrane domain (Webb et al., 2009). It is therefore likely that MRAP interacts 
with MC2R via hydrophobic interactions with one or more of its transmembrane 
domains. However, the ability of MRAP to interact with MC2R is not in itself sufficient 
to promote receptor trafficking.  
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Using confocal microscopy and a cell surface assay to assess receptor trafficking 
and a cAMP reporter assay following ACTH stimulation to gauge receptor function, the 
N-terminus of MRAP was identified as essential for MC2R trafficking. The key domain 
controlling trafficking is a 15 amino acid tyrosine rich region between residues 9 and 24 
of MRAP. It is not necessary for MRAP/MC2R interaction and it does not seem to be 
required for MRAP cell surface expression (Webb et al., 2009; Sebag and Hinkle, 
2009b). Sebag and Hinkle performed alanine-substitution of mouse MRAP amino acids 
18-21 (LDYI) and showed that in mutating these four residues, MRAP maintained the 
ability to traffic MC2R to the cell surface but the MC2R failed to signal and generate 
cAMP. This suggests that residues 18-21 of MRAP are important for ACTH binding 
and subsequent signalling (Sebag and Hinkle, 2009b). The separation of functions 
within accessory proteins is seen with other accessory proteins. For example in  
RAMPs, where deletion of amino acids 91-103 of RAMP1, 86-92 of RAMP2 and 59-65 
of RAMP3 results in an accessory protein that enables trafficking of CLR to the cell 
surface but not ligand binding or signalling (Parameswaran and Spielman, 2006; 
Kuwasako et al., 2003).  
Sebag and Hinkle also showed through generation of MRAP deletion constructs 
that MRAP amino acids 31-37 (LKANKHS), just proximal to the transmembrane 
domain, were required for dual topology (Sebag and Hinkle, 2009b). Deletion of these 
residues resulted in a single orientation of MRAP Nout/Cin. This deletion construct failed 
to traffic the MC2R to the cell surface and it was proposed that dual topology was a 
requirement to enable MC2R trafficking to the cell surface.  Transfer of MRAP amino 
acids 29-37 to RAMP3 protein enabled RAMP3 to adopt a dual topology conformation, 
indicating that this region is necessary and sufficient to transfer dual topology (Sebag 
and Hinkle, 2009b).  
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 MRAP constructs, in which the entire C-terminus was deleted, appeared to 
function normally. The C-terminus is therefore not required for MRAP to interact with 
MC2R or for MRAP to traffic MC2R to the cell surface. Instead, the MRAP C-terminal 
deletion construct resulted in significantly higher MC2R cell surface expression than 
wild-type MRAP. The C-terminus may therefore have a regulatory effect on the amount 
of MC2R that reaches the cell surface (Webb et al., 2009). This is supported by 
observations made by Roy et al. which showed that MRAPβ resulted in higher MC2R 
surface expression compared to MRAPα, which differed only in the C-terminus (Roy et 
al., 2007).  The enhanced trafficking seen with the C-terminal deletion construct is in 
contrast to previously published data using a mouse MRAP construct with a C-terminal 
deletion (Sebag and Hinkle, 2007). The mouse construct supported functional MC2R 
expression; however, no increase in MC2R at the cell surface was seen. This could 
either be explained by species differences or may be due to the presence of both N- and 
C-terminal epitope tags on the mouse MRAP fusion, which could impair or alter its 
function (Webb et al., 2009).  
 
1.4 GPCRs 
G protein-coupled receptors (GPCRs) are the largest group of cell surface 
receptors. GPCRs have seven transmembrane domains and are activated by an 
extracellular ligand which in turn activates a G protein that ultimately triggers a variety 
of signal transduction pathways (Pierce et al., 2002). GPCRs are responsible for a wide 
variety of physiological and disease states. GPCRs can be divided into group A, 
Rhodopsin like (which includes the MCR family), group B, Secretin like and group C,  
the metabotropic glutamate/pheromone group of receptors 
(http://www.gpcr.org/7tm/classes/), based on sequence similarities (Pierce et al., 2002).   
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1.4.1 Membrane trafficking of GPCRs 
Cell membrane localisation of GPCRs is essential for ligand binding and 
function. This requires GPCRs to assume a correct conformation before they are 
transported to the cell surface. Only a small percentage of GPCRs contain the N-
terminal signal peptides needed for translocation across the ER. On entering the ER, 
GPCR folding and assembly are monitored by its quality control system. Improperly 
folded proteins are retained for refolding or degradation by the ubiquitin-proteosome 
pathway (Castro-Fernandez et al., 2005; Conn et al., 2006).  
Inactivating mutations in GPCRs can lead to their intracellular retention and are 
known to give rise to a number of diseases including retinitis pigmentosa (rhodopsin 
receptor) (Humphries et al., 1992), hypogonadotropic hypogonadism (gonadotropin 
releasing hormone receptor) (Layman et al., 1998), X-linked nephrogenic diabetes 
insipidus (V2 vasopressin receptor) (Oksche and Rosenthal, 1998) and familial 
glucocorticoid deficiency (FGD) (melanocortin 2 receptor) (Metherell et al., 2005; 
Chung et al., 2008).  
There are many aspects to correct GPCR protein maturation and trafficking to 
the cell surface. For example, many GPCRs are able to form homo- and heterodimers 
with other GPCRs. It is recognised that this dimerisation process is necessary for GPCR 
quality control and export to the cell surface (Bulenger et al., 2005). MCRs themselves 
have been described to form homo- and heterodimers (Biebermann et al., 2003; 
Mandrika et al., 2005). Furthermore, GPCRs are able to interact with a plethora of 
proteins, other than G proteins or other GPCRs, that are vital for GPCR function, such 
as scaffolding proteins and accessory/chaperone molecules (Brady and Limbird, 2002).  
Molecular chaperones are a class of proteins that mediate the correct assembly 
and folding of proteins, hence forming a critical component of the ER quality control 
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system (Ellis, 1987). By interacting reversibly with incompletely folded protein 
subunits that emerge from ribosomes, chaperones act to minimise inappropriate 
interactions that can lead to irreversible and detrimental protein conformations 
(Jaenicke, 1995; Smith et al., 1998). Heat shock proteins (Hsps) are an example of such 
chaperones and act to resolve misfolded proteins at times of severe physical and 
chemical cellular stress such as elevated temperatures (Parsell and Lindquist, 1993).  
Accessory proteins are another growing class of proteins essential for GPCR cell 
surface localisation, and are described below. 
 
1.4.2 GPCR accessory proteins 
Accessory proteins are required for the functional expression of some GPCRs. 
These accessory proteins may have several roles including: (1) assisting the correct 
folding of GPCRs, (2) trafficking of GPCRs out of the ER to the cell surface, (3) 
forming part of the GPCR complex helping their retention at the cell surface during 
ligand binding, (4) conveying ligand specificity by either comprising part of the ligand 
binding pocket or by modulating the receptor conformation and (5) being part of the 
desensitisation and internalisation processes (Cooray et al., 2009).  
 
1.4.3 RAMPs and Calcitonin like receptor (CLR) (group B GPCR) 
The calcitonin like receptor (CLR) was identified in 1993 (Njuki et al., 1993). 
CLR shared 55% overall identity with the calcitonin receptor and was presumed to be 
the receptor for calcitonin gene-related peptide (CGRP). However, attempts to show 
that it was indeed the CGRP receptor were hampered by the failure to demonstrate any 
functional expression in transfected cells (Fluhmann et al., 1995). In 1998, McLatchie et 
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al. identified a novel single domain transmembrane protein in an attempt to clone the 
CGRP receptor (McLatchie et al., 1998). This protein was named RAMP1 (Receptor 
Activity Modifying Protein 1). Although McLatchie et al. showed that this was not the 
CGRP receptor itself, heterodimerisation of RAMP1 with CLR enabled the CLR to 
behave as a CGRP receptor. Further sequence data analysis led to the identification of 
other RAMP proteins, RAMP2 and RAMP3, which shared similar basic structure but 
only ~30% amino acid sequence identity. RAMP2 and 3 did not allow the CLR to 
behave as a CGRP receptor, despite being as effective as RAMP1 in the trafficking of 
the CLR to the cell surface (McLatchie et al., 1998). Since the CLR, which was 
expressed at the cell surface with the aid of RAMP2 and 3, was not a conventional 
CGRP receptor, it was hypothesised that another ligand might activate this receptor. 
Adrenomedullin (ADM) was explored as the potential ligand as ADM and CGRP are 
related peptides and there was evidence that both CGRP and ADM receptors may exist 
in the lung where CLR, RAMP2 and RAMP3 were co-expressed. When CLR was co-
expressed in HEK293 cells with RAMP2 or RAMP3 the cells responded preferentially 
to ADM and not to CGRP. 
In this way, RAMPs were acting as a group of small single transmembrane 
domain accessory proteins with the ability not only to traffic the CLR to the cell surface 
but also to determine ligand specificity (McLatchie et al., 1998; Parameswaran and 
Spielman, 2006). Further studies showed that RAMP1 was involved in the terminal 
glycosylation of CLR (Hilairet et al., 2001) and may be involved in CLR desensitisation 
and internalisation.  RAMPs are typical examples of accessory proteins that act as 
activity modifiers by either comprising part of the ligand-binding pocket or by 
modulating the receptor conformation. It has also been suggested that RAMPs may bind 
ligand directly since the partial deletion of the transmembrane domain of the RAMPs 
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has led to a significant loss in CGRP potency, despite normal trafficking of the receptor 
complex to the plasma membrane (Hilairet et al., 2001).  
RAMPs can also interact with the calcitonin receptor, allowing it to bind to 
amylin as well as calcitonin. In this case RAMPs are not required for the trafficking of 
the receptor and only act as activity modifiers (Christopoulos et al., 1999). RAMPs 1 
and 3 have also been shown to regulate the calcium sensing receptor (CasR), a class C 
GPCR, from the ER to the Golgi and to mediate the terminal glycosylation of the 
receptor (Bouschet et al., 2005). Several other members of the class B family of GPCRs 
have also been shown to interact with RAMP proteins (Christopoulos et al., 2003).  
 
1.4.4 Odorant receptors, ODR 4, RTPs 1/2 and REEP1 
The olfactory receptors (ORs) are a large and diverse group of GPCRs. ORs are 
poorly expressed at the cell surface in heterologous cells and are usually retained at the 
ER. In 1998, Odorant defective receptor protein (ODR-4) was identified as being 
necessary for the efficient targeting of odorant receptors to olfactory cilia in C. elegans 
chemosensory neurons (Dwyer et al., 1998). ODR-4 was thought to act as a molecular 
chaperone for the receptor by supporting its folding. It has also been suggested that 
ODR-4 may have an effect on facilitating cell surface expression of one rat OR but not 
another (Gimelbrant et al., 1999).  
In an attempt to identify accessory proteins for mammalian ORs, receptor 
transporting proteins 1 and 2 (RTP1 and RTP2) which are expressed specifically by 
olfactory neurons were identified (Saito et al., 2004). The RTP1 protein is 263 amino 
acids in length while RTP2 is 223 amino acids in length, and they share 73% sequence 
identity at the amino acid level. Both proteins contain a single putative transmembrane 
domain and immunostaining experiments have revealed that the N-terminus is 
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intracellular while the C-terminal end is extracellular. They were found to interact with 
OR proteins (MOR203-1, OREG, OR-S46, olfr62 and rat 17) and enhance response to 
odorants when expressed in HEK293 cells (Saito et al., 2004). 
Another olfactory neuron specific protein, named receptor expression enhancing 
protein (REEP1), was shown to have a positive effect on expression of these ORs 
although it was found to be less effective than the RTPs. The REEP1 gene encodes a 
201 amino acid protein with two putative transmembrane domains. The C-terminus of 
REEP1 is suggested to be extracellular (Saito et al., 2004). However, REEP1 was 
recently shown to be localised to the mitochondria and mutations in REEP1 were found 
to be associated with hereditary spastic paraplegia (Zuchner et al., 2006). Another study 
showed that two other members of the RTP protein family, RTP3 and 4, as well as 
REEP1, can influence the cell surface trafficking of the bitter taste receptors hTAS2R16 
(Behrens et al., 2006). It was suggested that RTP1, RTP2 and REEP1 may function as 
molecular chaperones promoting the correct folding of ORs and taste receptors at the 
ER. In addition, these proteins may also facilitate the transport of ORs from the ER to 
the cell surface and/or even be associated as a co-receptor with ORs during ligand 
binding. 
 
1.4.5 Rhodopsin receptors, ninaA and RanBP2 
Rh1, which is the predominant rhodopsin in Drosophila, is synthesised in the 
ER of photoreceptor cells. From here it is transported via the secretory pathway to the 
rhabdomeres where it functions in phototransduction. The Drosophila cyclophilin gene 
ninaA (neither inactivation nor after potential A) encodes an integral membrane protein 
that is necessary for the biogenesis of rhodopsin. Immunocytochemistry and 
biochemical studies demonstrated that Rh1 accumulates in the ER and is unable to be 
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transported to the rabdomeres in the absence of ninaA (Colley et al., 1991). NinaA and 
rhodopsin co-localise in transport vesicles (Colley et al., 1991). This led to the 
suggestion that ninaA acts as a molecular chaperone which may be required for the 
proper synthesis, folding or stability of rhodopsin (Baker et al., 1994). In addition to this 
role, ninaA may act in escorting rhodopsin through the secretory pathway (Baker et al., 
1994). 
RanBP2 (Ran binding protein 2), which is the mammalian homologue of ninaA, 
is also expressed in a tissue specific manner in photoreceptor cells. The two contiguous 
domains in RanBP2, RBD4 (Ran binding domain 4) and cyclophilin, are believed to act 
as chaperones for the red/green opsin. However, unlike ninaA, the cyclophilin domain 
of RanBP2 does not bind opsin directly. Nevertheless, it is found to mediate the 
interaction between RBD4 and opsins, thereby probably acting as a chaperone in the 
processing and transport of opsins (Colley et al., 1991; Ferreira et al., 1996). 
 
1.4.6 Dopamine receptor and DRiP78 
Dopamine receptor interacting protein 78 (DRiP78), an ER membrane 
associated protein, is another protein that is implicated as an accessory protein, in this 
case for the trafficking of the D1 dopamine receptor (Bermak et al., 2001). DRiP78, 
also known as DnaJc14/DnaJ (Hsp40) homologue, subfamily C, member 14, contains 
two centrally located transmembrane domains with a putative cytosolic orientation for 
both the N- and C-termini. DRiP78 is found to bind to the transport motif FxxxFxxxF 
within the C terminus of the D1 dopamine receptor at the ER, and promotes its 
trafficking. Because this DRiP78 binding motif within the C-terminus is conserved in 
many GPCRs it has been suggested that DRiP78 may also regulate the export of other 
GPCRs. More recent studies have demonstrated a role for DRiP78 in the trafficking of 
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AT1 angiotensin II receptors and M2 muscarinic acetylcholine receptors to the plasma 
membrane (Leclerc et al., 2002). It was recently suggested that DRiP78 also plays a role 
as a molecular chaperone in the assembly of the G protein subunits Gβ/γ by protecting 
Gγ from degradation until it associates appropriately with the Gβ subunit (Dupre et al., 
2007).  
1.4.7 MRAP and other GPCR accessory proteins 
MRAP, being a small transmembrane protein capable of forming a complex 
with MC2R which allows this receptor to traffic to the cell surface for normal function 
(Metherell et al., 2005), shares some functional similarity with the other accessory 
proteins described above (Cooray et al., 2008).  However, unlike the RAMPs 
(McLatchie et al., 1998), there is no evidence so far that MRAP can affect ligand 
selectivity of the MC2R. The presence of MRAP did not allow MC2R to respond to 
NDP-MSH (Sebag and Hinkle, 2009b). Another similarity to the RAMPs is the ability 
to homodimerise, although the functional importance of this has yet to be fully 
characterised (Sebag and Hinkle, 2007; Cooray et al., 2008). Despite functional 
similarities, MRAP shares no sequence homology with the RTPs, REEPS or RAMPs 
and hence provides no indication that they function by a common mechanism. REEP1 
does have a tyrosine rich region in its N-terminus, like MRAP (Saito et al., 2004; Webb 
et al., 2009). It is therefore possible that a tyrosine rich domain may be a feature of 
some proteins involved in GPCR trafficking. The identification of the MRAP 
transmembrane domain as the site of MRAP/MC2R interaction also highlights 
differences between the mechanisms of MRAP and the RAMPs. For RAMP1 it is the 
large extracellular N-terminal domain that has been shown to be sufficient for its 
interaction with the CLR (Steiner et al., 2002; Fitzsimmons et al., 2003; Ittner et al., 
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2004; Hay et al., 2006). RAMPs contain a signal polypeptide and are orientated with 
their N-terminus outside the cell. In contrast, MRAP contains no signal peptide.  
 There are also differences in protein topology between these accessory proteins. 
RTPs and REEPs are found at the cell surface with their N-terminus on the inside of the 
cell and their C-terminus on the outside of the cell. Until recently MRAP was thought to 
be a type II transmembrane protein with an extracellular C-terminal. However, Sebag 
and Hinkle showed that MRAP forms unique antiparallel homodimers at the cell surface 
(Sebag and Hinkle, 2007) (Fig. 1.7). 
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Fig. 1.7: Membrane associated accessory proteins involved in the trafficking of GPCRs from the ER 
to the cell surface. DRiP78 (containing two transmembrane domains) is involved in trafficking of 
dopamine D1 receptor. ninaA is required for Drosophila rhodopsin whilst its mammalian 
homologue RanBP2 assists the trafficking of mammalian opsins. RAMPs which possess single 
transmembrane domains are known to exist as dimers at the ER and are required for the function 
of the CLR. RAMPs have Nout/Cin orientation. Several mammalian odorant receptors require the 
single transmembrane domain proteins RTP1 and 2 (Nin/Cout orientation) and are linked to a 
weaker extent with REEP1 containing two transmembrane domains. ODR4 enhances the function 
of the C. elegans odorant receptors. MRAP which is also a small single transmembrane protein is 
essential for the function of the melanocortin 2 receptor and is known to exist as dual topology 
homodimers. Image from (Cooray et al., 2009). 
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1.5 Other Melanocortin receptor regulatory proteins - Agouti and 
Agouti-related peptide (AGRP)  
The mouse agouti gene was cloned in 1992 and shown to encode a small 131 
amino acid secreted protein (Bultman et al., 1992; Miller et al., 1993). The human gene 
located on 20q13, was shown to encode a highly conserved 130 amino acid protein 
(Kwon et al., 1994; Wilson et al., 1995). It was long known that the agouti loci was 
involved in the regulation of coat colour in mice (Wilkison, 2000). Following the 
discovery of the MC1R in the same year and the finding that agouti was a small 
secreted protein, it was hypothesised that agouti may act as an antagonist for the MC1R 
(Robbins et al., 1993). In mice, agouti has limited expression  primarily in skin, whilst 
in humans mRNA is detectable in testis, foreskin and adipose tissue (Bultman et al., 
1992; Miller et al., 1993). Following the production of recombinant agouti protein, it 
was possible to show that agouti was indeed an endogenous antagonist for the MC1R 
(Lu et al., 1994). Furthermore, no activity was seen with the MC3R and MC5R but 
potent antagonistic effects were observed with the MC4R (Lu et al., 1994). The MC4R 
antagonism was interesting and led to the hypothesis that this could explain the so 
called ‘agouti obesity syndrome’ observed in mice with dominant alleles at the agouti 
locus, where upregulation of agouti expression occurs (Lu et al., 1994; Cone, 2006). 
Agouti was the first high affinity endogenous GPCR antagonist to be described. Inverse 
agonistic effects, with inhibition of constitutively active MC1R, have been observed in 
some animals such as the fox (Vage et al., 1997). The expression of agouti in adipocytes 
is interesting and suggests a role independent of MC1R and MC4R. Neither of these 
two MCRs are expressed in adipocytes (Boston and Cone, 1996; Mynatt et al., 1997).  
 45
Introduction                    
As agouti was expressed in skin, it did not explain its effects on the centrally 
expressed MC4R. However, the discovery of a brain homologue of agouti, Agouti-
related peptide (AGRP), provided an explanation (Ollmann et al., 1997; Shutter et al., 
1997). AGRP is a 132 amino acid long peptide 80% identical to agouti in the cysteine-
rich C-terminal domain and contains a signal peptide, but is largely unrelated to agouti 
in the N-terminus. AGRP is expressed in the arcuate nucleus, almost exclusively in 
neuropeptide Y positive neurons (Shutter et al., 1997; Ollmann et al., 1997; Chen et al., 
1999; Haskell-Luevano et al., 1999). AGRP expression is also found in the adrenal 
cortex and medulla (Ollmann et al., 1997; Shutter et al., 1997). The role of AGRP is yet 
unknown, but does not appear to be related to MC2R function (Doghman et al., 2004). 
Doghman et al. suggested that AGRP may play a role in MC4R/MC3R dependent 
adrenal steroidogenesis (Doghman et al., 2004; Doghman et al., 2007), but data 
supporting this is sparse. Using recombinant AGRP peptide, several groups showed that 
AGRP was a specific high affinity competitive antagonist of MC3R and MC4R 
(Ollmann et al., 1997; Fong et al., 1997; Yang et al., 1999). One group demonstrated 
limited antagonistic effects on MC5R (Yang et al., 1999). Subsequently, AGRP was 
shown to act as an inverse agonist with the ability to inhibit basal, agonist-independent 
receptor activity (Nijenhuis et al., 2001; Breit et al., 2006). Binding affinity was 
localised to C-terminal amino acids 83-132 and AGRP[83-132] was capable of 
stimulating food intake in rats following direct administration into the third ventricle 
(Rossi et al., 1998). Transgenic mice, where AGRP expression is driven by the β-actin 
promoter, develop obesity similar to that seen with agouti obesity syndrome (Ollmann 
et al., 1997; Graham et al., 1997). Increased AGRP expression is seen in leptin deficient 
ob/ob mice (Graham et al., 1997), as well as in wild-type mice fasted for 48 hrs 
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(Mizuno and Mobbs, 1999) and reduced expression  is seen in anorectic anx/anx mice 
(Broberger et al., 1997).  
 
1.6 MRAP2 
1.6.1 Identification, gene/protein prediction and conservation 
Sequence analysis of the human genome showed that MRAP was similar to 
another putative protein encoded by gene C6orf117, located on chromosome 6q14.3, 
which has been renamed MRAP2 (Metherell et al., 2005; Chan et al., 2009c). The 
human MRAP2 gene consists of four exons (three are coding) and its protein product 
comprises 205 amino acid residues, with a predicted molecular weight of 23.5 kDa (Fig. 
1.8 [A]). MRAP2 is also a small single pass transmembrane domain protein 
homologous to MRAP, with 39% amino-acid identity to MRAP in the N-terminal and 
transmembrane domains (Fig. 1.8 [B]). A putative N-linked glycosylation site with the 
consensus sequence NRTS was identified at amino acid positions 9-12 (Fig. 1.8 [A]).  
MRAP2 is highly conserved through vertebrates (Fig. 1.8 [C]), and like MRAP 
has no predicted signal sequence. Conservation between species of MRAP2 is much 
higher than MRAP with 87% sequence identity between human and mouse, and 44% 
identity between human and fugu MRAP2. Interestingly, the MRAP2 gene has been 
duplicated in zebrafish. The two copies, one transcribed from chromosome 4 and one 
from chromosome 16, show 46% and 52% sequence identity to human MRAP2. In 
comparison, MRAP shows little conservation in either gene structure or protein 
sequence. There is only 63% sequence identity between human MRAPα and mouse 
MRAP, with most of the homology covering the N-terminus and transmembrane 
regions.  
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1.6.2 Nomenclature used in the study 
Following submission of the data presented in chapter 4 of this thesis, C6orf117 
has now been officially renamed MRAP2 (Melanocortin-2-receptor accessory protein 2) 
by the HUGO Gene Nomenclature Committee. In 2005, Metherell et al. suggested the 
presence of two human isoforms of MRAP2 (Metherell et al., 2005). In this study 
MRAP2 refers to the alpha isoform, unless stated otherwise. Similarly MRAP refers to 
the alpha isoform of MRAP.   
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Fig. 1.8: MRAP2 encodes a glycosylated single transmembrane protein (A) Schematic diagram of 
the human MRAP2 gene and protein. Illustrations of gene and protein are not to scale. (B) Protein 
alignment of human MRAP isoforms and human MRAP2. The highest level of sequence identity is 
in the N-terminal and transmembrane domains. Transmembrane domain is underlined. (C) Protein 
alignment of MRAP2 orthologues: Hs; homo sapiens, Mm; Mus musculus, Rn; Rattus norvegicus, 
Gg; Gallus gallus, Xt; Xenopus tropicalis, and Dr; Danio rerio showing conservation of MRAP2 
across vertebrates.   
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1.7 Hypothesis and Aims 
The clinical phenotype of FGD patients suggests that MRAP is specific to the 
MC2R, as no other clinical defects are apparent. Therefore, the hypothesis proposed was 
that MRAP2 was a melanocortin receptor accessory protein for one or more of the other 
melanocortin receptors. The other MCRs are known to traffic to the cell surface in 
heterologous cell-lines. However, there is some suggestion that both the MC1R and 
MC4R may require assistance in cell surface trafficking, and specific trafficking factors 
have been postulated (Beaumont et al., 2005; VanLeeuwen et al., 2003). To show that 
MRAP2 is an MCR accessory protein the following was undertaken: (1) analysis of 
MRAP2 expression (mRNA and protein), (2) proof of direct interaction with other 
melanocortin receptors by co-immunoprecipitation and (3) demonstration of the 
functional consequence of this interaction in the generation of cAMP or the trafficking 
of the receptor to the cell surface. If the hypothesis is correct, then MRAP2 could be 
involved in mechanisms and diseases associated with defects in melanocortin signalling 
pathways. 
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2.1 Equipment, reagents and plasticware 
Details of laboratory equipment are listed in the Appendix 1. General laboratory 
reagents and chemicals were purchased from Sigma-Aldrich, UK and general 
plasticware from VWR, UK unless stated otherwise. General buffers and solutions were 
prepared in deionised water and autoclaved or filtered where necessary.  
 
2.2 Nucleic acid amplification, extraction, purification and 
modification 
2.2.1 Oligonucleotide design 
After establishing the gene sequence of interest using internet databases NCBI and 
ENSEMBL, primer pairs were designed according to the basic principles listed below:  
• Primers should ideally be 17-25 bp in length  
• Sequences should be non-repetitive and non-palindromic  
• G/C content should designed to be 40-60% 
• Forward and reverse primers should anneal at approximately the same 
temperature  
• Tm should be between 58 and 68˚C and is calculated (approximately) as follows: 
Melting temperature (˚C) = (number of C/G bases) x 4 + (number of A/T bases) 
x 2 
• Primers should not form secondary structures  
Primers used in RT-PCR were intron-spanning to ensure the PCR reaction amplified 
only cDNA and not contaminating genomic DNA. Primers designed for cloning of 
MRAP2-FLAG and MYC-MRAP2 involved incorporation of DNA sequence that 
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translates to a FLAG or MYC tag protein sequence respectively. Primers used for site-
directed mutagenesis were created with the help of Stratagene’s web-based 
QuikChange® program (http://www.stratagene.com/qcprimerdesign). Primer sequences 
are shown in Appendix 4.  
 
2.2.2 Extraction of RNA from tissues  
2.2.2.1 Human RNA 
A cDNA panel derived from a variety of adult human tissues was obtained as described 
by Gnanapavan et al. (Gnanapavan et al., 2002).  
2.2.2.2 Total RNA extraction from animal tissues 
Animal tissues were collected in liquid nitrogen and stored at -70°C until the extraction 
procedure. Equipment and work surfaces were treated with RNaseZAP® and RNase-
free water was used where necessary to minimise the degradation of extracted RNA by 
RNases. 10 mg of tissue was either homogenised using a rotator homogeniser in 350 μl 
of RLT lysis buffer (Qiagen, UK) or ground to a powder using a pestle and mortar in 
liquid nitrogen with subsequent suspension into 350 μl lysis buffer. The mixture was 
passed through a 25G needle and syringed five times. Samples were centrifuged at 
14000 rpm for 3 min. The supernatants were transferred to new tubes, 350 µl of 70% 
ethanol added and mixed thoroughly. RNA extraction proceeded using the RNAeasy 
(Qiagen, UK) kit according to manufacturer’s instructions. This extraction technique is 
based on selective binding of RNA to a silica gel based membrane, hence enabling wash 
steps to remove contaminants such as DNA and protein. In brief, the samples 
(approximately 700 μl) were applied to an RNAeasy mini column in a 2 ml collection 
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tube and centrifuged for 15 sec at 14000 rpm. The flow-through was discarded and the 
column transferred to a new collection tube and washed with 700 μl of Buffer RW1 
after transfer to a new collection tube. 500 μl of Buffer RPE was added and centrifuged 
for 2 min at 14000 rpm. This step was repeated, followed by centrifuging the column 
alone at 14000 rpm for 1 min to dry the silica-gel membrane. The RNA was eluted into 
a new 1.5 ml collection tube using 30-50 μl RNase-free water directly pipetted onto the 
membrane and left for 1 min before centrifuging at 14000 rpm for 1 min. RNA 
collected was quantified using the Nanodrop ND 1000 spectrophotometer.  
 
2.2.3 DNase treatment of RNA 
To ensure that the RNA sample was not contaminated with genomic DNA, total RNA 
extracts underwent DNase treatment (reagents were obtained from Promega, UK unless 
specified). Essentially 2.5 μg total RNA was added to 2 μl 10x RQ1 DNase buffer, 0.75 
μl (30 units) RNasin, 10 μl (10 units) DNAseI and made up to 20 μl total volume using 
RNase-free water. The mixture was incubated at 37˚C for 1 hr. The samples were either 
frozen to stop the reaction or phenol extracted as described in section 2.2.8.  
 
2.2.4 First strand cDNA synthesis  
All reagents were purchased from Promega, UK. 2 µg of RNA was added to a sterile 
RNase-free microcentrifuge tube. 0.5 µg/1 μl of random primers was added and a total 
volume made up to a total of 15 µl with RNase-free water. The tube was heated to 70°C 
for 5 min to melt secondary structures within the template. The tube was cooled 
immediately on ice to prevent secondary structures reforming. It was spun briefly to 
collect the solution at the bottom of the tube.  
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The following were added to the mixture:  
 
M-MLV 5X buffer       5 µl 
dATP, 10 mM        1.25 µl 
dCTP, 10 mM        1.25 µl 
dGTP, 10 mM        1.25 µl 
dTTP, 10 mM        1.25 µl  
rRNasin ® ribonuclease inhibitor      25 units (1 µl) 
M-MLV reverse transcriptase(Molony murine leukemia virus) 200 units (1µl) 
Nuclease-free water to final volume      25 µl  
The reaction was mixed gently, spun briefly and incubated at 37°C for 1hr. Samples 
were either stored at -20˚C or used immediately.  
 
2.2.5 Polymerase Chain Reaction (PCR) 
PCR was performed to amplify genes of interest. The basic principle involves 
denaturing double stranded DNA at high temperatures, ~95˚C. This is followed by 
annealing of sequence-specific oligonucleotide primers typically at temperatures 50-
60˚C before synthesis of complementary DNA strands from 5’ to 3’ by a thermostable 
polymerase. Repeated cycles allow exponential multiplication of a specific portion of 
DNA.  
 55
Materials and Methods                    
A PCR reaction mixture, typically in a total volume of 25 μl was as follows:  
 
Template      0.5-1 µl 
dH2O      19.75-20.25 µl 
10Xbuffer     2.5 µl  
dNTPs (10 mM)    0.5 µl  
Primer 1 – Forward (10 µM)   0.5 µl  
Primer 2 – Reverse (10 µM)   0.5 µl 
Taq DNA polymerase (5 U/µl)  0.25 µl    
Total volume     25 µl 
 
PCR automated cycling was typically carried out as follows. After the initial 
denaturation at 95°C for 5 min, a touchdown program was used i.e. 16 cycles of 95°C 
for 30 sec, x°C for 30 sec and 72°C for 1 min (where x was 65°C for the first cycle and 
decreased by 1°C with each cycle). This was followed by 25 cycles of 95°C for 30 sec, 
45°C for 30 sec and 72°C for 1 min, with a final extension step at 72°C for 5 min.  
 
2.2.6 Agarose gel electrophoresis  
All PCR products were run on 1-2% (w/v) agarose gel made in 1X TAE (40 mM Tris-
acetate, 2 mM disodium ethylenediaminetetraacetate (Na2EDTA), pH 8.3; National 
Diagnostics, UK), and visualised along side DNA markers (GeneRulerTM DNA Ladder 
Mix, 0.5 mg DNA/ml, Fermentas) with ethidium bromide (0.2 μg/ml) staining. Usually 
5 μl of each reaction was mixed with loading dye solution (40% w/v sucrose, 0.25% 
w/v bromophenol blue or Orange G, DEPC water) at a 1:5 ratio prior to loading the 
wells of a 1% (w/v) agarose gel. Electrophoresis was typically carried out at 120V for 
30 min or until clear separation of bands was achieved. Ethidium bromide intercalated 
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into DNA will fluoresce under UV light at 300 nm, allowing the DNA to be visualised. 
An Uvitec transluminator was used to visualise bands, and capture an image of the 
resultant gel.  
 
The separation of RNA on a gel was performed in equipment (gel tank, comb, gel cast) 
treated for 30 min with a solution of 0.1 M NaOH and 0.5 M ethylenediaminetetraacetic 
acid (EDTA) to remove RNases that might degrade the RNA. 1 μl of RNA was mixed 
with 5 μl of orange G loading dye and loaded into the wells of the agarose gel (typically 
1% w/v). For all work with RNA, RNase-free water/DEPC water was used. DEPC 
water was prepared by adding 1 ml of diethyl pyrocarbonate 1 litre of distilled water. 
The solution was incubated for 12-24 hr at 37 ºC and then autoclaved. 
 
2.2.7 Extraction of DNA from agarose gels 
DNA was extracted from gel slices using the QIAquick® Gel Extraction Kit (Qiagen, 
UK) according to the manufacturer’s instructions. In brief, the DNA fragment of interest 
was visualised under UV light, and excised with a sharp clean blade. The gel slice was 
weighed in a microcentrifuge tube and the volume estimated, assuming 100 mg = 100 
µl. 3 x volume of buffer QG (binding and solubilisation buffer) was added to 1 volume 
of gel. The sample was incubated at 50°C, vortexing intermittently until complete gel 
solubilisation was achieved. The sample was applied to the QIAquick column and 
centrifuged for 1 min at 13000 rpm. The flow-through was collected and discarded. The 
column was washed with 0.75 ml of buffer PE and centrifuged at 13000 rpm for a 
further minute. The column was placed in a clean microcentrifuge tube and allowed to 
dry at room temperature for 2 min. Using 30-50 µl dH2O applied to the membrane the 
DNA sample was eluted by centrifugation at 13000 rpm for 1 minute. The exact 
 57
Materials and Methods                    
composition of buffers is unavailable but the principle of QIAquick is based on binding 
properties of DNA to a silica membrane in the presence of high salt buffer. This allows 
washes with high salt buffers to remove impurities and contaminants, and elution of 
DNA from the membrane is then accomplished with low salt concentrations. Extracted 
DNA was stored at -20°C.  
 
2.2.8 Nucleic acid precipitation 
An equal volume of phenol was added to the nucleic acid solution. The sample was 
mixed vigorously to create an emulsion and centrifuged for 5 min at 13000 rpm to 
separate the nucleic acids (upper aqueous phase) from contaminating proteins, lipids 
and carbohydrates (in phenol phase). The clear upper phase was carefully removed and 
placed in a new RNase/DNase-free microcentrifuge tube. Precipitation of nucleic acids 
was performed by the addition of 1/10th volume of 3 M sodium acetate pH 5.3, 2.5 
volume absolute ethanol and 1 μl glycogen (5 mg/ml). The solution was mixed, 
vortexed briefly and incubated at -70˚C for a minimum of 15 min and a maximum 
overnight to precipitate nucleic acids. Precipitated nucleic acids were centrifuged at 
13000 rpm for 10 min. After visualisation of the pellet, the supernatant was carefully 
removed by pipetting. The pellet was washed with 70% ethanol and centrifuged again 
for a further 10 min at maximum speed. After removal of the ethanol, the pellet was air-
dried and resuspended in 10 μl of RNase/DNase-free water.    
 
2.2.9 Determination of Nucleic Acid concentration and purity 
The concentration of RNA or DNA in solution was determined by optical density (OD) 
at 260 nm using a DNA quantifier, Genequant (Pharmacia Biotech, UK). Several 
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dilutions of the sample were made. The basal reading of the spectrophotometer was 
established by filling the curvette with dH2O and taking a reading. Taking an average of 
three readings the DNA or RNA yield was calculated using one of the following 
formulae:  
Concentration of dsDNA (µg /ml) = 50 µg /ml x absorbance at 260nm x dilution 
Concentration of RNA (µg /ml) = 40 µg /ml x absorbance at 260nm x dilution  
Ensuring that OD readings at 260 nm were between 0.2 and 0.8 (the linear range of the 
spectrophotometer).  
OD260/OD280 ratios were used to determine the purity of the sample.  
Pure DNA and RNA have ratios of 1.8 and 2.0 respectively. Ratios <1.8 indicate that 
the sample may be contaminated with protein whereas ratios >2.0 may mean that the 
sample is contaminated with chemicals. In addition, the NanoDrop ND-100 
spectrophotometer (Labtech International, UK) was also used to quantify nucleic acid 
concentration in accordance with the manufacturer’s instructions.  
 
2.2.10  DNA sequencing 
Sequencing of PCR products or clones was performed to ensure that they were specific. 
Sequencing was performed by the Genome Centre (Bart’s and The London, Queen 
Mary, University of London) using BigDye 3.1 chemistry (Applied Biosystems, UK), 
which is based on the Sanger dideoy-mediated chain termination method (Sanger et al., 
1977). Analysis of sequence chromatograms was carried out using BioEdit (Hall, 1999). 
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2.3 Plasmid preparation, propagation and modification  
2.3.1 Cloning constructs and design of oligonucleotides 
Two sets of primers to human MRAP2 were designed, one to introduce a FLAG tag 
(DYKDDDDK) on the C-terminus and the other a MYC tag (EQKLISEEDL) on the N-
terminus. Enzyme cutting sites (Xho1 and EcoR1) were also incorporated into the 
primer sequences to enable direct cloning into the mammalian vector pcDNA3.1(+) 
(Invitrogen, Carlsbad, CA) in the correct orientation. RT-PCR was performed as 
previously described (section 2.2.5) using human brain cDNA as a template 
(Gnanapavan et al., 2002). The PCR product was cloned into the mammalian vector. 
cDNA clones for human MCRs (MC1R-MC5R) and other GPCRs triple HA tagged at 
the N-terminus (including angiotensin I receptor,  β2Adrenergic receptor and calcitonin-
like receptor) were obtained from the Missouri S&T cDNA Resource Center 
(www.cdna.org).  
Primers used include:  
F–5’ATCGGAATTCATGTCCGCCCAGAGGTTA 3’,  
R-5’ 
AATCTCGAGTCACTTGTCATCGTCGTCCTTGTAGTCATCCAGGTCTTTGTGTG
A 3’ for MRAP2-FLAG,  
and  
F – 5’ 
ATCGGAATTCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGATGTCCGC
CCAGAGGTTA 3’ and R- 5’ AATCTCGAGTCAATCCAGGTCTTTGTGTGA 3’ for 
MYC-MRAP2.  
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Other basic vectors used in this study included pGEM®-T Easy (Promega, UK) and 
pEGFP-N1 (Clontech). Vector maps are shown in Appendix 3. Rhodopsin and MRAP-
FLAG vectors were obtained from Prof Mike Cheetham and Dr Tom Webb respectively 
(Saliba et al., 2002; Webb et al., 2009). MRAP-FLAG was constructed by directional 
cloning of human MRAPα into p3xFLAG-CMV-14 expression vector (Webb et al., 
2009). All constructs were confirmed by sequencing.  
 
2.3.2 Restriction endonuclease digestion 
Restriction endonuclease digestion was used as part of the cloning strategy, to linearise 
vectors and to verify the presence and orientation of a given insert in a particular vector. 
Enzymes were obtained from New England Biolabs (NEB) or Promega, UK.  A typical 
reaction is shown below.  
DNA      1 µg  
10X reaction buffer    5 µl 
Restriction enzyme (2-10U/µl)  1 µl  
dH2O to a final volume of    50 µl 
 
Digests were typically performed for 2 hr at 37°C. The program NEB CUTTER V2.0 
was used to determine enzyme restriction sites. Double digests were performed in a 
similar manner in either a one or two step procedure; the reaction buffers were selected 
using information available from manufacturers.  
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2.3.3 Ligations 
Ligation reactions were set up as follows:  
T4 DNA Ligase (1-3 U/μl ; Promega, UK)   1 µl 
T4 DNA Ligase 10X buffer (Promega, UK)   1 µl  
(300 mM Tris-HCl (pH 7.8 at 25°C), 100 mM MgCl2, 100 mM DTT and 10 mM ATP) 
*Vector        1 µl 
Insert DNA       x µl 
dH2O to a final volume of      10 μl   
 
*the vector was digested with relevant enzymes and run on an agarose gel to ensure 
linearisation. The digested vector was gel cleaned as described in section 2.2.7, prior to 
ligation. The ligation reaction was left overnight at 16°C. The ratio of insert/vector 
DNA was varied for optimal ligation using the following equation as a guide, where x is 
the optimal amount of insert DNA.  
 
ng of vector x kb size of insert  ×  molar ratio of  insert  = ng of insert  (x) 
kb size of vector                             vector 
 
For example: A molar ratio for a 5.5 kb plasmid and a 600 bp insert DNA fragment at 
an insert: vector ratio of 3:1 would be as follows:  
100ng vector x 0.6 kb insert           ×                     3  =  33 ng of insert 
5.5 kb vector                 1  
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2.3.4 Transformation of competent bacteria 
Transformations were undertaken according to the protocol provided with JM109 E.coli 
competent cells (Promega, UK or Stratgene, USA). For each transformation a 50 µl 
aliquot of competent cells was transferred to a sterile 15 ml round bottom Falcon tube. 5 
µl of ligation mixture was added to the cells. The sample was placed on ice for 10 min 
and swirled intermittently. The cells were heat shocked at 42°C for 47 sec and returned 
immediately to ice for 2 min. 950 µl of SOC medium (Invitrogen Ltd, UK) was added 
to each tube and incubated at 37°C for 1 hr at 225 rpm. Following this, the cells were 
centrifuged for 10 min at 2000 rpm. The supernatant was poured away under sterile 
conditions and the remaining cells resuspended in the residual SOC media, 
approximately 100 µl. This was plated using a sterile glass spreader onto a LB/agar 
plate with 100 µg/ml ampicillin plate (or 30 µg/ml kanamycin) and incubated overnight 
at 37°C. A positive control using the vector pGEM®-3Z (Promega, UK) was conducted 
for each set of ligations using control plasmid to assess transformation efficiency of 
cells.  
 
2.3.5 Blue/white screening 
In the case of the pGEM®-T Easy, cells were plated onto agar plates previously coated 
with 50 µl of 50 mg/ml X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside, 
Promega, UK) and 100 µl of 0.1 M Isopropylβ-D-1-thiogalactopyranoside (IPTG) 
(Promega, UK). The pGEM®-T Easy vector contains a segment of the LacZ gene that 
encodes the amino terminal fragment of the β-galactosidase enzyme that converts X-Gal 
into a blue product. Insertion of a piece of DNA into the multiple cloning site, which 
lies within the LacZ gene segment, would result in disruption of this gene and therefore 
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prevent the production of the β-galactosidase enzyme fragment. Hence, bacteria with 
plasmids containing the desired DNA insert would fail to metabolise X-Gal and remain 
white. On this basis the white colonies were picked after overnight incubation.  
 
2.3.6 Screening of colonies by PCR and restriction digests 
The selected colonies were screened for the presence of an insert by either a colony 
PCR amplifying across the cloning site or restriction digestion of the plasmid. After 
screening, sequencing across the cloning site was performed to confirm that the insert 
was correctly introduced into the vector, in frame and in the correct orientation.  
 
2.3.7 Bacterial cultures 
For each bacterial colony selected, 5 ml of sterile LB broth containing 100 µg/ml of 
ampicillin (or an appropriate alternative antibiotic) was poured into a 50 ml Falcon tube 
under sterile conditions. Colonies were selected from the LB/agar plate with a sterile 
pipette tip and transferred to the broth. The samples were incubated overnight at 37°C in 
a shaking incubator at 225 rpm. 
 
2.3.7.1 Glycerol stocks 
500 µl of the cultured transformed bacterial cells were pipetted into a sterile 
microcentrifuge tube. 500 µl of sterile glycerol (Sigma-Aldrich, UK) was added and 
mixed thoroughly. Glycerol stocks were stored at -70°C.  
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2.3.7.2 Preparation of LB-Agar plates 
500 ml LB/Agar (10 g LB broth, 7.5 g agar, 500 ml water) was prepared and 
autoclaved. Once cooled to a temperature ~37˚C, antibiotic was added to a total 
concentration of 100 μg/ml for ampicillin or 30 μg/ml for kanamycin. The mixture was 
poured into 10 cm petri dishes under sterile conditions and left to set at room 
temperature. Once set these were sealed and stored at 4˚C or used immediately.  
 
2.3.8 Plasmid DNA purification 
Depending on the amount of plasmid DNA required, either Qiagen mini- or midipreps 
(Qiagen, UK) were performed according to the protocol provided by the manufacturer. 
Although the exact compositions of the reagents are unavailable, the principle is based 
on alkaline lysis (Birnboim and Doly, 1979) of bacterial cells followed by absorption of 
plasmid DNA onto a silica membrane under high-salt conditions (Vogelstein and 
Gillespie, 1979).  
 
2.3.8.1 Miniprep for preparation of up to 20 μg of high-copy plasmid 
DNA 
Plasmid DNA was recovered from cells using the Qiagen miniprep kit according to 
Qiagen protocol. Briefly, 5 ml of bacterial culture was centrifuged in a 50 ml Falcon 
tube for 15 min at 3000 rpm. After removing the culture media the cell pellet was 
resuspended in 250 µl ice-cold buffer P1 (cell resuspension solution).  The cells were 
transferred into a 1.5 ml microcentrifuge tube and 250 µl of buffer P2 (cell lysis 
solution) was added. This was then mixed by inversion until homogenous. 350 µl of 
buffer N3 (neutralisation solution) was immediately added and the sample mixed again. 
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The microcentrifuge tube was then spun at 13000 rpm in a tabletop microcentrifuge for 
10 min. The supernatant containing the plasmid DNA was applied to a QIAprep spin 
column and centrifuged for 30-60 sec. The flow-through was discarded and the column 
washed by adding 0.75 ml of buffer PE (wash buffer). The column was placed in a clean 
1.5 ml microcentrifuge tube and the DNA eluted by the addition of 30-50 µl of dH2O to 
the column, which was then centrifuged for 2 min at 13000 rpm.  
 
2.3.8.2 Midiprep for preparation of up to 100 μg of high-copy plasmid 
DNA 
50 ml of bacterial cell culture was used for each midiprep. Bacterial cells were 
harvested after centrifugation at 3000 rpm for 15 min at 4˚C. The cell pellet was 
resuspended in 4 ml of buffer P1. 4 ml of lysis buffer was added and the tube inverted 
until thorough mixing was achieved. This was incubated at room temperature for 5 min. 
4 ml of neutralisation buffer was added and the solution mixed by inversion. The 
sample was then applied to a 20 ml syringe, having removed the plunger, and left for 10 
min. In the meantime, the midi 100 column was equilibrated with 4 ml buffer QBT 
(equilibration buffer). Once buffer QBT had run through the column the supernatant 
from the syringe was applied to the column.  This was allowed to flow through by 
gravity and the column was washed twice with wash buffer QC (2 x 10 ml). The DNA 
was eluted with 5 ml buffer QF (elution buffer). DNA precipitation was performed by 
the addition of 0.7 volumes of isopropanol (Sigma-Aldrich, UK) at room temperature 
and centrifugation at 4500 rpm for 1 hr at 4°C. The supernatant was decanted and the 
pellet washed with 2 ml of 70% ethanol at room temperature and recentrifuged at 4500 
rpm for 1 hr at 4°C, after which the supernatant was discarded and the pellet air dried. 
The DNA was then dissolved in a suitable amount of water and stored at -20°C.  
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2.3.9 Site-directed mutagenesis 
To remove the predicted MRAP2 glycosylation site, in vitro site-directed mutagenesis 
was employed. Using the full length human MRAP2-FLAG as a template, the 
QuikChange® II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA), was 
used to switch the arginine to gluatamine at amino acid position 9,  generating the N9Q-
FLAG mutant construct.   
 
The mutagenic primers below were designed using Stratagene’s web-based 
QuikChange® Primer Design Program available online at 
http://www.stratagene.com/qcprimerdesign
Sense    5' ctcacacaaagacctggattagtacaaggacgacgatgac 3' 
Anti-sense  3' gagtgtgtttctggacctaatcatgttcctgctgctactg 5’ 
 
These two complementary oligonucleotides containing the desired mutation, flanked by 
unmodified nucleotide sequences, were synthesised. Primers were designed to be 
between 25 and 45 bases in length, with a melting temperature (Tm) of ≥ 78°C. 
 
The sample reaction was prepared as follows in the given order: 
10X reaction buffer     5 μl      
dsDNA template     x μl (corresponding to 10 ng)   
oligonucleotide primer 1   y μl (corresponding to 125 ng)  
oligonucleotide primer 2   y μl (corresponding to 125 ng)   
dNTP mix      1 μl       
QuikSolution™ reagent    3 μl       
dH2O to a final volume of    49 μl 
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Then: 
1 μl of PfuUltra™ High Fidelity DNA polymerase (2.5 U/μl) was added.  
 
Cycling Parameters for the QuikChange® II XL Method were as follows:  
Segment Cycles Temperature Time 
1 1 95°C 1 min 
95°C 50 sec 
60°C 50 sec 
2 18 
68°C 1 min/kb of plasmid length 
3 1 68°C 7 min 
 
Following thermal cycling, the reaction was placed on ice for 2 min. 1 µl of DpnI 
enzyme (10 U/µl) was added directly to the amplification reaction. The reaction was 
mixed by pipetting the solution up and down several times, spun down in a 
microcentrifuge tube for 1 min and incubated at 37°C for 1 hr to digest the parental (i.e. 
the non-mutated) supercoiled dsDNA. 2 μl of the DpnI-treated DNA reaction mixture 
was used to transform 50 µl of XL10-Gold ultracompetent cells (Stratagene) as 
described below (2.3.9.1).  
 
2.3.9.1 Transformation protocol using XL10-Gold ultracompetent cells 
The XL10-Gold ultracompetent cells (Stratagene) were thawed on ice and 50 μl aliquots 
were added to prechilled 14 ml BD Falcon polypropylene round-bottom tubes. 2 μl of 
the β-mercaptoethanol mix provided with the ultracompetent cells was added to each 
tube of cells to increase transformation efficiency. The contents were swirled and 
incubated on ice for 10 min, swirling every 2 min. 2 μl of the DpnI-treated DNA 
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reaction sample was added to an aliquot of the ultracompetent cells. The transformation 
reaction was gently mixed and incubated on ice for 30 min. The cells were heat shocked 
by placing the tube into a 42°C water bath for 30 sec, and then immediately transferred 
to ice for 2 min. 950 µl SOC media was then added to the tube and incubated in a 
shaker at 37°C for 1 hr with shaking at 225 rpm. The mixture was plated onto agar 
plates containing 100 µg/ml ampicillin. Following overnight incubation at 37ºC, 
colonies were picked, cultured and miniprepped as described in section 2.3.8. Plasmids 
were sent for sequencing to confirm the correct nucleotide change was achieved and 
that no off-target changes had occurred.   
 
2.4 Cell culture protocols 
All cell culture procedures were performed under sterile conditions in a laminar airflow 
hood. Cells were incubated in a humidified atmosphere of 5% CO2, 95% air (LEEC Ltd. 
Research Incubator, Nottingham, UK). The cell-lines used in this study were:  
• HEK293T (Human Embryonic Kidney cells) 
• CHO (Chinese Hamster Ovary cells) 
The medium was changed every 2-3 days. When cells became 90-100% confluent they 
were passaged and placed in new tissue culture flasks or plated out for experiments.  
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2.4.1 Maintenance of cells 
The growth media for each cell-line is shown below:  
Cell-Line Maintenance Media 
HEK293T • Dulbecco’s Modified Eagles Medium with L-glutamate (GIBCO, 
UK) 
• 10% Foetal Bovine Serum (FBS) (Sigma-Aldrich, UK) filtered 
through a 0.2 µm microfilter 
• 1% Penicillin/Streptomycin mixture (PS) (Invitrogen Ltd, UK) 
CHO  • 50/50 Dulbecco’s Modified Eagles Medium with L-glutamate 
(GIBCO, UK) and Ham’s F-12 medium (GIBCO, UK) 
• 10% Foetal Bovine Serum (FBS) (Sigma-Aldrich, UK) filtered 
through a 0.2 µm microfilter 
• 1% Penicillin/Streptomycin mixture (PS) (Invitrogen Ltd, UK) 
 
The maintenance media was pre-warmed to 37°C before use. An appropriate medium 
was added into the flasks/plates containing cells. Passage numbers were recorded on 
each flask.  
 
2.4.2 Passaging cells 
The old media was aspirated from the flasks and the cells were washed with 1x 
autoclaved PBS (pH 7.4) buffer (7.5 mM Na2HPO4, 2.5 mM NaH2PO4, 150 mM NaCl, 
or PBS tablets (Sigma-Aldrich, UK)). The PBS was aspirated and about 2 ml of  
trypsin/EDTA solution (2.5 g porcine trypsin, 0.2 g EDTA) was added per T75 tissue 
culture flask. The flasks were put into the incubator for 1 min, then removed and tapped 
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to ensure detachment of the cells from the flask. Approximately 10 ml of fresh media 
with serum was added to the flask to stop the action of trypsin. The cells were then split 
between flasks or plates for further growth or experimentation.  
 
2.4.3 Freezing down cells 
Cells were trypsinised as described above and then spun down (900 rpm for 5 min). The 
supernatant was removed and the pellet washed once with PBS and respun for 5 min. 
The supernatant was again removed and the pellet resuspended in 1 ml FBS containing 
10% (v/v) Dimethyl sulphoxide (DMSO) (Sigma-Aldrich, UK). The suspension of cells 
was added to a sterile cryotube, wrapped in thick tissue to ensure gentle freezing of 
cells, and put in a -70°C freezer overnight. Once frozen, the cells were stored in liquid 
nitrogen.  
 
2.4.4 Thawing of cells 
The cryotube containing frozen cells was removed from the liquid nitrogen storage unit 
and thawed in a 37°C water bath. The contents were added to a cell culture flask with 
fresh media and incubated overnight at 37°C. The medium was changed the following 
day.  
 
2.4.5 Counting mammalian cells 
Cells were counted in a Neuberg Haemocytometer to determine cell 
density/concentration. The chamber was cleaned with 70% ethanol before applying a 
cover slip. 100 µl of a suspension of trypsinised cells was added to 10 ml of media and 
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mixed thoroughly. 100 µl of this was then applied to the cytometer by pipetting into the 
counting area. A 10x lens was focused on the grid lines of the 1 mm2 area and the cells 
visible in the region were counted.  
 
Cell concentration was determined as the average of two counts using the equation:  
Cell concentration (C) (cells/ml) = average number of cells per 1 mm2 area (N) (cells)  
     10-4 i.e. volume counted (ml) 
Thus: C=N×10000 
To determine cell viability, 25 μl Trypan blue, which is taken up by the nuclei of 
damaged or dead cells, was added to 75 μl of the cell suspension before counting as 
described above.  
 
2.4.6 Transient transfection into mammalian cell-lines 
Lipid based transfection of mammalian cells was performed using Lipofectamine™ 
2000 (Invitrogen Ltd, UK) according to manufacturer’s instructions. One day before 
transfection, cells were plated using growth medium devoid of antibiotics. Cells were 
~80% confluent at the time of transfection. In two separate tubes DNA and 
Lipofectamine were diluted in a suitable volume of Opti-MEM® I Reduced Serum 
Medium (Invitrogen Ltd, UK) (see table below), gently mixed and incubated at room 
temperature for 5 min. Following this, the diluted DNA was mixed with the diluted 
lipofectamine and left for 25 min for complex formation. The complex was then added 
to the flask/well containing cells with media. This was gently mixed by rocking and 
placed at 37°C in a CO2 incubator for 24 hr. Transfection efficiency was assessed by 
transfection of cells under the same condition with a pEGFP-N1 (Clontech) empty 
vector. The percentage of cells expressing GFP was determined by epi-fluorescence 
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using a Nikon Eclipse TS100 inverted microscope, equipped with a Nikon C-SHG and 
T1-FM epi-fluorescence module through a FITC filter (Ex 465-495, Dm 505, Bar 
155/555) (Nikon Instruments Europe B.V., Netherlands). In general, 90% transfection 
efficiency was achieved in HEK293T cells and 60% in CHO cells.   
 
The transfections were scaled up or down depending on the experiment, as shown 
below:  
Share of reagents DNA transfection Culture 
Vessel 
Surface 
area per 
well 
Volume of 
plating 
medium 
Volume of 
dilution 
medium 
DNA LipofectamineTM 
 
T25 25 cm2 5 ml 2 x 625 µl 5 µg 20 µl 
6-well 10 cm2 2 ml 2 x 250 µl 2 µg 5.0 µl 
24-well 2 cm2 0.5 ml 2 x 50 µl 0.2 µg 1 µl 
8-well 
chamber 
slides 
0.8 cm2 0.3 ml 2x31.25 µl 0.1-0.2 µg 0.625 µl 
 
2.5 Imaging of cells 
Confocal microscopy of transfected cells was performed on 8-well chamber slides 
(Labtec, UK).  
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2.5.1 Preparation of slides 
CHO cells that had become confluent in a T75 flask were trypsinised and resuspended 
into 10 ml of culture media. 100 µl of this solution was diluted with 6 ml media and 0.3 
ml aliquots placed into each well of a 8-well glass Confocal slide (Labtec, UK). The 
following day, the cells (~60% confluent) were transfected with the vector construct of 
interest (section 2.4.6). 24 hr after transfection the media was removed and the cells 
washed 3 x 5 min in PBS. Fixation followed using 3.7% formaldehyde in PBS for 10 
min. Cells to be permeabilised were incubated for 10 min with 0.1% Triton-X100 
(Sigma-Aldrich, UK) in PBS. After three more washes with PBS (10 min per wash), the 
cells were incubated for 45 min in blocking solution A (3% (w/v) BSA, 10% (v/v) 
normal donkey serum in PBS). Blocking with the appropriate primary antibody (anti-
FLAG M2 monoclonal antibody, polyclonal rabbit anti-HA antibody or polyclonal 
rabbit anti-Calnexin antibody) at a dilution of 1 in 200 ensued for 2 hr at room 
temperature. The cells were rinsed for 3x10 min with PBS and then stained with the 
appropriate secondary Cy2/Cy3-conjugated donkey secondary antibody (Jackson 
Immunoresearch) at a concentration of 1 in 50 for 1 hr. After three more 10 min PBS 
washes, nuclei staining took place using PBS containing 2 µg/ml of 4’,6-diamidino-2-
phenylindole (DAPI) incubating for 1 min. A final wash with PBS was performed for 
10 min. After peeling off the plastic chamber and silicon seal, 3 drops of 
DakoCytomation Fluorescent Mounting Medium (DAKO) were added to the slide and 
cover slip applied. Fluorescence was imaged using a Zeiss LSM510 confocal 
microscope. Slides were stored at 4°C in the dark.  
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2.5.2 Confocal microscopy 
Fluorescence imaging was performed with a Zeiss LSM 510 inverted confocal laser 
scanning microscope (Carl Zeiss Ltd, UK) using x63, 1.4 numerical aperture oil-
immersion objective. Pinhole size was set at 1 Airy unit. Excitation wavelengths 458 
nm (Argon laser) was used to detect GFP, and Cy-2 (green fluorophore), 405 nm (Diode 
laser) for DAPI and 543 nm (HeNe laser) for Cy-3 (red fluorophore). Images were 
captured at a resolution of 1024 x 1024 pixels, 8 bit data depth taken on average 4-6 
times for each optical section. Optical slices of 0.9-1.0 μm were taken. Image 
processing was performed using the Zeiss Image Browser software (Carl Zeiss Ltd, 
UK).  
 
2.6  Protein analysis and protein-protein interaction protocols 
2.6.1  Protein extraction 
2.6.1.1 Transfected cell-lines 
To detect MRAP2 protein in transfected cells, and for co-immunoprecipitation assays, 
total protein was extracted from confluent cells grown in T25 flasks. Cell lysis buffer 
was prepared, PBS + 1% n-Dodecyl β-D-maltoside (DM), containing 1:1000 protease 
inhibitor cocktail (0.085 mM aprotinin, 104 mM 4-(2-aminoethyl)benzenesulfonyl 
fluoride (AEBSF), 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-64 
dissolved in DMSO), freshly prepared for each cell lysate preparation. Adherent 
transfected cells were washed in PBS three times and residual solution aspirated. The 
cells in a T25 flask were ‘snap frozen’ at -70°C for 15 min. After this time 400-800 µl 
of ice-cold lysis solution was added. The flask was placed on ice and the cells scraped 
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and dispersed into solution by pipetting up and down. The mixture was collected into a 
cold 1.5 ml microcentrifuge tube and incubated on ice for 30 min. The sample was 
centrifuged at 4°C for 30 min at 14000 rpm. The supernatant was removed and placed 
in a clean cold 1.5 ml centrifuge tube. This was either used immediately or otherwise 
stored at -70°C until required.  
 
2.6.1.2 Tissues 
Tissues from CB57/BL6 15 week old mice or adult Wistar rats were placed in a 
precellys 24 ceramic bead tube with lysis buffer and homogenised using a Precellys 24 
rotator homogeniser for 2 cycles of 40 sec pausing in between for 10 sec. The lysate 
was centrifuged (14000 rpm for 15 min at 4˚C) and the supernatant, now free from cell 
debris, was transferred to a new ice-cold microcentrifuge tube. Protein concentration 
was determined by the Bradford protein assay (section 2.7.2) and samples were stored at 
-70°C.  
 
2.6.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The protein sample was mixed with an equal amount of 2x sodium dodecyl sulphate 
(SDS) loading buffer (125 mM Tris-HCl (pH 6.8), 4% (w/v) SDS, 5% (v/v) β-
mercaptoethanol, 20% (v/v) glycerol, 0.002% (w/v) bromophenol blue) in a 1.5 ml 
eppendorff tube. SDS functions as an ionic detergent which coats the protein with a 
negative charge, allowing the proteins to separate on a gel based on their size. The 
samples were heated to 95˚C for 5 min, to denature the protein complexes, centrifuged 
briefly and loaded into a pre-cast 12% Tris-HCl gels (Bio-Rad Laboratories, CA, USA). 
In some cases denaturing at 60°C was performed, in particular to improve resolution of 
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GPCRs on gels. Lysates were run alongside protein markers such as 10 μl of full range 
rainbow molecular weight markers (10-250 kDa, Amersham, UK), 5 μl of prestained 
protein marker (broad range 6-175 kDa, New England Biolabs, UK) or 5 μl 
Kaleidoscope polypeptide standards (4-37.7 kDa, Bio-Rad Laboratories, CA, USA) to 
enable an approximation of the molecular weight of indentified proteins. Using a Mini-
PROTEAN 3 Electrophoresis system (Bio-Rad Laboratories Ltd, UK), proteins were 
separated by SDS-PAGE at 120 V until the dye front reached the bottom of the gel. 
Running buffer (25 mM Tris-base, 192 mM Glycine, 0.1% (w/v) SDS) was used.  
 
2.6.3 Western blot analysis 
2.6.3.1 Protein transfer 
Protein transfer was effectively achieved using a semi dry-transfer technique. Two 
sheets of Bio-Rad extra thick blotting paper (Bio-Rad Laboratories, CA, USA) were 
soaked in transfer buffer (25 mM Tris base, 192 mM glycine, 20% methanol). A piece 
of Hybond-P TM hydrophobic polyvinylidene diflouride membrane (PVDF) 
(Amersham, UK), cut to size, was soaked in dH2O. A Trans-Blot SD Semi-Dry Transfer 
Cell (Bio-Rad Laboratories Ltd, UK) was used for protein transfer according to the 
manufacturer’s instructions. The semi-dry blotter was run for approximately 25-30 min 
at 15 V with a current of 0.4 A per gel. At the end of the transfer, the membrane was 
reversibly stained with Ponceau S (Sigma-Aldrich, UK) to ensure adequate transfer of 
proteins throughout the blot. The staining was removed by washing with TBS (20 mM 
Tris-base, 200 mM NaCl, pH 7.6) and water before immunoblotting was performed.  
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2.6.3.2 Immunoblotting 
After immobilisation of proteins onto HybondTMP PVDF membrane (GE-Healthcare, 
UK) the membrane was incubated in blocking buffer (TBS, 0.1% (v/v) Tween-20 
(polyoxyethylene (20) sorbitan monolaurate) and 5% (w/v) reduced fat milk powder) 
for 2 hr at room temperature or overnight at 4˚C with gentle agitation. Membranes were 
subsequently incubated with primary antibody (mouse monoclonal anti-HA clone HA-
7, rabbit anti-myc antibody (Abcam) or monoclonal anti-FLAG M2 antibody), generally 
at a concentration of 1: 2000, in blocking buffer and left overnight at 4°C with agitation. 
This was followed by 3 x 10 min washes with wash buffer (TBS, 0.1% Tween-20) and 
incubation with either goat anti-rabbit IgG, horseradish peroxidase (HRP) conjugate or 
goat anti-mouse IgG HRP conjugate (Upstate Biotechnology, USA) at a dilution of 1 in 
3000 for 1.5 hr at room temperature. Enhanced chemiluminescence (ECL) Western 
Blotting Detection Agents (Amersham, UK) were prepared and applied to the 
membrane according to instructions from the manufacturer. This was left for a 2 min at 
room temperature in the dark and then wrapped in saran film and exposed to 
HyperfilmTM ECL (Amersham, UK) inside a film cassette. Exposure varied from 
several seconds to 20 min. To obtain the optical image the film was developed using the 
Compact X4 automatic X-ray film processor (Xograph Imaging Systems, UK).  
Later in the project, a fluorescence-based detection method for Western blotting 
was employed due to the availability of an Odyssey Infrared Imagaing system. The 
technique was identical with the exception of using fluorescent secondary antibodies 
such as Goat anti-rabbit® IRDye® 800CW or anti-mouse® IRDye® 800CW (LI-COR 
Biosciences, UK), instead of HRP antibodies, at a dilution of 1:10000. Incubation with 
the secondary antibody and subsequent steps were performed in the dark in a blacked-
out box.  
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2.6.3.3 Re-probing Western blots 
To determine the total protein loaded in each lane, blots requiring further probing with 
either mouse monoclonal β actin (Abcam plc, UK) antibody or rabbit polyclonal 
GAPDH (Santa Cruz Biotechnologies Inc, Germany) antibody were stripped of 
antibody by incubating with stripping buffer (62.5 mM Tris-HCl, pH 6.7, 2% (w/v) 
SDS, 100 mM β-mercapthoethanol) at 60ºC for 1 hr.  The membrane was then rinsed 
with TBS-T and subjected to three 10 min washes at room temperature with agitation, 
then re-probed as described in section 2.6.3.3.   
 
2.6.4 Co-immunoprecipitation 
Cells lysates were prepared as previously described in section 2.6.1. Co-IP using anti-
HA agarose conjugate, Clone HA-7 (Sigma-Aldrich, UK) or anti-FLAG M2 Affinity 
gel (Sigma-Aldrich, UK) was performed according to the manufacturer’s instructions. 
For HA agarose, 40 µl agarose was placed into a 1.5 ml microcentrifuge tube. The 
agarose was washed five times in 1 ml PBS and after each wash the agarose was 
centrifuged at 10,000 rpm for 1 min. PBS was discarded carefully leaving the agarose 
intact. 700 µl of lysate was added to the agarose and placed on a rolling rotor overnight 
at 4°C. Following overnight incubation the agarose was washed five times with 1 ml 
PBS. On the last wash approximately 10 µl of supernatant was left on the agarose. 50 µl 
sample SDS buffer was added and the sample boiled for 3 min. The samples were then 
spun at 14,000 rpm for 2 min. The supernatant was carefully removed, passed through a 
0.22 µm filter (Millipore), before being used for Co-IP. Typically 20 µl of this sample 
was loaded alongside 20 µl of untreated protein lysate for comparison. Blotting was 
performed using rabbit anti-myc antibody (Abcam). For IPs with FLAG, Anti-FLAG 
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M2 Affinity gel (Sigma-Aldrich, UK) was used. Blotting was performed using 
monoclonal anti-HA TAG, Clone HA-7 (Mouse IGG1) (Sigma-Aldrich, UK) or anti-
myc antibody.  
 
2.6.5 Deglycosylation 
CHO cells were transfected in T25 flasks and harvested as described above. 10 µl of the 
protein lysate was used for the deglycosylation experiment using N-Glycosidase F 
(PNGase F) and Endoglycosidase H (Endo H); NEB. The reaction mixture was as 
follows:  
 
Protein lysate       10 µl (typically 15 μg protein) 
Glycosidase (Endo H/PNGase F) (NEB)  1 µl  (500000 U/ml) 
Buffer (G5/G7) 10X (NEB)    1.5 µl  
_____________________________________________________________________ 
Lysis buffer to a total volume of   15 µl 
_____________________________________________________________________ 
 
In accordance with manufacturer instructions, the buffers were vortexed vigorously 
prior to use to ensure that the precipitated salts were dissolved prior to being added to 
the mixture. After the addition of all components, the reaction was then mixed gently, 
centrifuged briefly and incubated at 37°C for 2 hr. Following deglycosylation, the 
samples were run on a gel and Western blotted as described in sections 2.6.2-2.6.3.  
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2.7 Functional assays 
cAMP content was measured using a competitive binding assay (Brown et al., 1971). In 
this assay ‘cold’ unlabelled cAMP in the sample competes with [3H] radiolabelled 
cAMP for the binding protein extracted from bovine adrenal glands. Any free unbound 
cAMP, whether [3H]-cAMP or unlabelled cAMP from the sample, is absorbed by 
charcoal and removed by centrifugation. The amount of bound [3H]-cAMP which 
remains in the supernatant can be determined by liquid scintillation counting. Using this 
measurement, the amount of non-radiolabelled cAMP in each sample can be calculated. 
In general, the lower the count the higher the cAMP content of the sample.  
 
2.7.1 cAMP accumulation assays 
2.7.1.1 Stimulation of cells 
HEK293T cells were seeded into 6-well plates and allowed to be transfected when at 
~80% confluence (section 2.4.6). The cells were washed 24 hr after transfection with 
serum-free medium, then left in serum-free medium for 1 hr. The medium was aspirated 
and replaced with 500 µl serum free medium containing 1 mM 3-isobutyl-1-
methylxanthine (IBMX), a phosphodiesterase inhibitor, to prevent the degradation of 
cAMP. After incubation for 1 hr at 37°C, ACTH 1-39 (Bachem, Switzerland) / NDP-
MSH (Bachem, Switzerland) and Forskolin (Sigma-Aldrich, UK) were added to final 
concentrations of 10-6 M, 10-9 M and 10-5 M respectively in different individual wells. 
ACTH(1-39) and NDP-MSH peptide sequences are shown in Appendix 2. This was 
performed in triplicate in each independent experiment. The cells were stimulated for 
1/2 hr at 37 ºC, then placed on ice immediately to stop the reaction.  
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2.7.1.2 Preparation of cells for the cAMP assay 
After stimulation the cells were harvested, on ice, by scraping cells into the medium. 
They were transferred into a 1.5 ml microcentrifuge tube and mixed thoroughly. A 50 µl 
aliquot from each sample was put aside in a fresh 0.5 ml microcentrifuge tube for 
protein quantification (section 2.7.2). The remaining cells were lysed by boiling for 5 
min to release intracellular cAMP. The tube was spun at 14000 rpm for 3 min to pellet 
cellular components and the supernatant removed for use in the cAMP assay. 
 
2.7.1.3 Preparation of cAMP binding protein 
cAMP binding protein was prepared from fresh bovine adrenal glands obtained from an 
abattoir. The fat, connective tissue and medulla from eight adrenal glands were removed 
and the remaining cortex was chopped and homogenised with 1.5 volume of ice-cold 
buffer (250 mM sucrose, 25 mM KCl, 5 mM MgCl2, 40 mM pH 7.4 Tris-HCl). After 
filtering the homogenate through 100 μm muslin and centrifuging at 2000 g, 4˚C for 5 
min the filtrate was collected into fresh 50 ml Falcon tubes and centrifuged again (15 
min at 5000 g at 4 ˚C). The supernatant was extracted, divided into 0.5-1 ml aliquots 
and stored at -70˚C.  
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2.7.1.4 cAMP accumulation assay 
Materials 
• pH 7.4 Tris-HCl assay buffer (50 mM Tris-HCl, 4 mM IBMX, 0.5 ml/L 2β-
mecaptoethanol) 
• cAMP stock solution,  100 pmol/µl (Sigma-Aldrich, UK) made up to a 
concentration of 0.125-64 pmol cAMP in 100 μl assay buffer, by serial dilution 
of stock solution  
• [3H] cAMP (Amersham, UK) diluted in assay buffer to give a total count of 
~4000 cpm  
• Charcoal suspension, 5% charcoal (Norit GSX, BDH Ltd), 0.15% bovine serum 
albumin (Sigma-Aldrich, UK) 
• Ecoscint A scintillation fluid (National Diagnostics) 
• Binding protein (section 2.7.1.3) diluted in assay buffer 1 in 15 to achieve 30-
50% B0/total count 
Methods 
For each experiment a standard curve was generated using serial dilutions of the stock 
cAMP (100 pmol/µl). The range of standards, set up in duplicate, was 0.125-32 pmol in 
100 µl assay buffer (Table 2.1). For each reaction the ‘total count’ (400 µl buffer and 50 
µl [3H] cAMP) together with the charcoal blank (200 µl buffer and 50 µl [3H] cAMP) 
were prepared to ensure that the [3H] cAMP would not bind to endogenous factors in 
the buffer. B0 (100 µl assay buffer, 100 µl binding protein and 50 µl [3H] cAMP) was 
prepared in duplicate for each centrifuge run. The sample tubes (in duplicate) were 
prepared by adding 100 µl of the cAMP extracted sample to 0.5 ml microcentrifuge 
tubes. 50 µl of [3H] cAMP was added to all tubes followed by 100 µl of diluted binding 
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protein. The tubes were vortexed briefly and incubated at 4°C for 2 hr. At the end of 
incubation, 200 µl of ice-cold charcoal suspension was added to each tube with the 
exception of the ‘total count’ tube. The tubes were vortexed and the free [3H] cAMP 
absorbed to the charcoal was removed by centrifugation at 4°C for 7 min at 10,000 rpm. 
Finally, 200 µl of the clear supernatant containing bound [3H] cAMP was carefully 
removed and placed into a scintillation vial containing 3 ml Ecoscint A scintillation 
fluid (National Diagnostics, UK). Tritium counting was performed in a β-scintillation 
counter (Wallac 1409 DSA Liquid Scintillation Counter, Wallac, UK).  A program 
count of 3 min per sample was used.  
 
Table 2.1: Set-up of competitive binding assay for cAMP 
Tube Assay 
Buffer 
(μl) 
Cold 
cAMP 
(μl) 
Hot 
cAMP 
(μl) 
Binding 
Protein 
(μl) 
Charcoal 
(μl) 
Total count 400 - 50 - - 
Non-specific binding 200 - 50 - 200 
Total binding (B0) 100 - 50 100 200 
Standards (pmol):      
32 68 32 50 100 200 
16 84 16 50 100 200 
8 92 8 50 100 200 
4 96 4 50 100 200 
2 98 2 50 100 200 
1 99 1 50 100 200 
0.5 99.5 0.5 50 100 200 
0.25 99.75 0.25 50 100 200 
0.125 99.875 0.125 50 100 200 
Sample (100 μl) - - 50 100 200 
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2.7.1.5 Calculation of results 
For each independent experiment a standard curve was constructed (Table 2.1). The 
count (X) from each sample or standard was standardised by representing it as a 
percentage of total binding (B0) after the subtraction counts from non-specific binding.  
 
The formula below was used:  
%B0 = (X-NSB)/(B0-NSB)×100 
X=count for sample, NSB=count for charcoal blank.  
%B0 (y-axis) is then plotted against log [cAMP] of the standards (x-axis). A typical 
standard curve is shown in Fig. 2.1. The cAMP content of each sample was determined 
by interpolation from the standard curve.  
 
Fig. 2.1: Example of standard curve for cAMP accumulation assays.  
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2.7.2 Protein quantification by Bradford Assay 
Protein concentration was determined with the Bio-Rad protein assay (Bio-Rad 
Laboratories Ltd, UK). The assay is based on the maximum absorbance shift from 465 
nm to 595 nm of Coomassie Brilliant Blue G-250 when bound with protein (Bradford, 
1975). Protein standards were prepared by diluting a 50 mg/ml BSA solution to a range 
of concentrations varying from 0.195 to 25 mg/ml. 10 µl of a protein standard or sample 
was added to 500 µl 1x Bradford reagent (containing Coomassie Brilliant Blue G-250) 
in a 1.5 ml microcentrifuge tube. The samples were vortexed and incubated at room 
temperature for 10 min. Following this 150 µl of each sample in triplicate was placed 
into a well of a 96-well plate. The plate was placed in a reader (Bio-Rad Laboratories 
Ltd, UK) and read at 595 nm. A standard protein concentration curve plotting OD (595) 
(y-axis) against log [BSA] (x-axis) was constructed after measurement of protein 
standards (0.195 – 25 mg/ml). Using the standard curve, the protein concentration of 
each sample was interpolated (Fig. 2.2). The Bradford protein assay was used to 
determine the protein concentration of each sample used in the cAMP assay and also to 
determine the concentration of cell lysates for protein loading in Western blotting.  
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Fig. 2.2: Example of standard curve for determination of protein concentration.   
 
 
2.7.3 Immunofluorescent cell surface immunoassay 
CHO cells were grown in 24-well plates and transfected with HA-MCR with and 
without MYC-MRAP2, MRAP-FLAG or both. Transfections were performed in 
triplicate in duplicate plates. 24 hr post-transfection the cells were washed with PBS, 
fixed for 10 min with 3.7% paraformaldehyde (BDH, UK). Cells from one plate were 
then subjected to permeabilisation with PBS/0.1% Triton-X100 (polyethylene glycol p-
(1,1,3,3-tetramethylbutyl)-phenyl ether). Both plates were then washed in PBS and 
blocked in Odyssey blocking buffer (LI-COR Biosciences, UK) for 1 hr. Primary anti-
HA antibodies were employed at a concentration of 1/1000 (Sigma-Aldrich, UK), 
incubating for 1 hr. This was followed by three washes (10 min) in PBS and secondary 
antibody incubation (IRDye 800CW Goat Anti-Mouse IgG, LI-COR) at a concentration 
of 1:750 for 1hr. After three further washes (10 min) the plates containing permeabilised 
and non-permeabilised cells were then scanned using the LI-COR's Odyssey Infrared 
Imaging System (LI-COR Biosciences, UK). Data are presented as cell surface protein 
over total protein and normalised to receptor alone.  
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2.8 Polyclonal MRAP2 antibody design, production and 
characterisation 
Polyclonal MRAP2 antibody was raised against a peptide based on part of the protein 
sequence of the C-terminus in the rat. The peptide sequence targeted 
(LLENKPVSQTSRTDLD) is similar to human and mouse MRAP2 (Fig. 2.3).    
 
2.8.1 MRAP2 peptide design 
A rat C-terminal peptide (NH2-K-LLENKPVSQTSRTDLD-COOH) (MRAP2-C) was 
synthesised and purified at The Advanced Biotechnology Centre (ABC), Imperial 
College London. The synthetic C-terminal antigen peptide was chosen since epitopes at 
either end of the native protein are more likely to be exposed, hence more readily 
accessible to an antibody. An N-terminal lysine was added to provide a reactive site for 
coupling to carrier protein thyroglobulin (porcine), prior to immunisations into a rabbit 
host for antibody production. BLAST analysis against known protein databases using 
the 16 amino acid residue confirmed that this sequence was unique to MRAP2. The 
chosen rat peptide (MRAP2-C) differs from the mouse C-peptide by one amino acid 
residue (shown in red) and from the human C-peptide by five amino acid residues (Fig. 
2.3).   
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Fig. 2.3: Protein alignment of the C-terminal amino acid sequences of rat, mouse and human 
MRAP2 (rMRAP2-C, mMRAP2-C, hMRAP2-C). Amino-acids are represented by standard 
abbreviations. The targeted region used in the generation of polyclonal antibodies is shown in the 
red box. Differences in the amino acid sequence compared with the rMRAP2 are represented by 
red letters.   
 
 
2.8.2 Peptide conjugation to thyroglobulin 
Coupling to a large carrier protein, in this case thyroglobulin, allows for efficient 
peptide presentation to the immune system of animals to stimulate the production of 
polyclonal antibodies. The amount of C-terminal peptide subjected to conjugation was 
determined by the amount required to immunise two rabbits with a total immunisation 
requirement of 350 nmol of peptide per rabbit. Assuming a conjugation efficiency of 
50% and a peptide purity as stated by ABC as 90%, a total of 2100 nmol/4.6 mg of C-
peptide was required. Conjugation of  K-LLENKPVSQTSRTDLD to thyroglobulin was 
performed with the coupling agent glutaraldehyde (Sigma-Aldrich, UK) (Skowsky and 
Fisher, 1972). In brief, a glass bijou bottle was coated overnight at 4°C with 
thyroglobulin (10 mg/ml) (Sigma-Aldrich, UK) to avoid peptide sticking to the glass. 
After diluting the C-terminal peptide in sterile PBS buffer to a final concentration of 10 
mg/ml, the conjugation reaction mixture was set up in the coated bijou bottle in the 
following order below:   
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        Volumes  Amount 
MRAP2-C   (10 mg/ml)   410 µl   1 
(4.6 mg peptide (90%) in 410 µl of phosphate buffer) 
Thyroglobulin solution (10 mg/ml)   410 µl   1 
0.1 M Phosphate buffer solution     3280 µl 6 
Finally add 5% v/v glutaraldehyde     100 µl  0.25 
 
Total volume        4200 µl 
 
The reaction mixture was left at room temperature for 2 hr on a rocking table until 
conjugation had occurred, this being indicated by the solution turning yellow. The 
solution was placed in dialysis membrane SnakeSkin®7000MWCO (Pierce 
Biotechnology, USA) and dialysed overnight at 4°C in 4 litres of sterile distilled water 
to remove unconjugated reagents.  
 
2.8.3 MRAP2 immunisation and bleeds 
The rat MRAP2 (MRAP2-C) conjugated peptide was injected into two rabbits (rabbit 
099 and rabbit 100) with the following customised protocol using the commercial 
company Eurogentec (Seraing, Belgium). In brief, the rabbits were injected with 100 
nmol (i.e. 200 µg) peptide in Freund’s complete adjuvant for the primary injection per 
rabbit. This was then followed by four booster injections administering 50 nmol/100 µg 
peptide in Freund’s incomplete adjuvant at 4-weekly intervals. The rabbits were bled 
before the injection (‘pre-immune sample’) and seven days after each injection (post- 
immunisation). This resulted in bleeds 1, 2, 3 and 4, the 4th being the final bleed. The 
immunisation schedule is summarised in Table 2.2. Serum from bleeds was tested for 
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the presence of rMRAP2 antibodies by a combination of dot-blot assays, ELISA and 
Western blotting.  
 
Table 2.2: Schedule for immunisation performed by EUROGENTEC.  
Week Action 
0 Take pre-immune samples 
1 Primary injection: 100 nmol peptide per rabbit 
6 2nd immunisation: 50 nmol peptide per rabbit 
7 1st bleed 
10 3rd immunisation: 50 nmol peptide per rabbit 
11 2nd bleed 
14 4th immunisation: 50 nmol peptide per rabbit 
15 3rd bleed 
18 5th immunisation: 50 nmol peptide per rabbit 
19 Terminal bleed 
 
2.8.4 Dot blots 
Dot blots were performed to detect the presence of MRAP2 antibodies in the sera. 
Nitrocellulose membrane was cut into 0.5 cm x 10 cm strips. 1 µl (1 nmol) of MRAP2-
C peptide was pipetted onto the top of each strip. 1 μl (1 nmol) of MRAP-C peptide 
(KQSPSASAPGPLALP, ABC Imperial) and dH2O were dotted onto the nitrocellulose 
paper in the middle and bottom section of the strip respectively and left to dry. The 
strips were blocked for 1 hr in 5% marvel/PBS/0.1% Tween for 1 hr at room 
temperature. These were then washed three times for 10 min each with 0.1% Tween in 
PBS. 500 μl of primary antibody diluted to various concentrations was applied and left 
overnight at 4°C. The strips were then washed for 3x10 min with 0.1% Tween in PBS. 
Secondary HRP-goat anti-rabbit antibody (GE Healthcare, UK) was applied for 1 hr and 
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the excess antibody removed by three further 10 min washes. Detection was achieved 
using enhanced chemiluminescence (ECL) Western Blotting Detection Agents 
(Amersham, UK) according to manufacturer’s instructions. Detection reactant was 
applied to the strips and the strips exposed to X-ray film inside a Kodak film cassette 
for an appropriate length of time typically 3-10 sec. To ensure that the antibody was 
targeting the correct peptide a control strip was incubated with ‘pre-absorbed 
antiserum’. This pre-absorbed antiserum was prepared by incubating the antibody with 
20 μM MRAP2-C peptide for 1 hr at room temperature. After a short spin to remove the 
peptide and associated MRAP2 antibody, the serum (now free of MRAP2 antibody) was 
applied to the control strip.  
 
2.8.5 Enzyme-Linked Immunosorbent assay (ELISA) 
96-well microtitre plates were coated with either 200 µl of MRAP2-C peptide solution 
(1 mg/ml) or 200 µl sodium carbonate buffer pH 9.6 (50 mM sodium carbonate) that 
acted as non-specific binding control. This was left overnight at 4ºC to allow the peptide 
to bind to the plastic microtitre plates. The plate was washed three times for 10 min 
each with PBS, 0.01% Tween. 300 µl of blocking solution (3% Blot-Block (BDH, UK) 
in 0.01% PBS tween-20) was subsequently placed into each well for 2 hr. 25 µl of 
antiserum was added to 2475 µl of 3% blot-block solution (antibody titre therefore 1 in 
100). Serial dilutions were then made to the final antibody titre of 1/200, 1/400, 1/800, 
1/1600, 1/3200, 1/6400, 1/12800, 1/25600, 1/51200 and 1/102400. Each dilution was 
tested in three separate wells. Primary antibody incubation was undertaken overnight at 
4ºC. Plates were washed for 3 x 10 min in PBS/0.01% Tween-20. Following this, 200 µl 
of secondary antibody (goat Alkaline Phosphatase Anti-Rabbit IgG) at a dilution of 
1/1000 in blocking solution was added to each well and incubated for 3 hr at room 
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temperature. Three further washes in PBS/0.01% Tween-20 and then one with sodium 
carbonate pH 10 buffer (0.1 M) were followed by the addition of 200 µl substrate mix to 
each well. The substrate mix was prepared immediately prior to use according to 
manufacturer’s instructions (Alkaline Phosphatase Yellow (pNPP, p-Nitrophenyl 
Phosphate, Disodium Salt) Liquid Substrate System for ELISA, Vector Laboratories, 
UK). The colour change was measured by spectophotometry at 415 nm (Bio-Rad model 
680 microplate reader). Reactions were performed in triplicate. The mean was plotted 
graphically after subtraction of non-specific binding.  
 
2.8.6 Affinity purification of antibodies from antisera 
2.8.6.1  Procedure for immobilising a protein 
AminoLink® Coupling Gel Column & kit (Perbio) was used to affinity purify 
antibodies from MRAP2 antisera. The affinity-purification columns (supplied as 50% 
slurry in 0.02% sodium azide (Na N3)) were prepared according to the manufacturer’s 
instructions. Briefly, 2.9 mg MRAP2-C peptide was dissolved in 2 ml coupling buffer 
(0.1 M sodium phosphate, 0.05% NaN3, pH 7.0). Following equilibration of the 
AminoLink® column and reagents at room temperature, the column was equilibrated 
with 5 ml coupling buffer. Once run through, the protein solution was added followed 
by 200 µl of the AminoLink® Reductant solution (sodium cyanoborohydride 
(NaCNBH3)) that ensured binding of the peptide to the gel bed. The column was capped 
and the coupling reaction took place overnight at 4°C on a rocking table. Following this, 
the unbound peptide was drained and column washed with 5 ml coupling buffer. The 
remaining active sites were blocked by adding 2 ml AminoLink® Quenching Solution 
(1 M Tris-HCl, 0.05% NaN3, pH 7.4) to the column and then by adding 200 µl of 
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AminoLink® Reductant Solution to the column. The column was mixed and left at 
room temperature for 30 min with gentle end-over-end rocking. The column was 
washed with 15 ml of AminoLink® wash solution (1 M NaCl, 0.05% NaN3) to remove 
excess blocking agent. The gel in the column was washed with PBS containing 0.05% 
v/v sodium azide. Following the washes, an additional 2 ml of buffer containing 0.05% 
v/v sodium azide was added. A polyethylene porous disc was inserted into the top of the 
column and gently slid to within 1 mm of the gel bed with the open tube end of the 
serum separator. The column containing protein, which was now covalently coupled to 
the gel through amine groups, was then stored upright at 4°C until use.  
 
2.8.6.2 Affinity-purification of antibodies 
The protein-coupled column was equilibrated to room temperature prior to use. The 
excess storage solution was allowed to drain from the column. The column was washed 
with 6 ml PBS. 1.5 ml of the sample (MRAP2 serum from bleeds number 3 and 4 from 
rabbit 099) was applied to the column and allowed to completely enter the gel bed. 0.2 
ml PBS was added and allowed to enter the gel bed. A further 0.5 ml of PBS was added 
to the column to cover the gel and prevent drying. The column was incubated for 2 hr at 
room temperature. Following incubation, the column was washed with 12 ml of PBS. 
The bound antibody was eluted using 10 ml glycine buffer (100 mM, pH 2.5). This was 
followed by an additional wash and a second elution step using basic elution buffer 10 
ml Tri-ethylamine (TEA) (100 mM, pH 11.5). These two fractions were collected and 
immediately neutralised with 1 ml 0.1 M Tris buffer, pH 8.0 and dialysed separately 
overnight at 4˚C in 4 litres of PBS pH 7.3 to eliminate sodium azide residue. The 
affinity-purified antibody aliquots were eventually collected and stored at 4°C with 
sodium azide 0.05%. After the TEA elution, the column was washed with 16 ml PBS. 
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The protein-coupled column was equilibrated in storage buffer consisting of PBS with 
0.05% sodium azide and stored at 4°C until further use.  
 
2.9 In vivo expression protocols 
2.9.1 In situ hybridisation 
2.9.1.1 Preparation of DNA template 
Full length rat MRAP2 cDNA was cloned into pGEM®-T Easy plasmid vector (section 
2.3). The presence of the insert was verified using restriction digestion and its 
orientation determined by sequencing. DNA was extracted from rat MRAP2 bacterial 
clones and purified using QIAprep miniprep kit. 10 μg of each construct was digested 
with either ApaI or PstI (flanking internal vector restriction sites). After endonuclease 
restriction was performed as described in section 2.3.2, 1 μl of the reaction mixture was 
run on an agarose gel and visualised with ethidium bromide. The remaining linearised 
DNA was extracted from the reaction mixture by phenol extraction (section 2.2.8). A 
second extraction was performed but this time using an equal volume of 
chloroform:isoamyl alcohol (24:1, v/v) to remove residual phenol. The DNA was 
ethanol was precipitated, collected and resuspended in RNase-free water.  
 
2.9.1.2 Sense and anti-sense transcription with digoxygenin (DIG) 
labelling 
To prepare digoxygenin (DIG)-labelled antisense and sense RNA probes, 1 μg of the 
linearised DNA vector was used as template for each transcription reaction. The 
reagents for the reaction were added in the following order:  
 95
Materials and Methods                    
 
Linearised plasmid DNA template       x μl (1 μg) 
5X transcription buffer        6 μl  
(200 mM Tris-HCl (pH 7.5), 30 mM MgCl2, 100 mM NaCl, 10 mM spermidine)  
DIG RNA labelling mix (Roche Applied Science)    2 µl 
DTT (0.1M DL-Dithiothreitol, Promega,UK)    3 µl 
RNasin® Ribonuclease Inhibitor (40 U/μl, Promega, UK)   1 µl 
SP6 or T7 RNA polymerase (50,000 U/ml; NEB, UK)   2 µl 
dH2O to a final volume of       30 µl 
 
The reaction was gently mixed and centrifuged briefly prior to incubation at 37ºC for 3 
hr. After a brief centrifugation at the end of the reaction, 1/20th (1.5 µl) of the mixture 
was extracted and run on an agarose gel to verify the quality of the riboprobe 
synthesised. The remaining reaction mix was subjected to DNase treatment for 30 min 
at 37˚C to remove the DNA template.   
 
Reaction mixture       28.5 µl 
DEPC-dH2O       9 µl 
5X transcription buffer     3 µl 
DTT (0.1 M)       1.5 µl 
RNase-free DNase I      1.5 µl 
___________________________________________________________________ 
Total volume       43.5 µl 
____________________________________________________________________ 
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2 μl of the sample was retained and analysed by agarose gel electrophoresis to 
demonstrate removal of the template.  
 
2.9.1.3 Precipitation, purification and quantification of DIG-labelled 
riboprobes 
(DIG)-labelled antisense and sense RNA probes were purified using a lithium chloride 
precipitation. RNase-free dH2O was first added to the sample mixture to a final volume 
of 80 µl. The RNA precipitation reaction was initiated by adding the following 
components to each tube: 
 
EDTA 0.2 M, (pH=8.0)    8 µl 
LiCl 4 M      10 µl  
100% pre-chilled Ethanol (-20˚C)   250 µl 
 
Reactions were vortexed and incubated at -70ºC for 2 hr or overnight. To recover all the 
precipitated riboprobes, tubes were centrifuged for 20 min at 14000 rpm, 4ºC. The 
riboprobes pellet was washed with 500 µl chilled ethanol solution (70%) and tubes were 
centrifuged for an additional 15 min at 14000 rpm, 4ºC. In this manner the probes were 
washed a second time. The supernatant was carefully removed and the pellet left to air 
dry. The riboprobe pellet was resuspended in 31 µl of sterile RNase-free water. 1 μl of 
the sample underwent quantification (section 2.2.9). The probe was divided to 800 ng 
aliquots and stored at -70ºC until use.  
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2.9.1.4 Dissection and fixation rat adrenal gland 
Timed-pregnant Wistar rats were sacrificed by asphyxiation with CO2 and E17.5 
(embryonic day 17.5 post conception) and E19.5 (embryonic day 19.5 post conception) 
embryos carefully collected in ice-cold PBS and fixed in 4% paraformaldehyde (PFA). 
Adult adrenals were collected from male and non-pregnant female Wistar rats. The 
glands were immediately placed in either liquid nitrogen and stored at -70ºC (for RNA 
extraction and tissue homogenisation) or 4% paraformaldehyde solution made up in 
PBS (PFA/PBS) (for tissue fixation). After transferring to clean 4% PFA/PBS solution, 
the latter adrenal glands were stored at 4˚C.  
 
2.9.1.5 Preparation of paraffin wax embedded sections 
The adrenal glands and the embryos were fixed in 4% paraformaldehyde solution for at 
least two days at 4˚C. The tissue was washed in dH2O for 1 hr at room temperature and 
then dehydrated by placing them in a series of ethanol solutions (50%, 70% and 90%), 
for 2 x 15 min in each solution. The tissues were then dehydrated in 100% ethanol for 2 
x 1 hr periods, after which the adrenal glands were left overnight in fresh 100% ethanol. 
Whole adrenal glands were incubated in xylene (BDH, UK), generally for 2 x 5 min 
then placed in paraffin wax (RA Lamb, UK) at 60ºC for 2 hr. The wax was replaced 
each hour to remove xylene from the tissues. The tissues were left in fresh paraffin wax 
at 60ºC and subsequently embedded in paraffin wax using brass L-piece brackets to 
hold the wax in place. After allowing the wax-embedded tissue blocks to cool down, 
longitudinal adrenal sections (7-10 µm) were prepared using a Leica RM 2146 
microtome and mounted on Superfrost® Plus Micro Slides (VWR, Lutterworth, UK). 
Sections were then dried at 37ºC for 24 hr and stored room temperature.  
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2.9.1.6 Slide preparation prior to in situ hybridisation 
Rehydration of adrenal paraffin sections was undertaken with initial incubation for 2 x 
10 min in fresh xylene solution to remove paraffin, followed by incubation in 100% 
ethanol twice for 10 min. After this the sections were rehydrated in consecutive 
immersions for 2 x 10 min in 90%, 70% and 50% ethanol solution. Following these 
rehydration steps, the tissue was permeabilised by the addition of 500 μl of 5 μg/ml 
proteinase K solution, diluted from 20 mg/ml proteinase K solution (Ambion, USA), in 
buffer comprising 0.1 M Tris-HCl, pH 7.5 plus 0.05 M EDTA, pH 8.0. The solution 
was warmed to 37ºC, before adding to the tissue and treated for 10 min at this 
temperature. The slides were washed for 2 x 10 min in DEPC treated PBS and fixed by 
immersion in a 4% PFA/PBS solution for 15 min at room temperature. After two further 
washes in RNAase-free PBS for 15 min, the slides were equilibrated in 5x SSC buffer 
(750 mM NaCl, 75 mM Trisodium citrate dihydrate).  
 
2.9.1.7 Pre-hybridisation, hybridisation and post-hybridisation 
protocol 
For pre-hybridisation, 400-500 μl of hybridisation solution (5x SSC, 50% formamide 
(Qbiogen, UK), 40 μg/ml salmon sperm DNA, in RNase-free dH2O) pre-warmed to 
58ºC was applied to each slide and incubated at 58˚C for 2 hr. Prior to hybridisation, an 
aliquot of DIG-labelled sense or anti-sense probe (800 ng/ml) in an eppendorf tube was 
denatured by boiling for 5 min and then immediately placed on ice for 10 min. The tube 
was briefly centrifuged and 500 μl of pre-heated hybridisation solution added and 
mixed. 400 μl of probe was added to each slide and covered by a parafilm cover slip. 
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Hybridisation was performed overnight (~16 hr) at 58˚C in a chamber saturated with 
buffer 1 consisting of 0.1 M Tris-HCl, pH 7.5; 0.15 M NaCl. Post-hybridisation washes 
consisted of four 30 min steps at 58˚C. Step 1: Wash with three parts (50% formamide 
in 5x SSC) and one part (2x SSC); step 2: one part (50% formamide in 5x SSC) and one 
part (2x SSC); step 3: one part (50% formamide in 5x SSC) and three parts (2x SSC), 
and step 4: (2x SSC). Slides were washed at room temperature in 0.2x SSC for 20 min 
three times prior to immunodetection of hybridised DIG-labelled probe.  
 
2.9.1.8 Immunodetection of hybridised DIG-labelled probe 
Slides were equilibrated in Buffer 1 (0.1 M Tris-HCl, pH 7.5; 0.15 M NaCl) for 5 min at 
room temperature. Sections were then blocked by the addition of 500 μl per slide of 
0.5% blocking reagent (Roche Applied Science) in Buffer 1.  After draining blocking 
solution from the slides, 500 µl of anti-DIG alkaline phosphatase-Fab fragments (Roche 
Applied Science) was added to each slide at a dilution of 1:5000, made up in 0.5% 
Blocking Reagent in Buffer 1. This was incubated at 4ºC overnight in a chamber 
saturated with Buffer 1. Slides were washed twice for 15 min in Buffer 1 at room 
temperature, followed by 5 min in Buffer 3 (0.1 M Tris-HCl pH 9.5; 0.1 M NaCl; 0.05 
M MgCl2). Alkaline phosphate substrate 5-bromo,4-chloro,3-indolylphosphate (BCIP) 
and nitroblue tetrazolium (NBT) (Roche Applied Science) were applied and left in the 
dark until staining had developed. The reaction was stopped by immersing the slides 
into Buffer 1 (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.5). After two washes with PBS, the 
slides were fixed with 4% PFA in PBS for 10 min at room temperature. The slides were 
then dehydrated through consecutive ethanol series consisting of 50%, 70%, 90%; 2 x 
100%. Slides were cleared with Xylene for 2 x 10 min, then mounted in VectaMountTM 
(Vector Laboratories, UK). After cover slips were applied, the slides were dried 
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overnight in a fume cupboard. Slides were viewed under a Leica DMRA2 compound 
microscope (Leica, Nussloch, Germany), and digital images captured with a 1300 
Retiga 12-bit camera (QImaging, Burnaby, BC, Canada). 
 
2.10 Bioinformatics 
In silico programs are listed in Appendix 5. MRAP2 conservation was determined using 
the http://www.ebi.ac.uk/clustalw program and alignment performed using Gendoc. The 
protein program PROSITE was used to predict protein structure, secondary 
modifications and molecular weight.  
 
2.11 Statistical analysis 
All statistical analysis was performed using PRISM4 software. The determination of 
significance was performed using a student’s t-test. In experiments where statistical 
analysis was used, experiments were performed in triplicate and represent at least 3 
independent experiments.  Error bars represent the standard error of the mean of the 
independent experiments. Statistical significance was taken as p<0.05.  
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3.1 Introduction 
In 2005, Metherell et al. described MRAP as the first melanocortin receptor  
accessory protein required for the trafficking and normal function of the MC2R to the 
cell surface of non-adrenal derived cells (Metherell et al., 2005). Since then several 
other groups have confirmed the importance of MRAP to MC2R function (Sebag and 
Hinkle, 2007; Roy et al., 2007). Metherell et al. identified that a putative gene C6orf117 
(now named MRAP2), was predicted to encode a small single transmembrane domain 
protein, similar to MRAP (Metherell et al., 2005). In silico data suggested two 
alternatively spliced human isoforms of MRAP2 (Fig. 3.1). These splice variants, 
termed α and β by Metherell et al., were originally identified as mRNAs from human 
fetal brain (CR609200.1) and purified pancreatic islet cells (CK825973) respectively. 
Expressed sequence tags (ESTs) representing MRAP2 have been identified from many 
tissues. Most are from the brain, but they are also found in the pancreas, kidney, testis 
and prostate. Both splice variants predict a single pass transmembrane protein, identical 
in the N-terminus and transmembrane domain but differing in the C-terminus. Only the 
α isoform is annotated in other species.  
Knowledge of MRAP2 expression, specifically overlapping expression with one 
or more MCR, may provide clues to the identity of the putative interacting partner(s), 
and hence the role of MRAP2. To demonstrate that the MRAP2 gene was indeed 
expressed and to assess the tissue distribution of MRAP2 mRNA, RT-PCR was 
performed using a combination of human, rat and mouse derived cDNA. In situ 
hybridisation was performed to further demonstrate localisation of MRAP2 mRNA 
within specified tissues.  
To analyse the MRAP2 protein, MRAP2 tagged with a FLAG epitope on the C-
terminus (MRAP2-FLAG) was cloned into mammalian expression vector, pcDNA3.1+. 
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Transfection of MRAP2-FLAG in cell-lines enabled determination of protein expression 
by Western blotting. Subcellular localisation of MRAP2-FLAG was established by 
immunocytochemical analysis and confocal microscopy studies.  
A polyclonal rabbit anti-rat MRAP2 antibody (rMRAP2189-204) was made to 
assess MRAP2 protein expression. Endogenous MRAP2 protein expression was 
assessed by Western blotting of tissues.   
 
Fig. 3.1: Schematic diagram showing the two possible splice variants of human MRAP2 and the 
predicted translated protein product. Intron and exon length, in base pairs, are shown numerically. 
The transmembrane domain is underlined. The differences in the C-terminus are shown as green 
italicised text.  
 
MRAP2α 
 183 5’ 134 100 1790
21428 7447 26098
3’
Non-coding  
Coding  
MSAQRLISNRTSQQSASNSDYTWEYEYYEIGPVSFEGLKAHKYSIVIGFWVGLAVFVIFMFFVLTLLTKTGAPHQDNAE
SSEKRFRMNSFVSDFGRPLEPDKVFSRQGNEESRSLFHCYINEVERLDRAKACHQTTALDSDVQLQEAIRSSGQPEEE
LNRLMKFDIPNFVNTDQNYFGEDDLLISEPPIVLETKPLSQTSHKDLD 
 
MRAP2β 
183 5’ 134 100 153
21428 7447 73407
3’71 47
4939 1309 
 
MSAQRLISNRTSQQSASNSDYTWEYEYYEIGPVSFEGLKAHKYSIVIGFWVGLAVFVIFMFFVLTLLTKTGAPHQDGLS
QQELTWVEKKNFSFLTVFGNADGTFWDTPSTLEPADEILAKLAEAGKRKIHGKHSDKYRLLITSRSYHLARNASY 
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3.2 Materials and Methods 
3.2.1 RT-PCR 
cDNA from normal human tissue samples was obtained as described 
(Gnanapavan et al., 2002). mRNA extraction and cDNA production from rat tissues 
were performed as described in sections 2.2.2-2.2.4 Specific intron-spanning MRAP2 
primers were used to perform RT-PCR in human and rat tissues (Appendix 4). GAPDH 
expression was used as a positive control. RT-PCR products were sequenced to confirm 
their sequence was that of the MRAP2 transcript.  
 
3.2.2 mRNA in situ hybridisation  
In situ hybridisation studies were performed on adrenal glands from adult Wistar 
rats and embryos at embryonic day 17.5 and 19.5 (E17.5 and E19.5). The adrenal glands 
were fixed in 4% PFA/PBS and embedded in paraffin wax, sectioned and prepared as 
described in section 2.9.1. Full length rat MRAP2 cDNA templates for sense and 
antisense RNA probes were derived from RT-PCR with rat brain, and cloned into 
pGEM®-T Easy vector. After plasmid preparation, propagation and selection (section 
2.3) the selected vectors were linearised with either ApaI or PstI (enzyme sites flanking 
the cloning site). Sense DIG-labelled riboprobes were prepared after restriction digest 
with ApaI and transcription with SP6 polymerase, whilst digestion with PstI and 
transcription with T7 polymerase resulted in the antisense probe (section 2.9.1.2). DIG-
labelled cRNA probes were phenol extracted and quantified prior to use on adrenal 
sections. Pre-hybridisation and hybridisation were undertaken at 58˚C. After overnight 
hybridisation, non-bound or non-specifically bound probe was removed with post-
hybridisation stringent washes (section 2.9.1.7).  The samples were incubated with anti-
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DIG-Alkaline Phosphatase (AP) -Fab antibody (1 in 5000) and left overnight at 4˚C in a 
humidified box. After 3 washes, bound antibody was visualised by the addition of AP 
substrate, NBT/BCIP chromogen solution (Roche Applied Science). Incubation in the 
dark was performed for 12-24 hr. The reaction was stopped once purple staining was 
seen. The stained sections were washed prior to fixing with PFA, dehydration, mounting 
and visualising under the microscope.   
 
3.2.3 Western blotting 
After cloning of a tagged vector as described in section 2.3, Western blotting 
using anti-FLAG antibody (Sigma-Aldrich, UK) was performed on CHO cell lysates 
transfected with MRAP-FLAG. Anti-FLAG antibody was used at a concentration of 
1/2000 as stated in section 2.6.3.2.  
 
3.2.4 Studies on MRAP2 glycosylation 
To determine MRAP2 glycosylation, lysates from CHO cells transfected with 
MRAP2-FLAG were treated with Endo H and PNGase F as previously described in 
section 2.6.5. Site-directed mutagenesis of the putative glycosylation site was used to 
confirm the site of glycosylation. Rhodopsin is known to undergo N-linked 
glycosylation (Saliba et al., 2002). Deglycosylation of Rhodopsin was used as a positive 
control. CHO cells were transfected with a wild-type Rhodopsin mammalian expression 
construct and immunoblotting performed using monoclonal antibody 1D4 at a 
concentration of 1/1000 (gifts from Prof Cheetham, UCL) (Saliba et al., 2002).  
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3.2.5 Confocal microscopy 
Immunocytochemistry was performed on CHO cells expressing MRAP2-FLAG. 
Cells were either permeabilised with 0.1% Triton-X100 or left intact without 
permeabilisation. The immunofluorescence protocol including preparation of slides for 
imaging is described in section 2.5.1. Primary antibody incubation with anti-FLAG M2 
monoclonal antibody, produced in mouse (Sigma-Aldrich, UK), was used at a titre of 
1:200. Antibody Cy™3-conjugated anti-mouse IgG (Jackson ImmunoResearch 
Laboratories, PA, USA) was used to detect anti-FLAG monoclonal antibody at a 
concentration of 1:50.  
 
3.2.6 Polyclonal MRAP2 antibody 
In order to look at MRAP2 protein expression in vivo, polyclonal MRAP2 
antibodies were made in collaboration with Professor Maurice Elphick (QMUL, Mile 
End) as described in section 2.8.  Antiserum samples from various bleeds were 
subjected to dot-blot assays, ELISAs and Western blotting of transfected cells as 
described in sections 2.8.4, 2.8.5 and 2.6.3). Antiserum from the fourth bleed of rabbit 
number 099 was used in Western blotting of tissues; this fraction is referred to as 
rMRAP2189-204 in subsequent sections.  
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3.3 Results 
3.3.1 MRAP2 gene expression 
3.3.1.1 Human MRAP2 expression 
MRAP2 mRNA expression was examined in 23 human tissues. Of these tissues, 
MRAP2α expression was only found in brain and adrenal (Fig. 3.2 [A]). Expression in 
adrenal and brain were consistent findings (Fig. 3.2 [B]). Sequencing of the PCR 
product confirmed the identity of MRAP2α.  IMAGE clones (4134852, 5782994) for the 
human MRAP2α and MRAP2β isoforms were used as positive controls. MRAP2β was 
not detected in any of the tissues studied.   
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Fig. 3.2: MRAP2 mRNA expression in human tissues was determined by RT-PCR analysis.  (A) 
Each number on the gel represents a tissue; a numerical key is shown below. The solid bars denote 
the three RT-PCRs performed in relation to that tissue. For most tissues RT-PCR was performed 
for both MRAP2α and MRAP2β with GAPDH as a control, which was then loaded in that order. 
The exceptions were tissues 22 and 23 where only MRAP2α and GAPDH were performed due to 
limited cDNA availability. Note RT-PCR was unsuccessful for tissue number 17. Symbols α and β 
represent positive PCR controls using MRAP2 IMAGE clones as templates. Full length MRAP2α 
expression (618 bp) in adrenal and brain are shown by an asterisk. (B) Repeated RT-PCR 
demonstrates that MRAP2 is expressed in human (h) brain and adrenal gland.  
 
(A) 
 
GAPDH
GAPDH
GAPDH
The numbers correspond to following tissues: 1=Adrenal, 2=Brain, 3=Liver, 4=Pancreas, 5=Lung, 
6=Oesophagus, 7=Fallopian tube, 8=Ileum, 9=Rectum, 10=Breast, 11=LN, 12=Buccal mucosa, 
13=Myocardium, 14=Gallbladder, 15=Atrium, 16=Kidney, 17=Fat, 18=Fundus, 19=Lymphocyte cell-
line, 20=Ovary, 21=Prostate, 22=Thyroid (MRAP2α, and GAPDH), 23=Placenta (MRAP2α and 
GAPDH).   
 
(B)  
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3.3.1.2 Rat MRAP2 expression 
Only the MRAP2α isoform was studied in rats. A limited number of rat tissues 
was analysed i.e. brain, adrenal, liver and hypothalamus. MRAP2 was most readily 
detected in brain and hypothalamus (Fig. 3.3).  
 
Fig. 3.3: Rat MRAP2 expression. MRAP2 mRNA expression in rat tissues were determined by RT-
PCR analysis. (A) MRAP2 expression is detected in rat brain and adrenal. RT-PCR for GAPDH 
was performed at the same time. GAPDH RT-PCR was unsuccessful in the case of brain. 
Sequencing was performed confirming MRAP2 expression in brain and adrenal tissues.  (B) 
MRAP2 expression in the hypothalamus is shown. RT-PCR products were confirmed by 
sequencing. 
 
3.3.2 MRAP2 adrenal localisation 
It is interesting that MRAP2 expression is found in the adrenal glands. As both 
MRAP and MC2R are expressed in the adrenal gland, localisation of MRAP2 in the 
different zones of the adrenal gland was performed by in situ hybridisation in rat adrenal 
glands. In situ hybridisation with full length MRAP2-DIG labelled anti-sense probe 
showed weak staining in the adrenal glands from adult Wistar rats (Fig. 3.4). 
Intriguingly, expression appears in all 3 zones of the adrenal gland.  
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Fig. 3.4: Localisation of MRAP2 mRNA by in situ hybridisation in rat adult adrenal gland. Images 
A-D represent different sections of the gland showing staining of  ZG (zona glomerulosa), ZF (zona 
fasciculata) and ZR (zona reticularis) at different magnifications. Some staining was also seen in 
the adrenal medulla (M).  Negative controls using a sense probe are shown in E and F. Scale bar in 
E represents 200 μm which applies to A and C, scale bar in F represents 100 μm and applies also to 
B and D. 
 
                   
 
From available public data it is clear that both MRAP and MC2R are expressed in the 
developing adrenal gland of mice. In situ hybridisation (ISH) data displayed on 
www.genepaint.org for MC2R and MRAP are shown in Fig. 3.5 (A&B). The adrenal 
glands from E17.5 and E19.5 rat embryos were assessed for MRAP2 expression by 
ISH.  Fig. 3.5 (C) demonstrates MRAP2 mRNA expression in the developing adrenal 
gland, detected using MRAP2 antisense probe (MRAP2 AS). A negative control with 
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sense MRAP2 probe (MRAP2 S) is also shown. No staining was detected in the 
developing medulla.  
 
Fig. 3.5: MRAP2 is expressed in the developing adrenal gland. (A) MC2R  and (B) MRAP 
expression in the adrenal gland of E14.5 C57BL/6 mice (images taken from www.genepaint.org) (C) 
MRAP2 is expressed in the adrenal gland of E17.5 and E19.5 rat embryos. In situ hybridisations 
were performed using Antisense (AS) probes and Sense (S) probes. Scale bars in panel C represent 
100 μm.  
 
             
3.3.3 MRAP2 protein 
To analyse the predicted translated product of MRAP2, cell-lines CHO and 
HEK293T were transiently transfected with the mammalian expression vector, 
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pcDNA3.1(+), containing human MRAP2, FLAG tagged at the C-terminus. Western 
blotting performed on transfected cell lysates using a FLAG antibody demonstrated two 
protein isoforms, approximately 27 kDa and 29 kDa in size (Fig. 3.6). The molecular 
weight of MRAP2-FLAG was determined after running samples alongside a range of 
commercially available protein markers. As the human MRAP2 protein has a predicted 
molecular weight of 23.5 kDa and the FLAG epitope is approximately 4 kDa in size, 
this would correspond to the lower molecular weight species. In CHO cells a non-
specific band was seen when immunoblotting with anti-FLAG antibody (Fig. 3.6 & 
3.7). When transfections were performed in HEK293T cells, this non-specific band was 
absent with anti-FLAG immunoblotting (Fig. 3.8).  
 
Fig. 3.6: Western blot analysis of MRAP2-FLAG. Immunoblotting with anti-FLAG antibody 
reveals two protein isoforms of human MRAP2-FLAG, approximately 27 kDa and 29 kDa in size 
(◄).  Lysates from untransfected CHO cells and CHO cells transfected with empty vector alone are 
shown as controls. (*)  represents a non-specific band seen when using the anti-FLAG antibody in 
CHO cells. Blotting with β-actin antibody was used to verify total protein in each lane.  
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3.3.4 Glycosylation of MRAP2   
To investigate the reason for a second protein MRAP2-FLAG isoform, an in-
silico protein prediction program PROSITE (http://www.expasy.ch/prosite/) was used to 
predict protein structure and identify possible post-translational modifications (de 
Castro et al., 2006). A putative N-linked glycosylation site with the consensus sequence 
NRTS (Asparagine-Arginine-Threonine-Serine) was identified at amino acid positions 
9-12 of MRAP2. Treatment with endoglycosidases PNGase F and Endo H resulted in 
the loss of the higher molecular mass band, indicating that MRAP2 is a glycosylated 
protein (Fig. 3.7 [A]). Rhodopsin was used as a positive control (Fig. 3.7 [B]). 
Treatment of wild-type Rhodopsin with endoglycosidases resulted in the detection of 
deglycosylated glycoforms of the receptor (~30 kDa in size) (Saliba et al., 2002).  
To confirm the putative glycosylation site, site-directed mutagenesis was 
undertaken to replace the asparagine (polar neutral aminoacid) at position 9 with a small 
polar neutral glutamine residue (N9Q-FLAG). The predicted single 27 kDa band was 
detected by Western blotting of cell lysates from HEK293T cells transfected with N9Q-
FLAG, in agreement with ablation of the putative glycosylation site (Fig. 3.8).  
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Fig. 3.7: MRAP2 undergoes N-linked glycosylation (A) Immunoblot with anti-FLAG antibody in 
transfected CHO cells reveals two MRAP2-FLAG protein species, ~27 and 29 kDa in size, indicated 
by arrows. Treatment with endoglycosidases, PNGase F (F) and Endo H (H), results in the removal 
of the 29 kDa band. (B) Deglycosylation of Rhodopsin was used as a positive control. 
Immunoblotting was performed using monoclonal rhodopsin antibody (1D4). Mature forms of 
rhodopsin are ~ 40 kDa, whilst deglycosylated forms are ~30 kDa. *=non specific band.  
 
 
 
Fig. 3.8: MRAP2 undergoes N-linked glycosylation at the N-terminus. HEK293T cells were either 
untransfected (UT) or transfected with N9Q-FLAG or MRAP2-FLAG. The N9Q-FLAG construct 
formed by site-directed mutagenesis of the putative glycosylation site (resulting in the substitution 
of the asparagine residue with a glutamine residue at amino acid position 9) was seen as a single 
band on Western blotting. This compares with wild-type MRAP2-FLAG which appears as two 
bands. Treatment with PNGase F and Endo H are shown as F and H respectively, whilst (-) denotes 
no treatment. 
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3.3.5 Subcellular localisation of MRAP2 
MRAP has been shown to localise to the cell surface in heterologous cells 
(Metherell et al., 2005). Localisation of MRAP at the plasma membrane was found to 
be unrelated to the presence or absence of MC2R. Hence if MRAP2 was to act in a 
similar manner, subcellular localisation and localisation at the cell surface should be 
like that seen with MRAP. Confocal microscopy of CHO cells transfected with 
MRAP2-FLAG proved that this was indeed the case (Fig. 3.9 [A]). Staining of non-
permeabilised cells with anti-FLAG antibody localised MRAP2 to the plasma 
membrane, similar to MRAP, and suggested that the C-terminus of MRAP2 was 
extracellular. Intracellular MRAP2 was visualised in permeabilised heterologous cells 
similar to MRAP. As MRAP and MRAP2 are transmembrane proteins this would 
suggest that these proteins must pass through the ER and golgi prior to cell surface 
localisation. Attempts at co-localisation with the ER marker calnexin, however, showed 
only partial co-localisation suggesting that a very small amount of protein was retained 
in the ER (Fig. 3.9 [B]).  
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Fig. 3.9: Confocal images showing the expression of MRAP2-FLAG in transfected CHO cells.  (A) 
MRAP2-FLAG is seen at the cell surface and ER by confocal microscopy and shows similar 
localisation to MRAP-FLAG (work by Dr Cooray). Bar represents 10 µm. (B) Co-staining of 
MRAP2-FLAG (green) and ER marker calnexin (red) in permeabilised cells. Nuclei staining with 
DAPI are seen in blue.  
(A) 
                          
(B) 
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3.3.6 Polyclonal MRAP2 antibody 
MRAP2 detection was assessed in eight serum samples derived from two 
rabbits.  Initially, dot blots were used as a guide to ensure that the antiserum derived 
from each animal could detect MRAP2-C peptide without cross-reacting with a MRAP-
C peptide (KQSPSASAPGPLALP) synthesised and purified by Advanced 
Biotechnology Centre, Imperial College London (Dr Isabel Almiro Do Vale, PhD thesis) 
or dH2O. Antisera from both rabbits 099 and 100 were able to detect MRAP2-C peptide 
without detecting MRAP-C peptide. Pre-absorption effectively removes the signal and 
preimmune serum was used as a negative control. A signal was detected in pre-immune 
serum from rabbit 100. This was seen on several occasions, suggesting the possibility 
that rabbit 100 had generated antibodies prior to immunisation with MRAP2-C peptide 
(Fig. 3.10[A]). Further work in the form of ELISAs concentrated on serum derived from 
rabbit 099.  
ELISA (n=2) was performed on serum derived from rabbit 099 (Fig. 3.10[B]). 
This suggested that antiserum from bleed number 4 could most readily detect MRAP2-
C antigen, compared with the other fractions. As the ELISA was only performed twice 
no statistical significance was obtained.  
To ensure that the polyclonal antibody in the antiserum could detect MRAP2, 
Western blotting was performed on CHO cells transfected with human MRAP2-FLAG, 
MYC-MRAP2 and N9Q-FLAG constructs. Peptide competition was undertaken 
(incubation with MRAP2-C peptide prior to Western blotting as described in section 
2.8.4) to ensure that the band seen was specific. Fig. 3.11 shows that antibody derived 
from the 4th bleed from rabbit 099 is able to detect human MRAP2. The bands detected 
are of the same size as seen when blotting with the anti-FLAG antibody, and the bands 
disappear with peptide pre-absorption. MYC-MRAP2 tagged on the N-terminus appears 
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as the strongest bands consistent with the ability of the antibody to bind freely to an 
untagged C-terminus. This fraction of serum was used in subsequent experiments and is 
referred to as rMRAP2189-204. 
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Fig. 3.10: Characterisation of MRAP2 antisera. (A) Dot blots were performed, dotting MRAP2-C 
and MRAP-C peptides alongside dH2O, demonstrating the recognition of MRAP2-C peptide 
without cross reaction with MRAP-C. Strips A-H were blotted with antiserum from rabbit 099, 
strips I-P represent antiserum from the rabbit 100. Strip A and I are preimmune samples. Strip H 
and P represent serum which has been preabsorbed for 1hr with 20 µM peptide prior to adding 
onto strips. Antiserum from bleeds 2, 3 and 4 was diluted 1/100, 1/250 and 1/500 and used on dot 
blots. (B) ELISA using serum from bleeds of rabbit 099. Dilution of antiserum is indicated below. 
Antiserum dilution points indicated in the graph are as follows: 1=1/100, 2=1/200, 3=1/400, 4=1/800, 
5=1/1600, 6=1/3200, 7=1/6400, 8=1/12800, 9=1/25600, 10=1/51200, 11=1/1024000. The means +/- 
SEM of two independent experiments are shown.     
(A)                                                    
                         
(B) 
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Fig. 3.11: Western blotting with MRAP2 polyclonal antibody. CHO cells were transfected with 
human constructs, MRAP2-FLAG (C-terminal tag), MYC-MRAP2 (N-terminal tag) and N9Q-
FLAG (C-terminal tag). Blotting (IB) was performed using the MRAP2 antibody, 099 (panel A) 
and 100 (panel B).  Pre-Ab represents antiserum incubated with MRAP2-C peptide prior to 
blotting. The last lane indicates IB with anti-FLAG antibody as a positive control.  
     
 
3.3.7 MRAP2 protein expression in adrenal and brain tissue 
To determine endogenous MRAP2 protein expression, Western blot analysis 
was performed on tissue lysates derived from mouse adrenal, brain and liver. Using 
rMRAP2189-204 polyclonal antibody an immunoreactive band was visualised with a 
molecular weight of ~47.5 kDa. The size of this band is consistent with an MRAP2 
dimer, resistant to denaturing and reducing conditions. This band disappeared with 
peptide competition suggesting that it was specific for endogenous MRAP2 (Fig. 3.12).  
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Fig. 3.12: Western blot analysis of mouse tissues using antiserum rMRAP2189-204. An 
immunoreactive band with a MW ~47.5 kDa was seen which disappeared with peptide competition. 
The size of the bands seen by Western blotting is consistent with an MRAP2 dimer, resistant to 
denaturing and reducing conditions.  No monomeric bands were detected.  
 
                        
 
3.4 Discussion 
3.4.1 MRAP2 is expressed in adrenal and brain and encodes a glycosylated 
protein 
MRAP2, like MRAP, is a single-pass transmembrane domain protein that is 
localised to the cell surface as seen by confocal microscopy. MRAP2 undergoes post-
translational modification such that it is glycosylated at the N-terminus, similar to 
MRAP (Sebag and Hinkle, 2007).  
In endogenously expressing tissue (adrenal), MRAP exists as a dimer that is 
insensitive to SDS and reducing agents, however, in contrast, in transfected cells it 
tends to migrate as a monomer (Cooray et al., 2008). MRAP2 seems to have the same 
properties. Western blotting using an antibody to the C-terminal region of MRAP2 
revealed a ~47.5 kDa band in adrenal gland and brain tissue. Mouse MRAP2 has a 
predicted molecular weight of 23.3 kDa, hence the immunoreactive band visualised 
could be consistent with an MRAP2 dimeric structure in vivo that is resistant to the 
actions of SDS, reducing agents and heat. Understanding the molecular basis of this 
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denaturation resistance in extracts from endogenously expressing cells and tissues, but 
not in heterologously expressing cells, is interesting. Western blotting of human MRAP-
FLAG shows that it runs as a monomeric isoform with two molecular species of 
approximately 27 and 29 kDa in size, representing the deglycosylated and glycosylated 
protein respectively. Dimerisation of small accessory proteins has previously been noted 
in cells highly expressing RAMP1 (McLatchie et al., 1998), although this was in 
transfected cells rather than tissue.  
Recent work suggests that MRAP adopts a dual topology homodimeric structure 
(Sebag and Hinkle, 2007). The membrane topology of MRAP2 as judged by prediction 
programs (e.g. TMHMM) resembles that of MRAP, suggesting that MRAP2 is a Type 
II membrane protein with an extracellular C-terminus and intracellular N-terminal 
domain (Metherell et al., 2005; Sebag and Hinkle, 2007). These prediction programs 
were deemed unreliable in the case of MRAP where dual topology has been 
demonstrated (Bernsel and Von Heijne, 2005; Sebag and Hinkle, 2007). N-terminal 
glycosylation and a C-terminal out orientation, as shown by deglycosylation studies and 
immunofluorescent staining of live cells respectively, suggest that MRAP2 also has 
dual topology. All these similarities with MRAP provide support for our hypothesis that 
MRAP2 may potentially act in a similar way to MRAP as an accessory protein for 
one/or more melanocortin receptor(s).  
 
3.4.2 Expression of MRAP2 and inferences 
The tissue expression pattern of MRAP2, observed primarily in the brain, 
particularly the hypothalamus, with some expression in the adrenal gland, is interesting. 
MC2R is expressed in the adrenal gland, whilst MC3R, MC4R and MC5R are all 
expressed in the brain. MC3R and MC4R expression in the hypothalamus is well 
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described (Cone, 2006). The overlapping expression pattern of MRAP2 with sites 
known to express members of the melanocortin receptor family supports the hypothesis 
that MRAP2 is a melanocortin receptor accessory factor.  
The expression of MRAP2 in the adrenal gland appears throughout all three 
zones of the adrenal cortex. MRAP2 mRNA is detected early in the developing adrenal 
gland and is seen in the cortex but not the medulla. The expression of mouse MRAP 
mRNA was assessed by Dr Isabel Almiro Do Vale (PhD, University of London). Her 
data shows that expression of MRAP mRNA was seen throughout the adrenal cortex. 
Genepaint data also shows that MRAP is expressed in the developing adrenal gland. 
MC2R is expressed in the adrenal cortex and although its main role is in glucocorticoid 
production, it has a role in aldosterone production as well as adrenal androgen 
production (Weber et al., 1997; Lin et al., 2007; Chida et al., 2007; Chan et al., 2009b). 
In this manner, MRAP, MRAP2 and MC2R appear to localise within the same zones of 
the adrenal gland, hence determining the role of MRAP2 within the adrenal gland, and 
in MC2R function in particular, is important. 
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4.1 Introduction 
Compelling evidence for the importance of MRAP in MC2R regulation is 
provided by the ability of MRAP to interact with MC2R, to enable the receptor to traffic 
to the cell surface and generate cAMP in response to ACTH (Metherell et al., 2005). 
Previous studies have shown MC2R retention in the ER in cells of non-adrenal origin 
(Noon et al., 2002). Non-adrenal cell-lines, such as SK-N-SH (human neuroblastoma 
derived cell-line) and HEK293T cells, transfected with MC2R, became ACTH 
responsive in the presence of MRAP (Metherell et al., 2005). In addition, knockdown of 
endogenous mouse MRAP in Y1 adrenocortical cells, that express endogenous MC2R, 
resulted in insensitivity to ACTH (Cooray et al., 2008). These stable cells expressing 
MRAP short hairpin RNA (shRNA) were rescued by the introduction of human MRAP, 
resistant to the action of mouse specific shRNA, allowing the cells to respond to ACTH 
and generate cAMP (Cooray et al., 2008).  
The importance of MRAP in MC2R function has been replicated by a number of 
groups (Sebag and Hinkle, 2007; Roy et al., 2007). In these studies it has been shown 
that GFP- tagging of the MC2R diminished the response to ACTH even in the presence 
of MRAP. In comparison, N-terminal MYC-tagged MC2R was able to generate cAMP 
in the presence of MRAP in response to ACTH, suggesting that the addition of a GFP to 
the C-terminus results in impaired trafficking and signalling of MC2R (Roy et al., 
2007). Smaller tags do not present such problems (Metherell et al., 2005; Roy et al., 
2007; Cooray et al., 2008).  
MRAP2 shares many similarities with MRAP and is also expressed in the 
adrenal gland. As the MC2R is the predominant melanocortin receptor in the adrenal 
gland, it was a logical next step to determine the ability of MRAP2 in assisting MC2R 
to the cell surface to enable normal function.  
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4.2 Materials and Methods 
4.2.1 MRAP2 and MC2R Co-immunoprecipitation (Co-IP) 
CHO cells were transfected with either MYC-MRAP2/N9Q-FLAG or HA-
MC2R, or a combination of the two. Immunoprecipitation was performed using anti-HA 
agarose or anti-FLAG agarose as described in section 2.6.4. Immunoblotting was 
performed with anti-MYC antibody, anti-FLAG antibody or anti-HA antibody.   
 
4.2.2 Confocal microscopy of MRAP2 and MC2R  
To ensure that MRAP2 and MC2R could co-localise and that the expression of 
MC2R was at the cell surface in the presence of MRAP2, immunostaining and confocal 
microscopy of cells co-transfected with MRAP2-FLAG or N9Q-FLAG and HA-MC2R 
was performed (section 2.5).  
 
4.2.3 cAMP competitive protein binding assay 
This was performed as described previously (section 2.7.1). Protein 
concentration was determined with the Bio-Rad protein assay. All results were 
expressed as a percentage compared to Forskolin response, after normalising cAMP 
with protein concentrations. Negative controls consisted of cells transfected with MC2R 
alone, MRAP alone, MRAP2 alone or vector alone stimulated and also unstimulated. 
Cells stimulated with 10-5 M Forskolin and cell co-transfected with MRAP and MC2R 
stimulated with ACTH were used as a positive controls.  
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4.2.4 Immunofluorescent cell surface assay 
A fluorescence cell surface immunoassay was performed on cells expressing 
HA-MC2R with and without MYC-MRAP2 as described in section 2.7.3. This assay 
was used to determine the extent of HA-M2CR at the cell surface in the presence of 
MRAP2, compared with MRAP. HA-MC2R expressing vector alone acted as a negative 
control, whilst HA-MC2R with MRAP was a positive control. To assess the importance 
of glycosylation, co-expression of HA-MC2R and N9Q-FLAG was performed.  Results 
are expressed as a percentage compared with HA-MC2R alone.  
 
4.3 Results  
4.3.1 MRAP2 interacts with MC2R 
Co-immunoprecipitation (Co-IP) was used to investigate protein-protein 
interaction between MRAP2 and MC2R. CHO cells were co-transfected with MYC-
MRAP2 and HA-MC2R. Immunoprecipitation of MC2R using anti-HA resulted in the 
Co-IP of MYC-MRAP2 (Fig. 4.1[A]). Reciprocal immunoprecipitation of MRAP2-
FLAG enabled detection of HA-MC2R on immunoblotting with anti-HA antibody. HA-
MC2R was detected as two bands and a smear in keeping with previously published 
data on MC2R (Fig. 4.1[B]). The deglycosylation mutant N9Q-FLAG also interacts 
with HA-MC2R (Fig. 4.1[C]).  
Human MC2R has a predicted molecular weight of 33.9 kDa. On Western 
blotting the receptor often runs as a smear due to either the general poor resolution of 
GPCRs by SDS-PAGE or because it is present in higher-order oligomers (Sebag and 
Hinkle, 2009a). In addition distinct 33 and 43 kDa sized bands have been reported in 
cells transfected with C-MYC-hMC2R, corresponding to immature and mature 
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glycosylated MC2R isoforms (Kilianova et al., 2006).  Although HA-MC2R has a 
predicted molecular weight of 37.3 kDa, a band correlating to the smallest band 
demonstrated in Fig.4.1 (B) has been detected following in vitro transcription and 
translation of HA-MC2R (www.cdna.org). Furthermore, smaller than predicted 
immunoreactive bands representing immature human HA-MC2R have also been 
previously reported (Sebag and Hinkle, 2009a). 
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Fig. 4.1: Co-immunoprecipitation assay showing interaction between MRAP2 and MC2R. (A) Co-
IP of MYC-MRAP2 and HA-MC2R in transfected CHO cells. Immunoprecipitation (IP) performed 
using anti-HA agarose and immunoblotting (IB) by anti-MYC. MYC-MRAP2 bands are indicated. 
L=input lysate, IP=immunoprecipitation lanes. (B) Reciprocal Co-IP of HA-MC2R and MRAP2-
FLAG. Immunoprecipiation of MRAP2-FLAG using anti-FLAG agarose and immunoblotting with 
anti-HA shows interaction between MRAP2 and MC2R. MC2R bands are shown. Vertical line 
represents poorly resolved HA-MC2R. (C) Glycosylation status does not affect the ability of 
MRAP2 to interact with the MC2R. * IgG Heavy chain, **IgG Light chain 
 
 
C          
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4.3.2 MRAP2 co-localises with the MC2R and enables the receptor to 
traffic to the cell surface.  
Previous studies have shown MC2R retention in the ER in cells of non-adrenal 
origin (Naville et al., 1996; Noon et al., 2002). Co-expression with MRAP supports the 
expression of MC2R at the cell surface (Metherell et al., 2005). To test the ability of 
MRAP2 to assist MC2R cell surface expression, CHO cells were co-transfected with 
MRAP2-FLAG and HA-MC2R. Confocal imaging of co-transfected cells revealed cell 
surface localisation of HA-MC2R in the presence of MRAP2-FLAG (Fig. 4.2[A]). 
MC2R trafficking in the presence of MRAP2 was further assessed using a fluorescent 
cell surface assay, where live cells are incubated with anti-HA antibody and surface HA 
epitopes measured. After normalising against total HA-MC2R in fixed permeabilised 
cells, the addition of MRAP2 resulted in a significant increase in the surface expression 
of MC2R (Fig. 4.2[B]). The glycosylation mutant, N9Q-FLAG, also enabled MC2R 
trafficking to the cell surface, suggesting that glycosylation of this residue is not 
required in this process. The addition of both MRAP and MRAP2 to MC2R does not 
appear to have an additive effect on MC2R trafficking to the cell surface Fig .4.2(B).  
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Fig. 4.2: MRAP2 assists in the trafficking of the MC2R to the cell surface. (A) HA-MC2R co-
localises with MRAP2-FLAG at the cell surface of transfected CHO cells as seen by 
immunofluorescence.  The deglycosylation MRAP2 mutant N9Q-FLAG also co-localises with HA-
MC2R at the cell surface. Bars represent 10 µm. (B) MRAP2 allows trafficking of HA-MC2R to the 
cell surface. Using a fluorescent cell surface assay, HA-MC2R is detected at the cell surface of 
transfected CHO cells when co-expressed with MRAP2, MRAP, MRAP+MRAP2 and N9Q. There 
is no significant difference between HA-MC2R trafficking with either MRAP or MRAP2. N9Q also 
enables HA-MC2R cell surface trafficking. Error bars represent standard error of the mean. The 
y-axis represents relative intensity normalised to MC2R alone (100%). ***p<0.0001. 
(A)  
             
(B)                           
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4.3.3 N- terminally glycosylated MRAP2 enables functional expression of 
MC2R 
To investigate whether the cell surface localised MC2R, promoted by MRAP2 
co-expression, could signal in response to ACTH, HEK293T cells, which lack 
endogenous MCRs (Rached et al., 2005; Blondet et al., 2004), were transfected with 
MC2R in the presence and absence of MRAP2, MRAP and N9Q. Cells were then 
stimulated with ACTH and cAMP production was measured. Cells transfected with 
MC2R alone did not respond to 10-6 M ACTH (1-39). The addition of MRAP2 resulted 
in the production of cAMP when stimulated with 10-6 M ACTH (1-39) (Fig. 4.3) and 
cAMP generation was comparable to that seen with MRAP and MC2R. Co-expression 
of MRAP and MRAP2 with MC2R did not enhance ACTH-stimulated MC2R cAMP 
production over and above that observed with MRAP or MRAP2 alone. Interestingly, 
the glycosylation status of MRAP2 appears to be functionally important. Despite 
assisting MC2R to the cell surface (Fig. 4.2), N9Q-FLAG failed to enable MC2R 
signalling. These data clearly suggest that MRAP2 may have two separate roles in 
MC2R regulation; firstly trafficking of the receptor to the cell surface, and secondly in 
enabling the receptor to respond to ACTH.   
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Fig. 4.3: N-terminally glycosylated MRAP2 enables HA-MC2R responsiveness to ACTH using a 
cAMP accumulation assay. MC2R was expressed alone or with MRAP2, MRAP, MRAP+MRAP2 
and N9Q in HEK293T cells. Cells were either unstimulated (Unstim) or stimulated with 10-6 M 
ACTH (1-39), or 10-5 M Forskolin. MC2R is responsive to ACTH when co-expressed with MRAP2. 
There is no significant difference in response generated when MC2R is co-expressed with MRAP, 
or both MRAP and MRAP2. With the MRAP2 glycosylation mutant, N9Q, MC2R shows no 
response to ACTH. ***p<0.0001.  
 
                                    
 
 
4.4 Discussion  
4.4.1 MRAP2 can enable the trafficking and normal function of the MC2R, 
but glycosylation appears to play an important role  
In these studies on the role of MRAP2 in MC2R function, it appears that 
MRAP2 is comparable to MRAP, with the ability to facilitate trafficking of the MC2R 
to the plasma membrane and to enable the receptor to signal in response to its unique 
ligand, ACTH. A novel finding with MRAP2 has been the uncoupling of receptor 
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trafficking from receptor signalling. With an MRAP2 mutant expression construct, 
which was non-glycosylated, MC2R trafficked to the cell surface. However, this 
MRAP2 mutant did not support a functional MC2R. Stimulation with ACTH did not 
result in cAMP generation when MC2R was co-expressed with the MRAP2 
glycosylation mutant. This result, therefore, suggests that MRAP2 has two separate 
MC2R accessory roles: firstly in trafficking of the receptor, and secondly in enabling 
receptor responsiveness to ACTH. A similar distinction has since been described with 
MRAP (Sebag and Hinkle, 2009b). The region that enabled mouse MRAP to confer 
ACTH responsiveness was localised to amino-acid residues 18-21 (LDYI) in the N-
terminus. Even though a mutant MRAP lacking these residues (MRAP∆18-21) was able 
to traffic the MC2R to the cell surface, MC2R binding of [125I]ACTH was abolished 
(Sebag and Hinkle, 2009b). However, unlike MRAP2, MRAP glycosylation status did 
not appear to play an important role as an MRAP deletion construct lacking the N-
glycosylation signal was capable of supporting the expression of an ACTH responsive 
receptor (Webb et al., 2009).  
More recently, studies on the full length mouse MRAP2 (which lacks the LDYI 
sequence at the N-terminus) confirmed that MRAP2 enabled the MC2R to traffic to the 
cell surface. However, in stark contrast to data reported here on human MRAP2, the 
MC2R at the cell surface was unable to respond to ACTH. Mouse MRAP2 with MRAP 
residues 18-21 (LDYI) inserted enabled MC2R responsiveness (Sebag and Hinkle, 
2009b). At present it is unclear why there are such marked differences between species 
especially as the MRAP2 N-terminus is highly conserved (Fig. 1.8[C]). Furthermore, 
mouse MRAP2 appears as multiple bands on Western blotting (Sebag and Hinkle, 
2009a), and although not formally assessed, might suggest protein glycosylation as 
shown in section 3.3.4. One additional difference relates to the tags on each of the 
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proteins studied. Functional data on mouse MRAP2 was generated using a protein 
tagged with a V5 epitope on the -NH2 terminus and 3xFLAG epitope on the -COOH 
terminus, whilst data on human MRAP2 used a protein tagged with either MYC or 
FLAG on the N- and C-terminus respectively. The difference in tags, especially at the 
N-terminus, could potentially inhibit glycosylation of the protein, but it would not 
explain how function is regained from the insertion of the LDYI residues. Likewise the 
different ACTH doses used to stimulate the human MRAP2 and mouse MRAP2 (10-6 M 
and 10-7 M respectively) would not account for the differences observed between the 
two studies and the rescue of mouse MRAP2 function following insertion of LDYI 
residues (Sebag and Hinkle, 2009b). Future investigation of species differences would 
be useful and would help to further characterise the mechanism of MC2R trafficking 
and signalling. MRAP functional domains described (sections 1.3.4 & 4.4.1) are 
schematically summarised in Fig. 4.4.  
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Fig. 4.4: Protein alignment of mouse and human MRAP proteins with schematic representation of 
identified functional domains. Work on human MRAP by Webb et al. identified two functional 
domains involved in MC2R trafficking and MRAP/MC2R interaction. There was also a possible 
suggestion that the C-terminus could regulate MC2R surface expression (Webb et al., 2009). In 
comparison, work on mouse MRAP has revealed three possible essential domains involved with 
ACTH binding of MC2R, dual topology and MC2R trafficking (Sebag and Hinkle, 2009b). Hs: 
homo sapiens, Mm: mus musculus.  
 
 
 
4.4.2 MRAP2 and MRAP interplay  
MRAP2 is expressed in the adrenal gland, the main site of MC2R expression. In 
vitro, the addition of MRAP2 to non-adrenal derived cells transfected with MC2R, 
enables the receptor to translocate out of the ER and Golgi apparatus to the cell 
membrane, allowing signalling and cAMP generation in response to ACTH. In this 
manner, MRAP2 is the second Melanocortin-2-receptor interacting protein to be 
identified.  
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Mutations in MRAP2 have not been identified as a cause of FGD. Sequencing of 
MRAP2 exons and intron/exon junctions was undertaken in 11 consanguineous patients 
with homozygosity in the MRAP2 locus (unpublished work). No mutations were 
identified. The clinical implication of MRAP2 deficiency has yet to be defined and is 
discussed in more detail in section 7.2.4.  
The possibility of MRAP2 heterodimerisation with MRAP is of interest, and it is 
tempting to speculate that these two proteins complex in vivo and this interaction play 
an important role in MC2R regulation. However, the temporal expression pattern of 
MRAP versus MRAP2 in development has yet to be determined which may provide 
insight into the possible differential or synergistic actions of these MC2R accessory 
proteins in vivo.  
MC2R is primarily expressed in the adrenal gland, although expression has also 
been noted in testis and ovary, the developing lung and in adipose tissue in mouse 
(Boston and Cone, 1996). Both MRAP and MRAP2 are expressed more widely than 
MC2R, suggesting that both may have MC2R-independent function (Metherell et al., 
2005) [Chapter 2]. 
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5.1 Introduction  
MRAP has been shown to form homodimers that appear resistant to the action of 
SDS and heat (Sebag and Hinkle, 2007; Cooray et al., 2008). Western blotting using a 
polyclonal MRAP2 antibody (rMRAP2189-204) demonstrated an immunoreactive band of 
a size consistent with a dimer that is resistant to denaturing and reducing conditions 
(section 3.3.7). By making comparisons with descriptions of other small accessory 
proteins, dimerisation of the RAMP proteins has been demonstrated (McLatchie et al., 
1998). Furthermore, RAMP1 multimers were detectable at higher expression levels 
under reducing conditions (McLatchie et al., 1998). As both MRAP and MRAP2 are 
expressed in the adrenal gland and brain, the additional possibility of MRAP and 
MRAP2 heterodimerisation was assessed by Co-IP. As discussed in chapter 4 the 
glycosylation status of MRAP2 appears to play a role in enabling the MC2R to respond 
to ACTH(1-39). The N9Q-FLAG construct had the ability to traffic the MC2R to the 
cell surface but not to enable signalling. It has been suggested that dual topology 
homodimerisation of MRAP is necessary for permitting MC2R function (Sebag and 
Hinkle, 2007). Therefore one possible explanation for the apparent inability of N9Q to 
support MC2R function at the cell surface could be the lack of N9Q dimerisation. 
Hence, the ability of N9Q to complex with MYC-MRAP2 was determined.  
 
5.2 Materials and Methods  
5.2.1 Co-IP  
To demonstrate MRAP2 dimerisation, CHO cells were transfected with MYC-
MRAP2 and MRAP2-FLAG. IP was performed with anti-MYC agarose and IB with 
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anti-FLAG antibody, and reciprocal Co-IPs were performed with anti-FLAG agarose 
and IB with anti-MYC antibody. To show heterodimerisation of MRAP2, Co-IP was 
performed on CHO cells co-transfected with MRAP-FLAG (human MRAPα isoform) 
(Webb et al., 2009) and MYC-MRAP2. Co-transfection of MYC-MRAP2 and N9Q was 
performed to demonstrate the ability of the deglycosylation mutant to form dimers.  
 
5.3 Results 
5.3.1 MRAP2 homodimerisation  
CHO cells were transfected with MYC-MRAP2 and MRAP2-FLAG. Co-IP 
showed that MRAP2 forms homodimers (Fig. 5.1). Transfections of MYC-MRAP2 and 
MRAP2-FLAG alone acted as controls.  
 
Fig. 5.1: MRAP2 forms homodimers. MRAP2-FLAG and MYC-MRAP2 were co-expressed in 
CHO cells. Immunoprecipitation (IP) with anti-FLAG followed by immunoblotting (IB) with anti-
MYC shows MRAP2 homodimerisation. The reciprocal Co-IP with IP of anti-MYC is also shown.   
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5.3.2 MRAP2 heterodimerisation 
Co-IP was performed on CHO cells co-transfected with MRAP-FLAG and 
MYC-MRAP2. IP of MRAP-FLAG resulted in pull down of MYC-MRAP2 (detected 
by IB using anti-MYC antibody). Similarly, IP of MYC-MRAP2 resulted in IB of 
MRAP-FLAG, demonstrating the ability of MRAP and MRAP2 to heterodimerise (Fig. 
5.2). Human MRAP-FLAG is detected as multiple bands between 16 and 32 kDa that 
were previously described by Webb et al. and thought to represent posttranslational 
modifications, cleavage products or even degradation products of the human protein 
(Webb et al., 2009).  
 
Fig. 5.2: MRAP and MRAP2 heterodimerise. MRAP-FLAG and MYC-MRAP2 were co-expressed 
in CHO cells. Co-IP with anti-FLAG followed by immunoblotting with anti-MYC shows 
MRAP2/MRAP heterodimerisation. The reciprocal Co-IP is shown.  MRAP-FLAG is detected as 
multiple bands (Webb et al., 2009).  
 
 
 
5.3.3 N9Q-FLAG can interact with full length MRAP2 
An interesting phenomenon is that the deglycosylation construct, N9Q-FLAG, is 
able to traffic the MC2R to the cell surface but this receptor cannot generate cAMP in 
response to ACTH. A recent discovery demonstrates that MRAP forms antiparallel 
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dimers at the cell surface (Sebag and Hinkle, 2007). Experiments on MRAP suggest that 
dual topology homodimerisation of MRAP is a requirement for the accessory protein to 
assist the MC2R to the cell surface and to enable binding and/or signalling of the 
receptor. To assess the ability of the N9Q-FLAG construct to dimerise, Co-IP was 
performed on cells co-expressing N9Q-FLAG and MYC-MRAP2, which showed that 
the N9Q-FLAG protein was able to interact with full length MRAP2.  
 
Fig. 5.3: N9Q can dimerise with full length MRAP2. N9Q-FLAG and MYC-MRAP2 were co-
expressed in CHO cells. Immunoprecipitation (IP) with anti-MYC and immunoblotting (IB) with 
anti-FLAG enabled detection of N9Q-FLAG as a single band.  
 
                               
 
5.4 Discussion  
5.4.1 Implications of MRAP2 homodimerisation and heterodimerisation 
with MRAP in vitro  
MRAP2 is expressed in the adrenal gland and in situ hybridisation data localises 
expression to all three zones of the adrenal cortex (zona glomerulosa, zona fasciculata 
and zona reticularis) (section 3.3.2). MRAP and MC2R are also expressed in all three 
zones of the adrenal cortex. The possibility of MRAP2 heterodimerisation with MRAP 
is interesting and may imply the requirement of both MRAP and MRAP2 interaction 
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with MC2R for expression and signalling of the receptor in vivo. The need for both 
MRAP and MRAP2 together could explain the apparent inability of intact MRAP2 to 
rescue MC2R function in FGD type 2 patients with MRAP mutations. However, the 
apparent ability of MRAP and MRAP2 to independently assist the MC2R to the cell 
surface for normal receptor responsiveness to ACTH in vitro would be evidence against 
this hypothesis. Furthermore, in a heterologous system, MRAP and MRAP2 in 
combination do not appear to have an additive effect.  
The temporal expression of MRAP, MRAP2 and MC2R appear similar, with 
expression in the murine developing and adult adrenal gland. However, further 
expression studies at different embryonic stages may provide some understanding 
towards the role of MRAP2 in the adrenal gland. Ultimately, the use of murine 
knockout models may be required to dissect the roles of MRAP and MRAP2 in MC2R 
adrenal physiology.  
MRAP has been shown to form unique antiparallel homodimers at the cell 
surface. Western blotting of human MRAP2-FLAG demonstrates two protein isoforms, 
glycosylated and unglycosylated. These could adopt similar dimeric Nout-Cin and Nin-
Cout orientations akin to MRAP (Sebag and Hinkle, 2007).  
 
5.4.2 Absent glycosylation at the N-terminus does not affect potential 
homodimerisation  
A novel phenomenon described in chapter 4 is the apparent importance of the 
glycosylation status of MRAP2. The deglycosylated MRAP2 isoform can traffic the 
MC2R to the surface but the receptor cannot generate cAMP in response to ACTH. One 
possible explanation is that the mutant accessory protein results in disrupted 
dimerisation and perhaps this is necessary for full MC2R accessory function. In testing 
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this hypothesis, mutant N9Q appears to maintain the ability to interact with full length 
MRAP2. This is not necessarily a surprise considering that the interacting domain of 
MRAP has been localised to the transmembrane domain (Webb et al., 2009). However, 
the potential changes in protein topology which result from the absence of glycosylation 
have yet to be established.  
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6.1 Introduction  
MRAP2 is more widely expressed than MC2R. MRAP2 is detected in the 
adrenal gland, brain and hypothalamus (section 3.3). The melanocortin 3, 4, and 5 
receptors are all expressed in the brain, with hypothalamic expression well established 
for MC3R and MC4R (Roselli-Rehfuss et al., 1993; Mountjoy et al., 1994b; Chhajlani, 
1996). MRAP2 may, therefore, regulate the expression and signalling ability of the 
other MCRs (which in this chapter refers to MC1R, MC3R, MC4R and MC5R 
collectively).  
MRAP2 and MRAP are capable of heterodimerising with each other (chapter 5). 
The potential interaction between MRAP and MRAP2 may play an important role in 
MCR function. In addition, human MRAP mRNA was also detected in a number of 
non-adrenal tissues (Metherell et al., 2005). Hence, MRAP interaction and subsequent 
effects on MCR function were also assessed. The other MCRs are known to traffic to 
the cell surface of heterologous cells, although there are some suggestions that 
trafficking factors may be involved (Beaumont et al., 2005; VanLeeuwen et al., 2003).  
Taking comparisons with other accessory proteins, RAMPs have been shown to 
interact with other GPCR family members, including GPCRs from class B, and also 
class C receptors (Bouschet et al., 2005; Christopoulos et al., 2003). To determine 
whether the MRAPs have the same ability to interact with other GPCRs outside the 
melanocortin receptor family, interaction between MRAP2 and other GPCRs and the 
subsequent effects were also examined.  
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6.2 Materials and Methods 
6.2.1 Co-IP 
In order to prove that MRAP2/MRAP can directly interact with MCRs, CHO 
cells were transfected with MYC-MRAP2 and MCRs tagged on the N-terminus with a 
3xHA tag. 24 hours post transfection, protein lysates were prepared and 
immunoprecipitation (IP) performed using anti-HA agarose to IP. Immunoblotting (IB) 
with either anti-MYC for MYC-MRAP2 or anti-FLAG for MRAP-FLAG was 
performed as described in section 2.6. Lysates derived from cells transfected with either 
MYC-MRAP2 alone or receptor alone were used as negative controls in each 
experiment. Reciprocal Co-IP involved transfecting cells with MRAP2-FLAG and HA-
tagged receptor. IP was performed using anti-FLAG agarose and IB with anti-HA 
antibody. Further Co-IPs were performed using angiotensin I receptor triple HA tagged 
(HA-AT1R), β2-adrenergic receptor-3xHA (Beta-Adr-R) and calcitonin-like receptor 
(HA-CLR).  
 
6.2.2 Cell surface immunofluorescence assay 
Cell surface immunofluorescence assays were performed according to 
methodology described in section 2.7.3. Cell surface receptor expression was 
determined in the presence or absence of MRAP, MRAP2 or both MRAP and MRAP2. 
Each experiment was performed in triplicate on at least three separate occasions. Data 
are presented as cell surface protein over total protein, normalised to receptor alone. 
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6.2.3 cAMP competitive protein binding assay 
In order to determine the effect of MRAP2 on MCR signal transduction, a 
cAMP assay was used (as described in section 2.7.1). HEK293T cells were transfected 
with MYC-MRAP2, MRAP-FLAG or HA-MCR alone or in combination. 
Untransfected cells stimulated with ACTH(1-39) or NDP-MSH (a synthetic analogue of 
α-MSH with prolonged biological activity, which is 26 times more potent than α-MSH)  
were used to confirm the absence of a cAMP response to ligand (Blondet et al., 2004; 
Rached et al., 2005). Cells stimulated with 10-5 M Forskolin were used as a positive 
control. Controls were performed in every assay. All results were expressed as a 
percentage compared to Forskolin response, after normalising cAMP with protein 
concentrations. MRAP and MC2R co-transfected and stimulated with ACTH was used 
as a further positive control.  
 
6.3 Results 
6.3.1 MRAP and MRAP2 can interact with all Melanocortin Receptors 
Experiments were performed using CHO cells co-expressing MYC-MRAP2 and 
HA-MCR. Co-IP with anti-HA conjugated agarose and IB with anti-MYC showed that 
MRAP2 can interact with each of the melanocortin receptors (MCRs) (Fig. 6.1[A]). The 
reciprocal Co-IP, using anti-FLAG-conjugated agarose to immunoprecipitate MRAP2-
FLAG, resulted in detection, by immunoblotting, of HA-MCR often as smears due to 
poor resolution of GPCRs on SDS-PAGE gels (Fig. 6.1[B]). MRAP-FLAG can also Co-
IP with each of the melanocortin receptors (Fig. 6.1[A]).  
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Fig. 6.1: MRAP and MRAP2 interact with all the other MCRs. (A) Both MRAP-FLAG and MYC-
MRAP2 interact with each of the HA-MCRs as seen by immunoblotting with anti-FLAG and anti-
MYC respectively following immunoprecipitation with HA. (B) MRAP2 reciprocal Co-IP is shown. 
IP performed with anti-FLAG agarose and HA-MCRs detected by IB with anti-HA antibody. 
MCRs appear as smears on SDS-PAGE. Co-IPs were performed using transfected CHO cell 
lysates. Co-IP lane indicated by an arrow. L=lysates, IP=immunoprecipitation, 
IB=immunoblotting, *=heavy chain, ** =light chain. 
 
(A) 
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(B)  
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6.3.2 MRAP and MRAP2 can reduce the cell surface expression of MC4R 
and MC5R 
As all the other melanocortin receptors (MC1R, MC3R, MC4R, MC5R) can 
interact with MRAP and MRAP2, the effect of these accessory proteins in the 
modulation of MCR cell surface expression was assessed using a fluorescent cell 
surface assay as described in section 2.7.3. CHO cells were transfected with a HA-MCR 
alone or in the presence of a melanocortin-2-receptor accessory protein construct 
(MRAP, MRAP2 or both).  The addition of MRAP or MRAP2 resulted in a significant 
reduction in the surface expression of MC4R and MC5R, but did not alter the surface 
expression of MC1R or MC3R (Fig. 6.2).  
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Fig. 6.2: MRAP and MRAP2 can modify surface expression of the other melanocortin receptors. 
MCR at the cell surface is quantified using a fluoresecent cell surface assay and normalised to 
MCR alone (100%). The addition of MRAP and MRAP2 either alone or in combination 
significantly reduced the expression of MC4R and MC5R at the cell surface in CHO cells. No 
change is seen in MC1R or MC3R cell surface expression when co-expressed with MRAP or 
MRAP2. Data are represented as means +/- SEM, * p<0.05, ** p<0.001. 
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6.3.3 MRAP and MRAP2 can downregulate the expression and signalling 
of the melanorcortin receptors and the addition of MRAP and MRAP2 may 
be additive 
To determine the effect of MRAP2 on melanocortin receptor signalling, cells 
expressing MCR in the presence or absence of MRAP2 were stimulated with NDP-
MSH. Receptor signalling was assessed by cAMP generation using a cAMP 
accumulation assay. The effect of MRAP with or without MRAP2 on MCR 
responsiveness was also assessed.  
MC1R cAMP generation was not significantly reduced in the presence of 
MRAP2 or MRAP. However, the addition of both accessory proteins together 
significantly reduced cAMP generated from MC1R stimulated with ligand NDP-MSH 
(Fig. 6.3[A)). MC1R constitutive activity was demonstrated (Fig. 6.3[A]) as an increase 
in basal cAMP generation in the absence of ligand. The high levels of cAMP in 
heterologous cell-lines were previously noted in HEK293T cells (Garcia-Borron et al., 
2005; Sanchez-Mas et al., 2004). Although a downward trend was noted with the 
addition of MRAPs, resulting in a reduction of cAMP generation, this was not 
statistically significant.  
MC3R cAMP generation in response to 10-9 M NDP-MSH was significantly 
reduced in the presence of MRAP2 alone or in combination with MRAP (Fig. 6.3[B]). 
Interestingly, reduction of MC3R cAMP generation appeared most marked when 
MRAP and MRAP2 were co-expressed. This suggests a possible additive inhibitory 
effect on MC1R and MC3R signalling in the presence of both accessory proteins (Fig. 
6.3 [A&B]).  
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MC4R cAMP generation in the stimulated state was significantly reduced in the 
presence of MRAP, MRAP2 or both (Fig. 6.3[C]). The MC4R is known to be 
constitutively active (Nijenhuis et al., 2001). The presence of MRAP and MRAP2 
together appears to reduce the basal MC4R cAMP generation in the absence of ligand. 
However, this observation is to be taken cautiously as the difference between 
unstimulated untransfected HEK293T cells and those expressing unstimulated MC4R 
did not reach statistical significance.  
A significant reduction in MC5R cAMP generation in response to ligand (10-9 M 
NDP-MSH) is seen with the addition of MRAP and MRAP2 (Fig. 6.3[D]).  
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Fig. 6.3: MRAP and MRAP2 can modify signalling of the other melanocortin receptors. (A) MC1R, 
(B) MC3R (C) MC4R and (D) MC5R. MCR response to NDP-MSH is reduced in the presence of 
MRAP and MRAP2. Signalling of the MCRs was determined using the cAMP generation assay in 
transfected HEK293T cells. In the presence of MRAP2, cAMP generation of MC3R, MC4R and 
MC5R in response to NDP-MSH (10-9 M) is significantly reduced. With MRAP a significant 
decrease in NDP-MSH response is seen with MC4R and MC5R. When co-expressed with both 
MRAP and MRAP2 there is a significant decrease in NDP-MSH response with each of the 
receptors. Data are represented as means +/- SEM, * p<0.05. 
 
 
 
 156
MRAP2 Interaction with other MCRs resulting in Downregulation of MCR Signalling                    
6.3.4 Interaction with other GPCRs 
The possibility that MRAP2 can also interact with GPCRs besides MCRs was 
investigated by Co-IP of MRAP2 with the β2-adrenergic receptor (Beta-Adr-R), AT1 
angiotensin receptor (AT1R) and calcitonin-like receptor (CLR) transfected into CHO 
cells. No Co-IP was identified with the AT1R or CLR, but Co-IP was detectable with 
the Beta-Adr-R (Fig. 6.4).  
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Fig. 6.4: Specificity of the interaction between MRAP2 and other G protein-coupled receptors. The 
HA-tagged AT1 angiotensin receptor (HA-AT1R), the β2-adrenergic receptor (Beta-Adr-R) or the 
calcitonin-like receptor (HA-CLR) were co-transfected into CHO cells with MYC-MRAP2 and co-
immunoprecipitation performed. MRAP2 co-precipitated with the β2-adrenergic receptor 
(arrowed), but not with the other receptors. 
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6.4 Discussion 
6.4.1 MRAP and MRAP2 regulation of MCRs 
MRAP and MRAP2 can reduce the cell surface expression of MC4R and MC5R 
and also the signalling of this receptor. MRAP2 can also regulate the signalling of the 
MC3R, but in this case without changing the surface expression of the receptor. In the 
presence of both MRAP and MRAP2 the ability of the MC1R and MC3R to generate 
cAMP in response to NDP-MSH is reduced again without a significant reduction in 
surface expression of the receptors. These data support the concept of a dual functional 
role for the MRAP proteins, firstly in receptor trafficking and secondly in regulating 
receptor responsiveness to ligand(s).  
The ability of MRAP to reduce surface expression of melanocortin receptors 
other than the MC2R was noted by Sebag and Hinkle (Sebag and Hinkle, 2007). In their 
studies looking at the effects of mouse MRAP, they investigated cell surface expression 
of the receptor by ELISA and found that the presence of MRAP resulted in a reduction 
of MC5R at the surface. MC4R surface expression was unchanged in the presence of 
MRAP, which differs from data presented here. One possible explanation is that the 
reduction seen in cell surface expression of MC4R reported in this thesis is relatively 
small and since Sebag and Hinkle analysed the results from only two experiments, each 
containing two to three replicates, this may not have been adequate to demonstrate a 
relatively small effect. Another explanation is the possibility of slight differences 
between mouse and human MRAP.  
The specificity of the effect of MRAPs on MCR function was further assessed in 
work performed in conjunction with Dr Teng-Teng Chung (Chan et al., 2009c). Despite 
interaction between MRAP2 and the β2-adrenergic receptor by Co-IP, neither MRAP 
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nor MRAP2 influenced cAMP generation in response to isoproteranol (Fig. 6.5). This 
would support the notion that the effect of MRAPs is specific to the melanocortin 
receptor family. However, further work on other GPCR receptors may reveal novel 
roles for MRAPs in the future.  
 
Fig. 6.5: Influence of MRAP or MRAP2 on cAMP generation by the β -adrenergic receptor in 
response to isoproteranol (10  M).
2
-7  CHO cells were transfected with the β2-adrenergic receptor 
expression vector and either empty vector, MRAP or MRAP2 expression vectors. cAMP signal 
transduction was measured using a cAMP luciferase reporter construct as described elsewhere 
(Cooray et al., 2008; Webb et al., 2009).  
 
The mechanism of MRAP2 action on downregulation of MC1R, MC3R, MC4R, 
and MC5R is unknown. In an attempt to explore the possible mechanisms of action of 
MRAP2 on the MCRs, dose response curves were generated to assess the effect of 
MRAP2 on MC5R in conjunction with Dr Eirini Meimaridou (Chan et al., 2009c). This 
work suggested that the accessory protein acts to reduce the maximal response of the 
receptor, rather than shifting the dose response curve to the right (Fig. 6.6). The 
reduction in maximal response would be consistent with a reduction in receptor 
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numbers at the cell surface, although effects on ligand binding and signalling cannot be 
excluded.  
The ability of accessory proteins to change ligand specificity is well described 
for the calcitonin-receptor-like-receptor (CRLR) whereby the binding of RAMP1 to 
CLRL enables the receptor to respond to calcitonin-gene-related peptide (CGRP). In 
contrast, binding of RAMP2 results in the CRLR to respond to adrenomedullin 
(McLatchie et al., 1998). The MRAPs could potentially act to change MCR ligand 
preference from NDP-MSH to ACTH. This is discussed further in chapter 7.  
 
Fig. 6.6: MC5R dose response curve in the presence or absence of MRAP2. CHO cells were 
transfected with the MC5R with or without the MRAP2 expression vector. After 24 hours cells 
were stimulated with various concentrations of NDP-MSH. cAMP signal generation was measured 
using a cAMP luciferase reporter assay as described previously (Cooray et al., 2008; Webb et al., 
2009).  Results are the mean +/- SD of two independent experiments. 
                     
 
6.4.2 Interplay between MRAP2 and MRAP 
Data presented in this thesis suggests that MRAP and MRAP2 may both have a 
novel role in the regulation of MCR functional expression through a combination of 
receptor cell surface trafficking and the modulation of signalling. Each of the MCRs 
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have been shown to interact with the two MRAP proteins. Unlike the MC2R, the other 
MCRs do not appear to require additional factors in order to traffic to the cell surface. 
Intriguingly, MRAP and MRAP2, as either homo or heterodimers, can act as negative 
regulators of MCR function. Precise cellular localisation of the MRAPs and MCRs may 
provide clues to which of the MRAPs is responsible for the modulation of which MCR 
in vivo. However, as the MRAPs can dimerise in vitro we may find in future that in 
some tissues both accessory proteins work in conjunction to enhance or alter their 
effects on a particular MCR.  
 
6.4.3 Non-adrenal localisation of MRAP and MRAP2 and possible 
physiological importance 
The tissue expression of MRAP2 extends beyond that of MC2R, suggestive of 
wider physiological roles of the MRAP proteins. MRAP2 is expressed in human brain 
and rat hypothalamus. Mouse MRAP2 (XM_147017) was examined as part of the 
genome-wide atlas of gene expression in the adult mouse brain (Lein et al., 2007) by in 
situ hybridisation and it appears to be expressed in the paraventricular hypothalamus 
(PVH). MC4R is highly expressed in the PVH and MC3R in the ventromedial nucleus 
(VMN) of the hypothalamus (Chen et al., 2000; Balthasar et al., 2005).  This is 
summarised in Fig. 6.7. The reported data in this thesis supports the possible role of 
MRAP2 in the regulation of the central melanocortin system.  
MRAP expression has been reported in a number of tissues including both 
human and mouse brain and mouse hypothalamus (Fig 6.8) (Metherell et al., 2005; 
Gardiner et al., 2002). MRAP could also potentially have a role centrally, although there 
is little suggestion of this in patients with FGD type 2, with the exception of one case 
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report of obesity in a family with a homozygous M1I mutation of MRAP (Rumie et al., 
2007).  
The MC2R appears unique amongst MCRs in requiring an accessory protein for 
expression and function (Metherell et al., 2005). This is not the only difference between 
the MC2R and other MCRs, the unique ligand specificity of the MC2R differentiates 
this receptor from the other MCRs. It is interesting that MRAP and MRAP2 have 
opposite effects in the modulation of different MCR family members. MRAP and 
MRAP2 separately and together can increase trafficking and signalling of the MC2R 
while reducing the signalling and in some cases plasma membrane expression of the 
other members of the MCR family. The reason for differential control of the MC2R and 
MC4R is unclear. Further studies may reveal the structural and mechanistic basis of 
these opposing melanocortin receptor actions. The identification of a role in the 
regulation of the melanocortin receptors by MRAP and MRAP2 is of significant 
interest. MC3R and MC4R - because of their involvement in the central regulation of 
metabolism, appetite and food intake - are the focus of much pharmaceutical research, 
and the MRAP proteins might prove to be important future targets of therapeutic 
manipulation. 
 163
MRAP2 Interaction with other MCRs resulting in Downregulation of MCR Signalling                    
Fig. 6.7: Brain localisation of MRAP2. Expression of mouse MRAP2 was examined as part of the 
genome-wide atlas of gene expression in the adult mouse brain (Lein et al., 2007). Staining in the 
region of the PVH is indicated by an arrow. Comparative section of brain staining for MC4R in the 
PVH is also shown (Balthasar et al., 2005).  
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Fig. 6.8: MRAP expression in brain. Tissue distribution studied by Metherell et al. demonstrates 
that MRAP expression extends beyond the adrenal gland (Metherell et al., 2005). MC2R expression 
is shown in blue, MRAPα in yellow and MRAPβ in green.  
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7.1 Summary of results 
 Work reported in this thesis demonstrates that MRAP2 is a highly conserved, 
expressed gene and translated protein, homologous to MRAP. Characterisation of this 
novel gene and protein reveals that MRAP2 is expressed in the adrenal gland and brain 
and is a small single pass transmembrane domain protein, glycosylated at the N-
terminus. Like MRAP, MRAP2 has a C-terminal out orientation, demonstrated by 
confocal microscopy. However, with N-terminal glycosylation this is suggestive that 
MRAP2, similar to MRAP which has been shown to adopt an antiparallel homodimer 
formation, is likely to also have both N- and C- termini orientated extracellularly.  
 MRAP2 can interact with all five melanocortin receptors. Interaction with the 
MC2R enables the receptor to traffic to the cell surface and signal in response to its’ 
ligand ACTH. The glycosylation of MRAP2 appears important in ligand binding and/or 
receptor signalling. Unlike MC2R, the other MCRs do not require additional factors in 
order to traffic to the cell surface. Intriguingly, it appears that MRAP2, as either 
homodimers or heterodimers with MRAP, act as negative regulators of MCR function. 
MRAP2 is capable of reducing the cell surface expression of MC4R and MC5R when 
co-expressed in CHO cells. MRAP2 did not change the cell surface expression of 
MC1R or MC3R. This could reflect the lack of method sensitivity. However, even when 
using an alternative technique such as ELISA, no change in MC1R or MC3R cell 
surface expression was detected in the presence of MRAP (Sebag and Hinkle, 2007). 
Reduced signalling, shown by a reduced cAMP response to NDP-MSH stimulation was 
identified with several of the MCRs. For MC3R decreased cAMP production was seen 
when co-expressed with MRAP2 or both MRAPs, and for MC1R when co-expressed 
with MRAP and MRAP2 together. The ability of MRAP to interact with the other 
MCRs was also assessed, and this showed that MRAP too has the ability to bind all five 
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members of the melanocortin receptor family, modulating the expression and/or 
function of these receptors. Therefore both proteins may have a novel role in the 
regulation of MCR functional expression in vivo, through a combination of receptor cell 
surface trafficking and the modulation of signalling.  
 Importantly, these results indicate that MRAP and MRAP2 are able to regulate 
the other MCRs in heterologous cells. However, further studies are required to ascertain 
the physiological relevance of the two MRAP proteins in the melanocortin system. 
Limited data is available on patients with null loss-of-function mutations in MRAP 
causing the clinical condition FGD type 2. Such patients do not appear to have 
additional clinical features indicative of the dysfunction of melanocortin receptors other 
than MC2R. MRAP2 is principally expressed in the brain within the hypothalamus and 
PVN. This pattern of expression makes MRAP2 a strong candidate regulator to other 
central MCRs, such as the MC4R.   
 
7.2 Future work 
This is the first demonstration of how MRAPs have the ability to regulate the 
melanocortin receptor family in a bidirectional manner, namely trafficking and 
subsequent stimulation of the MC2R and downregulation of the other MCRs. This work 
provides a potentially novel layer of MCR family regulation not previously described. 
Hence there are many areas yet to be explored in future. One major limitiation to the 
work described in this thesis is the fact that the majority of data generated utilises an in 
vitro system of heterologously expressing cells. Although a good start point to 
understanding the mechanism of action of a novel gene and protein, work on 
endogenous protein, at a cellular and organism level, is ultimately required to 
demonstrate the in vivo importance of MRAP2 function. This forms the basis of future 
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work with focus on establishing the physiological importance of MRAP2 and its 
mechanism of action.  
 
7.2.1 Mechanism of MRAP2 action to cause bidirectional regulation of 
different MCR family members 
 Recent studies have begun to dissect the mechanism of MRAP action, both in 
its interaction and trafficking of MC2R and with the identification of its unique 
antiparallel homodimeric structure (Sebag and Hinkle, 2007; Cooray et al., 2008; Webb 
et al., 2009; Sebag and Hinkle, 2009b). It is not yet known why the MRAP proteins 
promote the trafficking of MC2R but inhibit the cell surface expression of MC4R and 
MC5R, or indeed why they do not appear to alter the ability of MC1R and MC3R to 
reach the cell surface. Furthermore, it is unclear at present whether the decrease seen in 
cAMP production on receptor stimulation is through an inhibition of ligand binding or 
cellular signalling.  
 One recent study suggests that MRAP disrupts dimerisation of MC5R and as a 
result the monomeric MC5R is trapped in the ER, failing to traffic to the cell surface 
(Sebag and Hinkle, 2009a). In contrast, MRAP has little effect on MC2R dimerisation. 
Furthermore, the regions of MRAP reported to be responsible for MC5R inhibition 
versus MC2R promotion to the cell surface differ. The mouse MRAP deletion construct, 
where the first 30 amino acids are deleted (MRAP∆1-30), completely abolished the 
negative effects of MRAP on MC5R trafficking allowing the receptor to traffic the cell 
surface. The amino terminus was important for MC5R action. The mouse MRAP 
residues 31-37, just NH2-terminal to the transmembrane domain, were thought to be 
essential for trafficking. This was the region responsible for dual topology. 
Interestingly, in comparison deleting residues 31-37 had little effect on MC5R surface 
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inhibition (Sebag and Hinkle, 2009a). In human MRAP the trafficking region was 
localised to the 15- amino acid tyrosine rich domain between residues 9 and 24 (Webb 
et al., 2009). Dimerisation of the MC4R has been described, which would account for 
the dominant negative effect of some naturally occurring mutations described in obese 
patients (Nickolls and Maki, 2006; Biebermann et al., 2003; Elsner et al., 2006). Homo- 
and heterodimerisation have also been reported for MC1R, with associated naturally 
occurring dominant negative mutations (Zanna et al., 2008; Sanchez-Laorden et al., 
2006; Zanna et al., 2008), and MC3R (Mandrika et al., 2005). Data in this thesis show 
that MRAPs have little effect on MC1R and MC3R surface expression and this is 
supported by data from Sebag and Hinkle (Sebag and Hinkle, 2007).  
 As previously discussed, the bidirectional modulation of the melanocortin 
receptors is likely to result from more than simply disrupted receptor trafficking, hence 
other mechanisms should be investigated.   
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Fig. 7.1: Schematic diagram demonstrating the mouse MRAP domain thought to be responsible for 
disrupting MC5R dimerisation.  
 
7.2.1.1 Effects of MRAP and MRAP2 on MCR binding and ligand 
specificity 
In the presence of MRAP2 and/or MRAP, the responsiveness of MC1R, MC3R, 
MC4R and MC5R to NDP-MSH is reduced. Although this is probably partly through 
changes in surface expression, the extent of cAMP reduction is greater than that seen 
when surface expression is the sole mechanism. Investigating MCR ligand binding may 
reveal a further mechanism by which the MRAPs cause their effect. Other GPCR 
accessory proteins such as the RAMP proteins are known to affect ligand specificity 
(McLatchie et al., 1998). The affinity of each of the melanocortin receptors to 
melanocortins is well described (Ellacott and Cone, 2006). MC2R is only responsive to 
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ACTH, whilst MC3R responds equally to all four ligands (α-,β-, and γ-MSH as well as 
ACTH). MC4R responds best to α-MSH and ACTH, then to β-MSH and least of all to 
γ-MSH.  
Using heterologously expressing cells, receptor binding to each of the 125I-
radiolabelled ligands can be assessed and displacement curves created for each ligand in 
the presence and absence of MRAP and/or MRAP2. In addition, the comparative 
binding of inverse agonists such as AGRP would be important to investigate.  
 
7.2.1.2 MRAP2 homo- and heterodimerisation with MRAP and the 
effect of glycosylation and topology 
MRAP has been demonstrated to form SDS and reducing agent insensitive 
dimers in endogenously expressing tissue (adrenal), but this does not occur to any 
significant extent in transfected tissue where it tends to migrate as a monomer.  The 
same phenomenon seems to apply to MRAP2. This could suggest the presence of one or 
more factor(s) in tissues responsible for the formation of such dimers. Understanding 
the molecular basis of this denaturation resistance in extracts from endogenously 
expressing cells and tissues, but not in heterologously expressing cells may provide 
further understanding of the mechanisms that govern MRAP action in vivo.  
MRAP2 is expressed in the adrenal gland and in situ data localises expression to 
all three zones of the adrenal cortex (zona glomerulosa, zona fasciculata and zona 
reticularis). The possibility that MRAP2 heterodimerises with MRAP in vivo is 
tantalising as this may imply the requirement of both MRAP and MRAP2 interaction 
with MC2R for expression and signalling of the receptor. However, the lack of MRAP2 
mutations in FGD patients would argue against this. The temporal expression pattern of 
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MRAP and MRAP2 in development has yet to be established. Elucidation of this may 
enable dissection of MRAP and MRAP2 roles in MC2R adrenal physiology.  
 Another area of interest is the apparent importance of the MRAP2 glycosylation 
site in MC2R function but not surface trafficking. It would be of interest to determine if 
the abolition of the N-terminus glycosylation results in the inability of MRAP2 to 
reduce expression of MC4R and MC5R. The mechanistic changes of a single amino 
acid change would also be worth studying to ascertain whether it changes MRAP2 
topology. 
  
7.2.2 Co-localisation of MRAP2 in cells 
MRAP2 is clearly expressed in brain and most probably in nuclei that also 
express MC3R/MC4R. Further studies in the form of in situ hybridisation or co-
immunohistochemical analysis could demonstrate expression in the same cell. 
Unfortunately to date, attempts at in situ hydridisation in brain sections have been   
unsuccessful. Furthermore, co-immunohistochemical analysis of brain sections would 
require good quality MRAP2 and MC4R antibodies. MC4R antibodies are already 
commercially available and although some aspects of the polyclonal MRAP2 antibody 
were promising, with the ability to identify MRAP2 in transfected cell lysates and 
tissues by Western blotting, its usage on cryosections of brain and immunofluorescence 
of MRAP2 expressing cells have so far been unsuccessful with the detection of high 
background staining.  
 
7.2.3 In vivo work 
As previously discussed, the work described is primarily on transfected cells. 
The identification of cell-lines expressing sufficient quantities of endogenous MRAP2 
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and MCR would enable some in vivo work to be performed. A cell-line of this nature 
has yet to be identified. There is always the question of MRAP and MRAP2 redundancy 
but the highly conserved nature of MRAP2 would suggest that MRAP2 plays an 
important role in normal animal physiology. Ultimately, animal models should be 
employed to enable dissection of MRAP2 and MRAP function.  
 
7.2.3.1 Cell-lines and tissues 
7.2.3.1.1 MRAP2 knockdown in hypothalamic neuronal cell-lines 
As MRAP2 appears to be highly expressed in brain and hypothalamus where 
MC3R and MC4R are expressed, embryonic mouse hypothalamic cell-lines (N29, N39, 
N40, N42) and hypothalamic neuronal cell-lines (GT1-7 and GT1-1) would be 
candidate cell-lines for MRAP2 and MCR expression, to identify a cell-line expressing 
both MCR and MRAP2. Cell-lines should be screened for MRAP expression to exclude 
MRAP effects. Using a siRNA approach, successfully employed in the knockdown of 
MRAP in adrenal cell-lines (Cooray et al., 2008), knockdown of MRAP2 should be 
performed to assess the effect on expression and function of the MCRs. Assessment in 
the form of RT-PCR and cAMP accumulation assays could then determine MCR 
responsiveness to NDP-MSH in the absence of MRAP2.  
 
7.2.3.1.2 Endogenous MRAP2 interaction in tissues and cell-lines 
The polyclonal MRAP2 antibody has poor ability to immunoprecipitate MRAP2 
even in transfected cells in which immunoblotting (with the same antibody) shows the 
presence of the protein.  Furthermore, attempts to Co-IP MRAP2 with MC4R antibodies 
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in rat hypothalamus have not been successful probably due to inherent problems of the 
MC4R antibody when used in the application of Co-IP. Such MC4R antibodies also 
failed to convincingly IP transfected MC4R. Better commercially available MC4R 
antibodies would make endogenous Co-IPs possible in the future and show endogenous 
MRAP2 and MC4R interaction. Similarly, other tissues such as adrenal lysates could be 
used to examine endogenous interaction between MRAP2 and MCRs.  
 
7.2.3.2 Animal models 
MC3R and MC4R are essential for the control of energy homeostasis (Cone, 
2006). MRAP and MRAP2 are likely to prove to be important endogenous regulators of 
MC3R and MC4R. Future studies using transgenic mouse models are required to dissect 
the differential and synergistic functions of the two melanocortin accessory proteins 
MRAP and MRAP2.   
 
7.2.3.2.1 Characterisation of MRAP2 (and MRAP) knockout (KO) mice 
Knockout (KO) mice can be in the form of full KOs or conditional KOs. 
Complete KOs may be embryonic lethal hence creation of a targeting vector which 
contains Cre-recombinase ‘LoxP’ sites flanking the critical coding exon could enable 
tissue specific KO mice in the future. For example, brain conditional KO mice can be 
made by breeding animals with specific Cre transgenic mice. The tissue specific 
approach has been successful in a number of gene such as PPARγ, where early 
embryonic lethality is seen in global KOs (Kubota et al., 1999; Barak et al., 1999; Jones 
et al., 2005; Gavrilova et al., 2003; Rosen et al., 2003). Furthermore, double KO mice 
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may provide necessary information on MRAPs function, especially if there is an element 
of redundancy between MRAP and MRAP2.  
 
The following are possible areas of investigations: 
 
Growth, feeding behaviour and energy expenditure in KO mice.  
Detailed phenotyping including analysis of body weight and body length, body 
composition, assessment of food intake and analysis of energy expenditure/activity in a 
free living environment should be undertaken. Biochemical analysis including 
measurement of plasma glucose, insulin, leptin, thyroxine, ACTH and corticosterone 
would be useful. The phenotype of the MRAP KO and possibly MRAP2 KO mice may 
resemble human FGD. These mice may present severe glucocorticoid deficiency and die 
soon after birth, as with MC2R KO mice (Chida et al., 2007). In such cases, 
glucocorticoid replacement in MRAP and MRAP2 KO mice may be required for 
survival of mice beyond the neonatal period. The effects of corticosterone replacement 
would then need to be carefully assessed (Coll et al., 2005).   
 
Expression of MRAP, MRAP2, MC2R, MC3R and MC4R in KO mice.  
Most targeting vectors are designed to contain reporters such as LacZ. In the LacZ 
targeted null allele, the reporter is under the control of the KO gene promoter. In the KO 
animals MRAP and MRAP2 expression will therefore be replaced with LacZ. LacZ 
expression will be analysed using X-gal histochemical protocols (Schmidt et al., 1998). 
To determine the hypothalamic expression of MC3R and MC4R in MRAP KO and 
MRAP2 KO mice, perfused brains collected from terminally anaesthetised mice could 
be used for in situ hybridisation and immunohistochemical studies for MC3R and 
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MC4R. Adrenal sections could be used to determine MC2R mRNA and protein 
expression. In addition, the assessment of MRAP expression in the case of MRAP2 KO 
and MRAP2 in MRAP KO animals is warranted.  
 
Adrenal anatomy and function of the KO mice.  
MC2R KO mice have low aldosterone levels, in contrast to human FGD patients with 
MC2R mutations (Chida et al., 2007). Hence, further hormonal assays (serum 
electrolytes, aldosterone and renin) to assess zona glomerulosa function could reveal 
MRAP and MRAP2’s contribution to adrenal function. Adrenal morphology and 
histology would be useful. Corticosterone responsiveness to ACTH1-24 at different time 
points would be valuable, as some FGD patients are initially capable of producing a 
cortisol in response to ACTH1-24. However, with time they become unresponsive 
(unpublished data). This is an interesting phenomenon and MRAP KO mice may 
provide a useful model to investigate this potential novel mechanism of deteriorating 
adrenal function.  
 
Although KO mice are a powerful research tool to decipher the function of a 
particular gene in question, there are potential problems and limitations associated with 
this technique. For example, the phenotypes described in mice may not necessarily be 
completely representative of humans with mutations in that particular gene. The tumour 
suppressor gene p53 homozygous null and heterozygous mice were predisposed to a 
different array of tumours compared with humans. (Donehower et al., 1992; Tsukada et 
al., 1993; Jacks et al., 1994; Purdie et al., 1994). In addition, the genetic background of 
mice can affect the observed phenotype. p53 heterozygous mice on a Balb/c background 
were more likely to develop breast tumours compared to those on mixed C57BL/6-
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129/SV strains (Kuperwasser et al., 2000). Leptin deficient mice generated by 
spontaneous mutation had varying degrees of obesity and diabetes depending on the 
genetic background of the mouse strain (Coleman and Hummel, 1973; Ingalls et al., 
1996).  
The technical aspects and design of each knockout may account for some 
phenotypic differences seen in different knockouts of the same gene. The reported 
adrenal morphology of the POMC knockout mice differs between studies (Yaswen et 
al., 1999; Smart and Low, 2003; Coll et al., 2004). In some cases a murine phenotype 
may be enhanced when cross-bred with a particular phenotype or nutured in a given 
environment (Erickson et al., 1996; Erickson et al., 1997; Hollopeter et al., 1998). 
Finally, the timing of genetic knockouts can also play a role, for example phenotypic 
differences in adult versus embryonic AgRP knockouts (Qian et al., 2002; Wortley et 
al., 2005; Flier, 2006). In summary, murine models of disease are often essential in 
establishing a function of a given gene although interpretation of results and 
applicability to human phenotypes can be challenging.  
 
7.2.4 Screening of patient groups 
The clinical relevance of MRAP2 is unknown. MRAP2 KO mice may help 
define human disease phenotypes caused by mutations in this gene. Screening of the 
respective patient groups could prove fruitful. MC3R and MC4R have both been 
implicated in obese phenotypes. As MRAP2 can interact with both of these 
melanocortin receptors, this group of patients could potentially harbour gain-of-
function MRAP2 mutations. In contrast, loss-of-function mutations or deletions of the 
gene would be expected to result in increased MC3R and MC4R signalling, hence 
could play a role in maintaining leanness.  
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In the case of MC2R the fact that MRAP2 is expressed in the adrenal cortex 
and in vitro allows the receptor to traffic to the cell surface and signal in a manner 
similar to MRAP makes this a good candidate to cause non-MC2R and non-MRAP 
causing FGD, referred to as FGD type 3. Although homozygosity mapping has 
allowed identification of a number of patients with homozygosity of the MRAP2 
locus, mutational analysis has not so far revealed any causative mutations.  
Another unanswered question is how, despite having the same adrenal 
localisation and the ability to allow functional expression of MC2R, there is no rescue 
of patients with MRAP mutations, where MRAP2 is intact. A possible explanation for 
this is that MRAP and MRAP2 may work together in vivo as heterodimers and 
dysfunction of one results in the inability of the other to work. Murine models and 
screening of patient groups should hopefully answer such questions in the future.  
 
7.3 Conclusion 
MRAP2, together with MRAP, forms a new family of melanocortin-receptor-
accessory proteins important in the trafficking and signalling of the MCRs. Like 
MRAP, MRAP2 is able to support MC2R cell surface expression, producing a 
functional ACTH responsive receptor. In addition, a novel role of MRAP and MRAP2 
in the modulation of the other MCRs provides the basis of a new aspect of melanocortin 
receptor research previously unknown.  The melanocortin receptor family plays a 
diverse role in normal physiology and disease processes. MCRs are subject to intense 
pharmaceutical research, and identification of a novel accessory protein such as 
MRAP2 involved in the regulation of these receptors is of considerable importance. 
Much more has yet to be learnt about MRAP2 in the years to come. MRAP2 and 
MRAP join a number of GPCR accessory proteins that have been identified in the past 
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decade. MRAP and MRAP2 are unique having no signal peptide, dual topology and the 
ability to bidirectionally modulate receptor trafficking and function, distinguishing them 
from the other families of accessory proteins. Further investigation of the MRAPs may 
not only be applicable to the MCR receptor family but, by understanding the 
mechanisms of action, may provide insight into other GPCR modulation by similar 
accessory factors that are yet to be discovered.  
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Appendix 1 Laboratory equipment  
 
General 
 
Water purification system 
Purite Select Analyst HP50 (Purite Ltd, UK)  
 
Water baths 
Grant JB1 and SE10 (Grant instruments Ltd, UK) 
 
Ice machine 
Scotsman AF 10 ASB 2700 (Scotsman Ice Systems, Italy) 
 
Centrifuges 
Sorvall Cooling centrifuge legend RT (Thermal scientific, USA) 
Eppendorf Cooling centrifuge 5804R (Eppendorf, UK) 
Micro Centaur microcentrifuge (MSE, UK)
 
Balances 
B30015 balance (Mettler Toledo, UK)  
Micro balance AB54 (Mettler Toledo, UK) 
Ultra micro balance UMX2 (Mettler Toledo, UK) 
 
pH meter 
Mettler Delta 320 (Mettler Toledo Ltd, UK) 
 
DNA/RNA 
 
PCR machines 
GeneAmp PCR system 2400 (PE Biosystems, UK) 
GeneAmp PCR system 9700 (PE Biosystems, UK) 
 
Electrophoresis tanks 
Mini-Sub Cell GT (Bio-Rad Laboratories Ltd, UK) 
Wide Mini-Sub Cell GT (Bio-Rad Laboratories Ltd, UK) 
 
Electrophoresis power supply units  
Atto AE3105 (Genetic Research Instruments, UK) 
GIBCO BRL 400L (Life Technologies Ltd, UK) 
LKM Bromma 2197 (LKB Instruments Ltd, UK) 
 
Spectrophotometer  
GeneQuant RNA/DNA Calculator (Pharmacia Biotech, UK) 
NanoDrop ND1000 spectrophotometer (NanoDrop Technologies, USA) 
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Ultraviolet transilluminator  
UVP20 (UVP, CA, USA) 
UVIdoc (UVItec Ltd, UK)  
 
Proteins and tissues 
 
Homogeniser  
Precellys 24 tissue homogeniser (Bertin Technologies, France) 
 
Microtome 
Rotary microtome RM2145 (Leica Microsystems Ltd, UK) 
 
Western blotting equipment  
Mini PROTEAN 3 electrophoresis apparatus (Bio-Rad Laboratories Ltd, UK) 
Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad Laboratories Ltd, UK) 
Semi-dry blotter: Trans-Blot SD semidry transfer cell (Bio-Rad Laboratories Ltd, UK) 
 
Protein imaging/quantification 
Compact X4 automatic film processor (Xonograph Imaging Systems, UK) 
Odyssey Infrared Imaging System with Li-COR Odyssey Software 2.1 (Li-COR 
BioSciences Ltd, UK) 
UVmax kinetic microplate reader (Molecular devices, USA)  
 
Cell work 
 
Laminar flow cabinet 
Envair MSCII (Envair Ltd, UK) 
 
Microscopes 
Nikon Eclipse TS100 with Nikon C-SHG fluorescene observation device (Nikon 
Instruments, Netherlands) 
Leic DMIL with DC 200 digital camera system (Leic Microsystems, UK) 
LSM 510 confocal laser scanning microscope (Carl Zeiss Ltd, UK) 
 
Liquid nitrogen storage 
Cryolab25 (Statebourne Cryogenics, UK) 
 
Cell culture incubator 
CO2 research incubator (LEEC Ltd, UK) 
 
Assays 
 
Liquid Scintillation counter 
Wallac 1409 DSA (Perkin Elmer, UK) 
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Appendix 2 Commercial Peptides 
 
NDP-MSH (H-1100, Bachem, Switzerland) 
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 
 
ACTH[1-39] (human) (H-1160, Bachem, Switzerland)  
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-
Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-
Phe-OH 
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Appendix 3 Vector maps 
 
pcDNA3.1(+) Vector Map (Invitrogen Ltd, UK) 
 
                                              
 
 
pEGFP-N1 vector map (Clonetech, UK) 
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pGEM®-T Easy Vector Map (Promega, UK) 
  
 
p3XFLAG-CMV™-14 EXPRESSION VECTOR map (Sigma-Aldrich, UK)  
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Appendix 4 Primer sequences 
 
hMRAP2  F 5' ATGTCCGCCCAGAGGTTA 3'
hMRAP2  R 5' TCAATCCAGGTCTTTGTG 3'
hMRAP2  R 5' CTAATAAGAGGCATTTCT 3'
rMRAP2 F 5' ATGCCTGGAGACCCACAG 3'
rMRAP2 R 5' CTTACCTGTGGGGAGCCT 3'
GAPDH(276) F 5' TCCCATCACCATCTTCCA 3'
GAPDH(1038) R 5' GTCCACCACCCTGTTGCT 3'
GAPDH F 5' TGCACCACCAACTGCTTAG 3'
GAPDH R 5' GGATGCAGGGATGATGTTC 3'
MRAP2-
FLAGEcoR1 
F 5' ATCGGAATTCATGTCCGCCCAGAGGTTA 3'
MRAP2-
FLAGXho1 
R 5' AATCTCGAGTCACTTGTCATCGTCGTCCTTGTAG
TCATCCAGGTCTTTGTGTGA 
3'
MYC-
MRAP2EcoR1 
F 5' ATCGGAATTCATGGAGCAGAAACTCATCTCTGAA
GAGGATCTGATGTCCGCCCAGAGGTTA 
3'
MYC-
MRAP2Xho1R 
R 5' AATCTCGAGTCAATCCAGGTCTTTGTGTGA 3'
N9Q-FLAG F 5' TGTCCGCCCAGAGGTTAATTTCTCAGAGAACCTC
CCAG 
3'
N9Q-FLAG R 5' CTGGGAGGTTCTCTGAGAAATTAACCTCTGGGCG
GACA 
3'
T7  F 5' TAATACGACTCACTAT 3'
BGH R 5' CCTCGACTGTGCCTTCTA 3'
SP6 R 5' TTCTATAGTGTCACCTAAAT 3'
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Appendix 5 In silico programs  
 
BLAST (Basic Local Alignment Search Tool) WU-BLAST 2.0 searches were 
performed using the following databases (Altschul et al., 1997):  
www.ncbi.nlm.nih.gove/BLAST/
www.ensembl.org/Multi/blastview
 
Clustal W2 - multiple sequence alignment program for DNA or proteins (Larkin et al., 
2007).  
www.ebi.ac.uk/Tools/clustalw2/index.html  
 
GeneDoc - Full Featured Multiple Sequence Alignment Editor, Analyser and Shading 
Utility for Windows (Nicholas et al., 1997). 
http://www.psc.edu/biomed/genedoc
 
ExPASy (Expert Protein Analysis System) proteomics server of the Swiss Institute of 
Bioinformatics was used to determine protein structure, molecular weight and 
secondary modifications. Programs within this server included:  
• PROSITE (Database of protein domains, families and functional sites) 
http://www.expasy.org/prosite/ 
• TMHMM - Prediction of transmembrane helices in proteins (Moller et al., 
2001)                                                         
http://www.cbs.dtu.dk/services/TMHMM-2.0/ 
• TMpred - Prediction of transmembrane regions and protein orientation     
TMbase - A database of membrane spanning proteins segments (Hofman and 
Stoffel, 1993)                  
http://www.ch.embnet.org/software/TMPRED_form.html 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 215
Appendices                    
Appendix 6 Publications, abstracts, presentations 
and prizes relating to this thesis  
 
Principle paper  
Chan,L.F., Webb,T.R., Chung,T.T., Meimaridou,E., Cooray,S.N., Guasti,L., 
Chapple,J.P., Egertova,M., Elphick,M.R., Cheetham,M.E., Metherell,L.A., and 
Clark,A.J. (2009). MRAP and MRAP2 are bidirectional regulators of the melanocortin 
receptor family. Proc. Natl. Acad. Sci. U. S. A 106, 6146-6151. 
 
Published abstracts 
L F Chan, L A Metherell, T R Webb, M R Elphick, J P Chapple, A J L Clark. MRAP2, 
a Homologue of MRAP, Is a Novel Melanocortin-2-Receptor Accessory Protein. The 
Endocrine Society 90th Annual Meeting (San Francisco, USA) P1-1, 2008.  
 
L F Chan, L A Metherell, M R Elphick, J P Chapple, A J L Clark. MRAP2 permits the 
functional expression of the melanocortin-2-receptor: a new member of a new family of 
melanocortin receptor accessory proteins. Society for Endocrinology Annual Meeting 
BES (Harrogate, UK) OC6, 2008.  
 
Prizes 
Society for Endocrinology young investigator oral prize for 2008 (Harrogate, UK):  
‘MRAP2 permits the functional expression of the melanocortin 2 receptor: a new 
member of a new family of melanocortin receptor accessory proteins’. 
 
Meeting for Clinician Scientists in Training 2009 (Royal College of Physicians 
London). Poster prize - MRAP and MRAP2 are bidirectional regulators of the 
Melanocortin receptor family.  
 
Fellowship awards  
St. Bartholomew’s and The Royal London Charitable Foundation Research Advisory 
Board Training Fellowship. Is MRAP2 a melanocortin receptor escort protein? 2005-
2006 
 
MRC Clinical Research Training Fellowship. MRAP2 (Melanocortin Receptor 
Accessory Protein Two) and its role in melanocortin receptor trafficking and 
expression. 2006-2008 
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The melanocortin receptor (MCR) family consists of 5 G protein-
coupled receptors (MC1R–MC5R) with diverse physiologic roles.
MC2R is a critical component of the hypothalamic–pituitary–
adrenal axis, whereas MC3R and MC4R have an essential role in
energy homeostasis. Mutations in MC4R are the single most
common cause of monogenic obesity. Investigating the way in
which these receptors signal and traffic to the cell membrane is
vital in understanding disease processes related to MCR dysfunc-
tion. MRAP is an MC2R accessory protein, responsible for adrenal
MC2R trafficking and function. Here we identify MRAP2 as a
unique homologue of MRAP, expressed in brain and the adrenal
gland. We report that MRAP and MRAP2 can interact with all 5
MCRs. This interaction results in MC2R surface expression and
signaling. In contrast, MRAP and MRAP2 can reduce MC1R, MC3R,
MC4R, and MC5R responsiveness to [Nle4,D-Phe7]alpha-melanocyte-
stimulating hormone (NDP-MSH). Collectively, our data identify
MRAP and MRAP2 as unique bidirectional regulators of the MCR
family.
GPCR accessory proteins  receptor signalling  receptor trafficking
Themelanocortin receptor (MCR) family is involved in a diverserange of physiologic and disease processes (1). MC1R is im-
portant in pigmentation, MC2R in steroidogenesis, andMC5R has
an exocrine function especially in sebaceous gland secretion.MC3R
andMC4R are both highly expressed in the brain and play key roles
in energy homeostasis. Mutations in MC4R are the most common
cause of monogenic obesity. More recently, fat mass, weight, risk of
obesity, and insulin resistance were associated with common vari-
ants near the MC4R locus (2, 3). Both MC4R knockout mice and
humans with MC4R mutations display early-onset obesity associ-
ated with hyperphagia (4, 5). MC3R knockout mice, however,
develop a milder phenotype with later-onset obesity (6, 7).
We previously identified MRAP (melanocortin-2-receptor ac-
cessory protein), a small transmembrane protein, as an MC2R
accessory protein, enabling the functional expression of MC2R in
transfected cells. The identification ofMRAP provides amolecular
explanation for the difficulties encountered in the expression of the
MC2R in nonadrenal cell lines (8). Furthermore, mutations in
MRAP result in the autosomal recessive disorder familial glucocor-
ticoid deficiency type 2 (9).
Here we report the identification and characterization of a
unique MRAP homologue encoded by C6orf117 on human chro-
mosome 6q14.3, whichwe have namedMRAP2.We show that both
MRAP and MRAP2 can modulate the signaling of all 5 MCRs.
MRAP2 is primarily expressed in human brain and adrenal gland.
In the brain, MRAP2 expression is seen in the hypothalamus (10),
a site that also expresses a high level of MC3R and MC4R (6, 11).
MRAP expression in the hypothalamus has also been demon-
strated by in situ hybridization (12). These findings suggest that
MRAP and MRAP2 may regulate MC3R and MC4R function in
the central nervous system.
Results
MRAP2: A Unique Homologue of MRAP. The human MRAP2 gene
consists of 4 exons, and its protein product comprises 205 aa
residues, with a predicted molecular mass of 23.5 kDa (Fig. 1A).
MRAP2 is homologous to MRAP, with 39% amino acid identity
toMRAP in theN-terminal and transmembranedomains (Fig. 1B).
The protein is highly conserved through vertebrates (supporting
informationFig. S1) and likeMRAPhas no predicted signal sequence.
MRAP2 Is Expressed in the Brain and Adrenal Gland. MRAP2 gene
expression was assessed using a panel of cDNAs derived from
human tissues (13).MRAP2 expression was detected byRT-PCR in
the adrenal gland and brain (Fig. 1C). No expressionwas seen in the
other tissues analyzed (Fig. S2). PCR products were sequenced to
confirm MRAP2 transcript. MRAP2 protein expression was de-
tected in mouse brain and adrenal using the rMRAP2189–204
antiserum (Fig. 1D). OnWestern blotting a single large-molecular-
mass band of approximately 48 kDa was detected. This molecular
mass is consistent with a dimeric MRAP2 structure, resistant to
denaturing and reducing conditions. Furthermore, these data are
also consistent with the denaturation-resistant dimerization of
endogenous MRAP, which is seen in mouse Y1 cells (14).
MRAP2 Is a Glycosylated Protein. CHO cells (which have no endog-
enous expression of MRAP or MRAP2) were transfected with a
MRAP2-FLAG construct, and Western blotting for FLAG re-
vealed bands at approximately 27 and 29 kDa (Fig. 1E). A putative
N-linked glycosylation site, with the consensus sequence NRTS,
was identified at amino acid positions 9–12. Treatment with the
endoglycosidases peptideN-glycosidase F (PNGaseF) and endogly-
cosidase H (EndoH) resulted in increased mobility of the higher-
molecular-mass band, indicating that MRAP2 is a glycosylated
protein. To confirm the putative glycosylation site, site-directed
mutagenesis was undertaken to replace the asparagine at position
9 with a glutamine residue (N9Q-FLAG). A predicted single
27-kDa band was detected by Western blotting of cell lysates from
CHO cells transfected with N9Q-FLAG, in agreement with the
putative glycosylation site (Fig. 1E). To determine the subcellular
localization of MRAP2, CHO cells transfected with MRAP2-
FLAG were analyzed by immunocytochemistry using FLAG anti-
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bodies. Staining of transfected nonpermeabilized and permeabil-
ized cells localized MRAP2 to the plasma membrane and
endoplasmic reticulum (ER), respectively, similar to the distribu-
tion of MRAP (Fig. 1F).
MRAP2 Interacts with and Can Rescue the Expression and Function of
MC2R in Nonadrenal Cell Lines.Coimmunoprecipitation (Co-IP) was
used to investigate protein–protein interaction between MRAP2
andMC2R.CHOcells were cotransfected withMYC-MRAP2 and
HA-MC2R. Immunoprecipitation (IP) of MC2R using anti-HA
resulted in the Co-IP of MYC-MRAP2 (Fig. 2A). Previous studies
have shownMC2R retention in the ER in cells of nonadrenal origin
(8). Coexpression withMRAP supports the expression ofMC2R at
the cell surface (9). To test the ability of MRAP2 to assist MC2R
cell-surface expression, CHO cells were cotransfected with
MRAP2-FLAG and HA-MC2R. Confocal imaging of cotrans-
fected cells revealed cell-surface localization of HA-MC2R in the
presence of MRAP2-FLAG (Fig. 2B). MC2R trafficking in the
presence of MRAP2 was further assessed using a fluorescent
cell-surface assay (Fig. 2C). The glycosylation mutant N9Q-FLAG
also enabled MC2R trafficking to the cell surface, suggesting that
glycosylation of this residue is not required to facilitate MC2R
traffic to the plasma membrane.
To investigate whether MRAP2 could function in a similar
manner to MRAP, HEK293T cells, which lack endogenous MCRs
(15, 16), were transfected with MC2R in the presence and absence
of MRAP2, MRAP, and N9Q. Cells transfected withMC2R alone
did not respond to 106 M adrenocorticotropic hormone
(ACTH)(1–39). The addition of MRAP2 resulted in the produc-
tion of cAMP when stimulated with 106 M ACTH(1–39) (Fig.
2D), and cAMP generation was comparable to that seen with
MRAP and MC2R. Coexpression of MRAP and MRAP2 with
MC2R did not enhance ACTH-stimulated MC2R cAMP produc-
tion over and above that observed with MRAP or MRAP2 alone.
Interestingly, the glycosylation status of MRAP2 seems to be
functionally important. Despite assisting MC2R to the cell surface,
the addition ofN9Q-FLAG failed to enableMC2R signaling. These
data clearly suggest that MRAP2 may have 2 separate roles in
MC2R regulation: first in trafficking of the receptor to the cell
surface, and second in enabling the receptor to respond to ACTH.
Both MRAP and MRAP2 Interact with all Melanocortin Receptors.
MRAP2 and MRAP are more widely expressed than MC2R.
MRAP2 is detected in both the adrenal gland and brain (Fig. 1C),
whereas humanMRAP is expressed in a number of tissues (9). We
hypothesized that MRAP and MRAP2 may regulate the expres-
sion and signaling ability of the other MCRs. Experiments were
performed using CHO cells coexpressing MRAP-FLAG or MYC-
MRAP2 and HA-MCR. Co-IP with HA-conjugated agarose and
immunoblotting with either anti-FLAG or anti-MYC showed that
MRAPandMRAP2 interact with each of theMCRs (Fig. 3A). The
multiple MRAP bands seed in this figure are similar to those we
have observed previously in studies with human MRAP, although
the principal full-length MRAP migrates at 24 kDa (Fig. S1) (17).
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Fig. 1. MRAP2 encodes a glycosylated single trans-
membrane protein expressed in the brain and adrenal
gland. (A) Schematic diagram of the human MRAP2
gene and protein. (B) Protein alignment of human
MRAP isoforms and human MRAP2. The highest level
of sequence identity is in the N-terminal and trans-
membrane domains. Transmembrane domain is un-
derlined. (C) MRAP2 mRNA expression in human tis-
sues was determined by RT-PCR analysis. Full-length
MRAP2 mRNA (618 bp) was detected in human adre-
nal and brain. (D) Western blot analysis of mouse
tissues using antiserum rMRAP2189–204. An immunore-
active band with a molecular mass of approximately
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competition. The size of the bands seen by Western
blot is consistent with an MRAP2 dimer, resistant to
denaturing and reducing conditions. (E) MRAP2 un-
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munoblot analysis of MRAP2-FLAG transfected cells
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and shows similar localization to MRAP-FLAG. (Scale
bars, 10 m.)
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The reciprocal Co-IP, using FLAG-conjugated agarose to precip-
itate MRAP2-FLAG or MRAP-FLAG, resulted in detection of
HA-MCR by immunoblotting (data not shown). The possibility
that this was a nonspecific interaction was investigated by attempt-
ing Co-IP ofMRAP2 with the 2-adrenergic receptor (BAR), AT1
angiotensin receptor (AT1R), and calcitonin-like receptor (CLR)
transfected into CHO cells. NoCo-IP was identified with theAT1R
or CLR, but Co-IP was detectable with the BAR (Fig. S3).
MRAP2 Can Homodimerize and form Heterodimers with MRAP.
MRAP has been shown to form homodimers (14, 18). To demon-
strateMRAP2homodimerization,CHOcells were transfectedwith
MYC-MRAP2 and MRAP2-FLAG. Co-IP showed that MRAP2
forms homodimers (Fig. 3B). Because both MRAP and MRAP2
are expressed in the adrenal gland and brain, we tested the
possibility that MRAP and MRAP2 could form heterodimers.
Co-IP was performed on CHO cells cotransfected with MRAP-
FLAG and MYC-MRAP2 and showed that MRAP and MRAP2
can heterodimerize (Fig. 3C).
MRAP and MRAP2 Can Downregulate the Expression and Signaling of
the MCRs, and the Effects of MRAP and MRAP2 Can Be Additive.
Because all MCRs interact withMRAP andMRAP2 by Co-IP, we
investigated the effect of these accessory proteins on MC1R,
MC3R,MC4R, andMC5R cell-surface expression. CHOcells were
cotransfected with HA-MCR alone or in the presence of either
MRAP or MRAP2 or both. Cell-surface MCR expression was
analyzed using a fluorescent cell-surface assay (Fig. 4A). The
addition of MRAP or MRAP2 resulted in a small but significant
reduction in the surface expression of MC4R and MC5R but did
not alter the cell-surface expression of MC1R or MC3R.
To determine how MRAP and MRAP2 affect MCR signaling,
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we used a cAMP generation assay and compared MCR respon-
siveness with [Nle4,D-Phe7]alpha-melanocyte-stimulating hor-
mone (NDP-MSH) in the presence or absence of MRAP and/or
MRAP2 (Fig. 4B). A significant reduction in MC4R- and MC5R-
mediated cAMP generation in response to ligand (109 M NDP-
MSH) was seen with the addition of MRAP and MRAP2. Inter-
estingly, cAMP generation was significantly reduced forMC1R and
MC3R when both MRAP and MRAP2 were coexpressed. This
suggests a possible additive inhibitory effect on MC1R and MC3R
signaling in the presence of both accessory proteins. MRAP2 alone
also significantly reducedMC3Rresponsiveness toNDP-MSH.The
specificity of this effect was investigated in view of the Co-IP of
MRAP2 with the BAR (Fig. S3). However, neither accessory
protein influenced cAMP generation in response to isoproterenol
(Fig. S4). In an attempt to explore the possible mechanisms of
action of MRAPs on the MCRs, the dose-responsiveness of the
effect ofMRAP2on theMC5Rwas investigated and suggested that
the accessory protein acts to reduce the maximal responsiveness of
the receptor, in contrast to shifting the dose–response curve to the
right (Fig. S5).
Discussion
We have previously identified MRAP as an accessory protein for
MC2R, required for receptor trafficking to the cell surface and the
formation of a functional MC2R. Here we have identifiedMRAP2
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as a homologue ofMRAP. LikeMRAP,MRAP2 is able to support
MC2R cell-surface expression, producing a functional ACTH-
responsive receptor. In addition, we have shown a unique role for
MRAP and MRAP2 in the modulation of the other MCRs.
MRAP2, together with MRAP, therefore forms a new family of
MCR-accessory proteins important in the trafficking and signaling
of the MCRs.
In this study we show that MRAP2, like MRAP, is a single-pass
transmembrane domain protein that is localized to the cell surface.
Furthermore, MRAP2 undergoes posttranslational modification
such that it is glycosylated at the N terminus. Functionally for the
MC2R, MRAP2 is comparable to MRAP, with the ability to
facilitate trafficking of the MC2R to the plasma membrane and to
enable the receptor to signal in response to its unique ligand,
ACTH. Western blotting using an antibody to the C-terminal
region of MRAP2 revealed an approximately 48-kDa band in
adrenal gland and brain tissue, consistent with a MRAP2 dimeric
structure in vivo that is resistant to the action of SDS, reducing
agents and heat, as described previously for MRAP (14). Recent
work suggests that MRAP adopts a dual-topology homodimeric
structure (18). N-terminal glycosylation and a C-terminal out
orientation as shown by immunofluorescent staining of live cells
suggest that MRAP2 also has dual topology.
Our study reveals a unique observation: disruption of the single
MRAP2 glycosylation site enables normalMC2R trafficking to the
cell surface, but the receptor fails to generate cAMP in response to
ACTH. Importantly, this suggests that MRAP2 has 2 separate
MC2R accessory roles: first in trafficking of the receptor, and
second in enabling receptor responsiveness to ACTH.
MRAP2 is expressed in the adrenal gland, and in situ data
localizes expression to all 3 zones of the adrenal cortex (zona
glomerulosa, zona fasciculata, and zona reticularis) (data not
shown). The possibility of MRAP2 heterodimerization with
MRAP is interesting and may imply the requirement of both
MRAP and MRAP2 interaction with MC2R for expression and
signaling of the receptor. However, the temporal expression pattern
of MRAP and MRAP2 in development has yet to be established.
This would enable dissection of MRAP and MRAP2 roles in
MC2R adrenal physiology.
The tissue expression of both MRAP and MRAP2 extends
beyond that of MC2R, suggestive of wider physiologic roles of the
MRAP proteins. Here, we show that MRAP2 is expressed in
human brain. MouseMrap2 (XM147017) was examined as part of
the genome-wide atlas of gene expression in the adult mouse brain
(10). In situ hybridization is suggestive of expression in the para-
ventricular hypothalamus (PVH). MC4R is highly expressed in the
PVH and MC3R in the ventromedial nucleus of the hypothalamus
(6, 11).MRAP expression has been reported in a number of tissues,
including both human and mouse brain and mouse hypothalamus
(12). Our data support a role of MRAP and MRAP2 in the
regulation of the centralmelanocortin system.MRAPandMRAP2
can reduce the surface expression of MC4R and also the signaling
of this receptor. This seems to be specific for this receptor family in
that although Co-IP with the BAR was identified, this had no
influence on cAMP signal generation by this receptor.MRAP2 and
MRAP can also regulate the signaling of the MC3R, but interest-
inglywithout changing the surface expression of the receptor. These
data support the concept of a dual functional role for the MRAP
proteins, first in receptor trafficking and second in regulating
receptor responsiveness to ligand.
In addition, we observed a significant decrease in the cell-surface
expression of MC4R and MC5R in the presence of MRAP and
MRAP2. It is interesting that MRAP and MRAP2 have opposite
effects in the modulation of different MCR family members. The
MC2R seems unique amongMCRs in that it requires an accessory
protein for expression and function. In contrast, MRAP and
MRAP2 separately and together can reduce the signaling and in
some cases plasma membrane expression of the other members of
theMCR family. This is not the only difference between theMC2R
and other MCRs; for example, the unique ligand specificity of the
MC2R differentiates this receptor from the other MCRs. Further
studies may reveal the structural and mechanistic basis of these
differences. The reason for differential control of the MC2R and
MC4R is unclear; however, one may envisage a physiologic advan-
tage of switching off appetite in situations in whichmaximalMC2R
responsiveness is required, such as acute stress. The effect of
MRAP2 on the dose–response curve in which the maximum
responsiveness of the MC5R is reduced is consistent with the
hypothesis that interaction with an MRAP converts the receptor
into one that preferentially binds ACTH over MSH; this concept
will be the subject of future work.
MC3R and MC4R are essential for the control of energy
homeostasis. We anticipate that MRAP andMRAP2 will prove to
be important endogenous regulators of MC3R and MC4R. Future
studies using transgenic mouse models are now required to dissect
the differential and synergistic functions of the 2 melanocortin
accessory proteins MRAP and MRAP2.
Experimental Procedures
Tissue Distribution. Expression of MRAP2 and GAPDH was performed on a panel
of cDNA derived from adult human tissues (adrenal, brain, liver, pancreas, lung,
esophagus, fallopian tube, ileum, rectum, breast, lymph node, buccal mucosa,
myocardium, gallbladder, atrium, kidney, fundus, ovary, prostate, thyroid, and
placenta) (13). The reaction mixture and PCR program used were previously
described (9), using MRAP2 intron-spanning primers (Table S1).
Expression Constructs and Site-Directed Mutagenesis. MRAP2-FLAG (C-terminal
tag) and MYC-MRAP2 (N-terminal tag) constructs were prepared using MRAP2
cDNA derived from human brain, which was directly cloned into the mammalian
expression vector pcDNA3.1() (Invitrogen). MRAP-FLAG was constructed by
directional cloning into p3xFLAG-CMV-14 expression vector (Sigma) after PCR
amplification of human MRAP from human adrenal cDNA. N9Q-FLAG mutant
construct was made by site-direct mutagenesis (Stratagene QuikChange site-
directed mutagenesis kit) using the MRAP2-FLAG construct as a template. All
constructs were confirmed by sequencing. cDNA clones for human MCRs (MC1R–
MC5R) triple HA tagged at the N terminus (HA-MCR) were obtained from the
Missouri S&T cDNA Resource Center.
Cell Culture and Transfections. CHO cells were maintained in 1:1 DMEM/Ham’s
F12 media (Sigma) supplemented with 10% FCS and 1% penicillin/streptomycin
mixture (Sigma). HEK293T cells were maintained in DMEM with 10% FCS and 1%
penicillin/streptomycin. Transient transfections were carried out using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Total
plasmid DNA amounts were kept constant with pcDNA3.1().
Western Blotting and Co-IP. Whole-cell lysates were prepared 24 h after trans-
fection. Cells were washed 3 times with PBS and lysates generated using lysis
buffer (PBS/1% n-dodecyl-D-maltoside with protease inhibitors) and incubated
for 30 min on ice. Samples were then spun for 30 min at 19,000 g at 4 °C. The
supernatant was passed through a 0.22-m filter (Millipore) before use for either
Western blotting or Co-IP. For Co-IP, supernatant was incubated overnight at 4 °C
with anti-FLAG, anti-HA, or anti-MYC agarose (Sigma). After incubation, agarose
was washed 5 times in lysis buffer, supernatant removed, and SDS loading buffer
added. After boiling for 5 min, Western blotting was performed as previously
described (9). Anti-HA (Sigma), anti-FLAG (Sigma), or anti-MYC (Abcam) antibod-
ies were used at a dilution of 1:2,000 for immunoblotting.
rMRAP2189–204 Antibody Production.Antisera to rat MRAP2 (rMRAP2189–204) were
produced in rabbits by Eurogentec. Rabbits were immunized with a conjugate of
thyroglobulin and a peptide (KLLENKPVSQTARTDLD) comprising residues 189–
204 of rat MRAP2 (underlined) and an N-terminal lysine residue to provide a
reactive site for coupling to thyroglobulin. Conjugation of the peptide to thyro-
globulin was performed using glutaraldehyde as a coupling reagent (19). The
rMRAP2189–204 antisera were used for Western blot analysis of MRAP2 expression
in tissues at a dilution of 1:1,000. Antibody specificity in Western blots was
assessed by preabsorption of antisera with the KLLENKPVSQTARTDLD peptide
antigen (20 M for 1 h at room temperature). Tissue lysates were prepared in
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radioimmunoprecipitation assay buffer. Protein concentration of the superna-
tant was determined using a protein assay (Bio-Rad).
Deglycosylation. Deglycosylation was performed using EndoH and PNGaseF, as
previously described (20). Typically 15 g protein was digested with PNGaseF
(1,500 U) or EndoH (1,500 U) at 37 °C for 2 h and analyzed by Western blotting.
Immunofluorescence. Cells were grown on 8-well glass chamber slides (Labtec).
Twenty-fourhoursafter transfection, cellswerewashed(PBS;35min)andthen
fixed (3.7% formaldehyde; 10 min). After fixation, cells were either permeabil-
ized with 0.1% Triton X-100 in PBS or placed in PBS for 10 min. After washes (PBS;
3  10 min), blocking was performed for 45 min [3% BSA (Sigma) and 10%
donkeyseruminPBS].Primaryantibody incubation(anti-FLAGoranti-HA;Sigma)
was used at a titer of 1:200 for 2 h. After further washes (PBS; 3  10 min), a
secondary Cy2 or Cy3 antibody was used at a concentration of 1:50 (Jackson
Immunoresearch). Cells were washed (PBS; 3 10 min) and nuclei stained using
2 g/mL DAPI in PBS for 1 min. A final wash with PBS was performed for 2 min.
Fluorescent mounting media was added and a coverslip applied. Cells were
examined by a Zeiss LSM 510 confocal microscope.
cAMP Competitive Protein Binding Assay. This was performed as described
previously (9, 21). Protein concentration was determined with the Bio-Rad pro-
tein assay. All results were expressed as a percentage of forskolin response.
Fluorescent Cell-Surface Immunoassay. CHO cells were grown in 24-well plates
and transfected with expression constructs as indicated. Transfections were per-
formed in triplicate on duplicate plates. Twenty-four hours after transfection the
cells were washed with PBS and fixed for 10 min with 3.7% paraformaldehyde.
Cells from 1 plate were then subjected to permeabilization with PBS/0.1% Triton
X-100. Both plates were then washed in PBS and blocked in Odyssey Blocking
Buffer (LI-COR) for 1 h. Primary anti-HA antibodies were used at a concentration
of 1:1,000 (Sigma), incubating for 1 h. This was followed by 3 washes in PBS and
secondary antibody incubation (IRDye 800CW goat antimouse IgG; LI-COR) at a
concentration of 1:750 for 1 h. After 3 further washes the permeabilized and
nonpermeabilized plates were scanned using the Odyssey Infrared Imaging
System (LI-COR). Data are presented as cell-surface protein over total protein,
normalized to receptor alone.
Statistics. Statistical analysis to determine significance was performed using a
Student’s t test. Each experiment was performed in triplicate and represents at
least 3 experiments. Error bars represent the standard error of the mean of the
independent experiments. Statistical significance was taken as P 0.05.
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Fig. S1. Protein alignment of MRAP2 orthologues, showing conservation of MRAP2 across vertebrates. Hs, homo sapiens; Mm, Mus musculus; Rn, Rattus
norvegicus; Gg, Gallus gallus; Xt, Xenopus tropicalis; Dr, Danio rerio.
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Fig. S2. MRAP2 mRNA expression in human tissues was determined by RT-PCR analysis. Full-length MRAP2 mRNA (618 bp, indicated by asterisk) was only
detected in human adrenal and brain. PCR products were sequenced to confirm MRAP2 transcript.
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Fig. S3. Specificity of the interaction between MRAP2 and other G protein-coupled receptors. The HA-tagged AT1R, the BAR, or the CLR were cotransfected
into CHO cells with the MYC-tagged MRAP2 as described for the MCRs, followed by Co-IP as shown. MRAP2 coprecipitated with the BAR (arrowheads) but not
with the other receptors. IB, immunoblotting.
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Fig. S4. InfluenceofMRAPorMRAP2on cAMPgenerationby theBAR in response to isoproterenol (10–7M). CHOcellswere transfectedwith theBARexpression
vector and either empty vector, MRAP, or MRAP2 expression vectors. cAMP signal transduction was measured using a cAMP luciferase reporter construct as
described elsewhere (1, 2). 1. Cooray SN, et al. (2008) The melanocortin 2 receptor accessory protein exists as a homodimer and is essential for the function
of the melanocortin 2 receptor in the mouse y1 cell line. Endocrinology 149:1935–1941. 2. Webb TR, et al. (2009) Distinct melanocortin 2 receptor accessory
protein domains are required for melanocortin 2 receptor interaction and promotion of receptor trafficking. Endocrinology 150:720–726.
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Fig. S5. MC5R dose-response curve in the presence or absence of MRAP2. CHO cells were transfected with the MC5R with or without the MRAP2 expression
vector. After 24 h cells were stimulated with various concentrations of NDP-MSH. cAMP signal generation was measured using a cAMP luciferase reporter assay
as described previously (1, 2). Results are the mean  SD of 2 independent experiments. 1. Cooray SN, et al. (2008) The melanocortin 2 receptor accessory
proteinexists as ahomodimerand is essential for the functionof themelanocortin 2 receptor in themouse y1 cell line.Endocrinology149:1935–1941. 2. Webb
TR, et al. (2009) Distinct melanocortin 2 receptor accessory protein domains are required for melanocortin 2 receptor interaction and promotion of receptor
trafficking. Endocrinology 150:720–726.
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Table S1. Primers used in study
Primer Forward Reverse
MRAP2 5 ATGTCCGCCCAGAGGTTA 3 5 TCAATCCAGGTCTTTGTG 3
MRAP2-FLAG 5atcggaattcatgtccgcccagaggtta 3 5 aatctcgagtcacttgtcatcgtcgtccttgtagtcatccaggtctttgtgtga 3
MYC-MRAP2 5 atcggaattcatggagcagaaactcatctctgaagaggatctgatgtccgcccagaggtta 3 5 aatctcgagtcaatccaggtctttgtgtga 3
N9Q-FLAG 5 ctcacacaaagacctggattagtacaaggacgacgatgac 3 3 gagtgtgtttctggacctaatcatgttcctgctgctactg 5
MRAP-FLAG 5 ACGCTGAAAGCTTAGTG CCACAGACATG 3 5 ACCAGTTGAA TTCGCTATGGCCACGAT 3
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